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ABSTRACT 
Orthotopic liver transplantation (OLT) remains the only proven treatment for end-stage 
liver disease.  However the waiting list for OLT far exceeds the supply of donor organs.  
Hepatocyte transplantation may offer an alternative for these patients either as a bridge to 
OLT or replacing OLT altogether.  Unfortunately efforts so far have failed to result in long 
term benefit despite initial promising results.  The mechanisms regulating engraftment of 
transplanted hepatocytes into host liver, in particular the nature of their interaction with 
hepatic sinusoidal endothelial cells (HSEC), remain poorly understood.  I have 
significantly improved the outcome of human hepatocyte isolation from liver tissue and 
shown that human hepatocytes express a range of adhesion molecules including β1-
integrin.  Rather than reducing adhesion, β1-integrin blockade significantly improves 
hepatocyte adhesion to HSEC under flow, increases transmigration across HSEC and leads 
to greater engraftment in a murine model of hepatocyte transplantation.  Furthermore, I 
have shown that blocking β1-integrin on human hepatocytes leads to activation of the 
PKB/Akt signalling pathway, resulting in suppression of anoikis and improved viability, 
and promotion of cytoskeletal reorganisation that may lead to a more migratory phenotype.  
This work therefore demonstrates a possible target to improve hepatocyte engraftment and 
thus the outcome of hepatocyte transplantation. 
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CHAPTER 1:  GENERAL INTRODUCTION 
  
2 
 
1.1 Introduction to the Liver and Liver Disease 
1.1.1 The anatomy of the liver 
The liver is the largest solid organ in the human body, located on the right side in the upper 
abdomen immediately beneath the diaphragm.  It is unique in that it receives a dual blood 
supply.  In the healthy individual, oxygenated blood arrives from the hepatic artery via the 
coeliac trunk, the first major branch of the descending aorta within the abdomen, and 
accounts for approximately 25% of the total blood supply to the liver.  Approximately 75% 
of the blood supply arrives via the portal vein which is formed by the confluence of the 
splenic and superior mesenteric veins.  The superior mesenteric vein and inferior 
mesenteric vein, which usually drains into the splenic vein, provide venous drainage for 
the small and large bowel.  Hence the portal supply consists of deoxygenated but nutrient-
rich blood.  Venous drainage from the liver is via the left, middle and right hepatic veins 
which in turn drain into the inferior vena cava (IVC). 
The liver is divided into right and left hemilivers by the middle hepatic vein, and can be 
further divided into sections and segments (Figure 1.1) (Lopez-Terrada et al. 2014).  On 
entering the liver the hepatic artery and portal vein divide into separate branches supplying 
each segment before further dividing to supply individual lobules, travelling in portal tracts 
or triads consisting of a branch of the portal vein, a branch of the hepatic artery and a bile 
duct.  Individual lobules form the functional units within the liver, and are arranged into 
polyhedral structures separated by fibrous septa and arranged around a central vein which 
drain into the hepatic veins.  Portal triads lie within the septa at the corners of the lobules 
(Figure 1.2) (LeCluyse et al. 2012).  Hepatocytes are arranged into cellular plates that 
radiate out from the central vein like spokes of a wheel.   
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Figure 1.1  Blood supply and segmental anatomy of the human liver  
The liver received blood from branches of the hepatic artery (red) and portal vein (dark 
blue).  Bile ducts also run with these vessels (not shown).  Venous drainage is via three 
main hepatic veins which empty into the IVC (light blue).  Figure taken from the 
publication of Lopez-Terrada et al. 2014. 
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Bile canaliculi run between layers of hepatocytes within the hepatic plates and empty into 
bile ducts within the portal triad.  Blood arriving via the portal triads enters hepatic 
sinusoids which lie between the hepatic plates and empty into the central vein.  These 
coalesce forming the three main hepatic veins draining into the IVC. 
1.1.2 The function of the liver 
The liver performs a multitude of functions, the majority of which can be summarised into 
four categories: metabolism, synthesis, excretion, and storage.  Metabolic functions 
include the metabolism of amino acids and carbohydrates as well as the regulation of 
blood glucose levels.  The liver also metabolises ammonia via the urea cycle and 
metabolises endogenous and exogenous toxins and drugs.  The liver synthesises numerous 
proteins, clotting factors, complement components, enzymes, hormones and vitamins, and 
excretes bile pigments, bile salts and cholesterol through the bile.  It acts as a storage site 
for glycogen, vitamins (A, D and B12), iron and copper. 
1.1.3 Liver disease and liver failure 
The incidence of chronic liver disease is increasing worldwide largely due to the spread of 
Hepatitis B and C viruses as well as the increasing prevalence of alcoholic liver disease 
(ALD) and non-alcoholic fatty liver disease (NAFLD) particularly in developed countries 
(Williams 2006).  There are also a number of other less common conditions such as 
autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing 
cholangitis (PSC) and haemochromatosis that account for a smaller proportion of patients 
with chronic liver disease.  All of these disorders may ultimately progress to cirrhosis and 
end stage liver failure when the liver is unable to carry out its normal functions.  Cirrhosis 
is now one of the top 3 causes of death amongst those aged 35-65 in the UK (Office for 
National Statistics 2012).    
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Figure 1.2 The microscopic structure of the liver lobule 
The liver lobule is the functional unit of the liver.  (A) In cross section the lobule is a 
polygon, usually hexagonal.  Blood flows from the portal triads through the liver sinusoids 
towards the central vein at the centre of the lobule.  (B) This image shows a close up view 
of part of a liver lobule between a portal triad and the central vein.  Bile canaliculi run 
parallel but in the opposite direction to the blood flow carrying bile to the bile ducts 
situated within the portal triad.  Figure taken from the publication of LeCluyse et al. 2012. 
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Despite advances in antiviral medication and other medical therapy, liver transplantation 
remains the only effective treatment for end stage liver disease. 
Acute liver failure is less common but is associated with high mortality.  Viral causes, in 
particular hepatitis E, and drug induced liver injury, often due to paracetamol overdose, 
predominate in the developing and developed world respectively.  However, in many cases 
the cause is unknown (termed non-A non-B or seronegative acute liver failure) (Bernal et 
al. 2010).  Acute liver failure can be classified according to the time interval from the 
onset of jaundice until the development of hepatic encephalopathy, and may be divided 
into hyperacute, acute and subacute (O'Grady et al. 1993).  Hyperacute liver failure is 
more frequently associated with paracetamol overdose and hepatitis A or E and carries a 
more favourable prognosis.  Acute and subacute liver failure, associated with hepatitis B 
and non-paracetamol drug toxicity or non-A non-B hepatitis respectively, carry a poorer 
prognosis without emergency liver transplantation. 
1.2 Orthotopic Liver Transplantation and the Need for New 
Therapies 
1.2.1 The problems with orthotopic liver transplantation 
The first human liver transplant was performed in 1963 by Dr Thomas Starzl of Denver, 
Colorado, United States (STARZL et al. 1963).  Since then, orthotopic liver 
transplantation (OLT) has come a long way with improvements in operative technique, 
superior immunosuppression regimes, improved preservation of donor organs, and better 
selection of recipients.  Patient survival is now greater than 90% at 1 year and nearing 80% 
at 5 years (NHS Blood and Transplant 2011). 
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Liver transplantation is not without problems.  Firstly, the operation is still a formidable 
and costly procedure with significant morbidity and mortality (Lee et al. 2004).  It requires 
lifelong immunosuppression which in itself carries risks such as infection and malignancy.  
Further, due to the success of the technique and the increasing incidence of liver disease 
for which there is currently no other treatment, there is a growing demand for liver 
transplantation.  Unfortunately, despite attempts to promote organ donation, this has not 
been matched by a similar increase in the availability of donor organs.  Within the UK, the 
number of patients waiting on the active liver transplant list at 31 March 2011 was 510, an 
increase of 37% from 2010.  However, there was only a 1% increase in deceased liver 
donors during the same period (NHS Blood and Transplant 2011).  In light of this, there 
has been an interest in the use various alternatives to OLT in patients with acute and 
chronic liver failure as well as children with metabolic disorders. 
1.2.2 Alternatives to orthotopic liver transplantation 
Several alternative therapies for the treatment of liver failure are currently under 
development or are the subject of on-going clinical trials.  These can be broadly grouped 
into three categories: extracorporeal artificial liver devices; bioartificial liver devices using 
hepatocytes; and hepatocyte transplantation (Sgroi et al. 2009).  The objective of such 
treatments is to act as a bridge until such time that a suitable donor liver becomes available 
or to support the regeneration of the patient’s own liver. 
Hepatocyte cell transplantation has been suggested as an alternative to organ 
transplantation in patients with acute and chronic liver failure and is considered by some to 
be most appropriate in the management of patients with genetic or metabolic disorders 
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where a relatively small contribution to function could be curative and avoid the need for 
liver transplantation altogether (Gupta and Chowdhury 2002). 
Following years of research with animal modelling and preclinical studies, a number of 
patients have undergone hepatocyte transplantation as part of clinical trials in acute and 
chronic liver failure as well as various forms of metabolic liver disease.  The outcomes of 
these interventions have been mixed, and highlight the importance of careful patient 
selection as well as the problems facing hepatocyte transplantation.  Of note though, the 
safety of hepatocyte transplantation has been demonstrated by the follow up of surviving 
patients, who have remained free of malignant or infectious disease, for several years 
(Fisher and Strom 2006).  There is a growing experience of hepatocyte transplantation 
reported in the literature although treatment is limited by the availability of hepatocytes 
from unused donor tissue and the fact that any benefit of the procedure tends to be short 
lived with little effect on the clinical outcome and the majority of patients subsequently 
undergoing OLT (Hughes et al. 2012). 
1.3 Hepatocyte Transplantation 
1.3.1 Procurement of hepatocytes 
The majority of hepatocytes used for human transplantation so far have been primary 
hepatocytes obtained from cadaveric livers which have been considered unsuitable for 
transplantation.  This creates two problems: firstly the availability of cells for transplant is 
subject to the same shortage in donor tissue that exists for organ transplant; secondly, 
because livers made available for hepatocyte isolation have been rejected for organ 
transplant, the cells that are obtained from them are often not of the best quality (Lee et al. 
2004).  Other possible sources of primary hepatocytes which are likely to be of better 
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quality are unused tissue from split or reduced liver transplant, as well as whole organs for 
whom a suitable recipient is not identified (Strom et al. 1999). However these are 
relatively uncommon.   
Autologous hepatocytes are ideal for transplant as long term immunosuppression should 
not be required.  Combined with ex-vivo gene therapy, autologous hepatocyte 
transplantation has the potential to treat a wide range of metabolic disorders such as 
homozygous Familial Hypercholesterolemia (Raper et al. 1996).  Clearly patients 
undergoing such a procedure would require liver resection in order to retrieve tissue from 
which to isolate the hepatocytes.  However, this could be performed using minimal access 
surgery and would have a much lower morbidity than whole organ transplant. 
One way to optimise the availability of primary hepatocytes from discarded liver tissue 
would be to establish banks of cryopreserved hepatocytes.  Indeed, the feasibility of setting 
up such a bank, and the subsequent successful treatment of patients using banked 
hepatocytes in a bioartificial liver device, has already been demonstrated (Baccarani et al. 
2003;Baccarani et al. 2005).  However, the use of cryopreservation is still associated with 
reduced viability and other groups have reported an impact on metabolic function.  These 
and other problems associated with cryopreservation in relation to hepatocyte 
transplantation have been well described elsewhere (Terry et al. 2006). Further work is 
required to optimise the use of this technology if it is to provide a useful source of 
hepatocytes. 
In view of the difficulties in obtaining primary hepatocytes from donor liver tissue, various 
other potential sources have been considered.  Foetal hepatocytes from aborted foetuses 
have the benefit of being highly proliferative, which may facilitate liver repopulation (Lilja 
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et al. 1998), but further investigation will be required to demonstrate that these cells would 
express a fully differentiated phenotype after transplantation (Lee et al. 2004).  Stem cells 
offer a further possible source of hepatocytes, and there has been much work looking at the 
potential of various types such as embryonic, mesenchymal, and induced pluripotent stem 
cells as well as liver oval cells (Oertel and Shafritz 2008).  However, concerns remain 
about the possibility of malignancy as well as whether such derived `hepatocyte-like’ cells 
are capable of taking on the full repertoire of hepatocyte functions (Strom and Fisher 
2003;Thomas and Forbes 2009). 
A further possibility is that of xenotransplantation.  Animal studies have shown that it is 
possible to transplant hepatocytes from one species to another and for them to function and 
correct liver failure in the recipient (Nagata et al. 2003).  Problems with this approach 
include the risk of transmission of zoonoses (Porcine Endogenous Retroviruses), 
immunogenicity and, not least, the regulatory hurdles that would have to be overcome in 
order to introduce such a technique into the clinical setting. 
1.3.2 Anatomy of the liver and site of hepatocyte transplantation 
When considering the different steps en route to hepatocyte engraftment it is pertinent to 
consider the anatomy of the liver and sites of cell entry. 
Within the liver lobules, hepatocytes are arranged into cell plates separated by narrow 
sinusoidal vessels that are lined with specialised endothelium termed hepatic sinusoidal 
endothelial cells (HSEC).  Hepatocytes lie in close proximity to the sinusoidal 
endothelium, separated only by the space of Disse, as well as bile canaliculi into which 
bile is secreted. 
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The portal vein carries nutrient-rich blood and accounts for approximately 75% of the 
blood supply in the healthy liver.  The remaining 25% comes from the hepatic artery 
which carries oxygen-rich blood.  On entering the liver, these vessels divide into segmental 
branches before further dividing to supply individual lobules travelling in portal tracts or 
triads consisting of a branch of the portal vein, a branch of the hepatic artery and a bile 
duct. 
Blood entering the lobules via the portal tracts reaches the sinusoids, where the exchange 
of cells and substances between the blood and the liver parenchyma can occur, before 
draining into the central veins located at the centre of each lobule which in turn combine to 
form the hepatic veins draining into the IVC. 
The specialised extracellular matrix and portal blood supply make the liver the optimum 
site for transplanted hepatocytes to engraft and survive and so the liver itself is thought to 
be the most desirable site for transplantation (Mazaris et al. 2005).  This can be achieved 
by infusing hepatocytes directly into the portal vein or, using the spleen as a conduit, by 
injecting into the splenic pulp (Lee et al. 2004) following which hepatocytes will travel via 
the splenic vein into the portal vein and hence the liver.  Intraportal infusion is a relatively 
straight forward technique, and the majority of the animal studies of hepatocyte 
transplantation, as well as procedures performed in humans where it can be achieved using 
a percutaneous approach, have made use of this technique.   
Many ectopic sites for transplantation have been investigated including the kidney, lung, 
pancreas, spleen and peritoneal cavity (Gewartowska and Olszewski 2007). Several studies 
show that the spleen and liver are the optimum sites for hepatocyte transplantation (Gupta 
et al. 1994;Gupta et al. 1999b).  The spleen, as well as acting as a conduit to the liver as 
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described above, has also been used as a site for transplant.  The transplanted hepatocytes 
are trapped in the sinusoids and vascular spaces, which seems to be important for 
engraftment, and proliferate replacing up to 40% of the splenic pulp after a few months 
(Mazaris et al. 2005). The peritoneal cavity, in terms of its volume, also offers the potential 
for the transplantation of large numbers of cells.  Animal studies have shown that 
transplanted hepatocytes are able to survive and function within the peritoneal cavity.  
However due to the anchorage-dependent nature of hepatocytes they need to be attached to 
some sort of extracellular matrix to survive (Demetriou et al. 1986a;Demetriou et al. 
1986b).   
Whilst most models of hepatocyte transplantation have used rodents, a few investigators 
have looked at larger animals such as pigs.  In one such study hepatocytes were 
transplanted into other foregut structures including the stomach, pancreas, spleen, small 
bowel and mesentery with the latter two sites proving to be favourable (Sosef et al. 2007). 
However, the use of such techniques in the clinical setting would require more invasive 
techniques than percutaneous intraportal infusion and, even if they were to produce a 
substantial metabolically active `liver mass’, the long term effects are unknown.  Further 
investigation will be required in order to determine whether extra-hepatic sites will provide 
a feasible alternative for hepatocyte transplantation in humans. 
1.4 Hepatocyte Engraftment 
The successful engraftment of hepatocytes in the recipient liver is dependent on a 
multitude of different steps ranging from the method of isolation to the interaction with the 
liver endothelium and finally to the functional incorporation within the hepatic 
parenchyma.  Figure 1.3 illustrates some of these important steps.  It is useful to 
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systematically examine each of these stages, and the possible manipulations which may be 
undertaken to incrementally improve hepatocyte engraftment.  
1.4.1 Hepatocyte isolation 
The original technique of hepatocyte isolation was described in the 1960s for the isolation 
of rat hepatocytes using a combined mechanical and enzymatic digestion technique 
(Howard et al. 1967).  This was modified to become the two-step collagenase perfusion 
technique which is widely used today (Seglen 1976). Perfusion with warmed buffers to 
remove any remaining blood or clots from the tissue and to warm the tissue to 37°C takes 
place via cannulae inserted into the exposed vessels on the cut surface of the liver.  The 
liver is then perfused with a cation-chelating agent to remove calcium ions and disrupt 
desmosomal structures holding the cells together, prior to digestion with collagenase.  
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Figure 1.3 Steps involved during the engraftment of hepatocytes into liver during 
hepatocyte transplantation 
(1) Transplanted hepatocytes delivered intravascularly adhere to sinusoidal endothelium.  
(2) Disruption of endothelium allows transplanted hepatocytes to pass out of the 
sinusoidal lumen.  VEGF release from hepatocytes may be involved.  (3) Occlusion of 
sinusoids by transplanted hepatocytes leads to ischaemia which may activate Kupffer and 
Stellate cells.  (4) Kupffer cells and neutrophils activated during transplantation destroy a 
large proportion of transplanted hepatocytes.  (5) Transplanted hepatocytes that make it 
across the endothelial barrier are integrated into liver plates.  Stellate cells, activated by 
hepatocytes, HSEC, Kupffer Cells or ischaemia, may have a role in aiding this process 
through the release of various growth factors and matrix metalloproteinases.    
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Some groups add other enzymes such as DNase, dispase and hyaluronidase to the 
digestion buffer.  Hepatocytes are then separated and purified by low speed centrifugation.  
A density gradient such as Percoll may be used to separate non-viable cells.  The yield of 
isolated hepatocytes varies widely depending on how diseased the donor liver tissue is, as 
well as the exact techniques used for isolation.  This wide variation in yield and viability 
highlights the need for further research to optimise the isolation technique.  The use of 
collagenase and other such reagents in the isolation of hepatocytes may denude 
hepatocytes of vital adhesion molecules/receptors which may well impact on the ability of 
these cells to engraft.  This has been demonstrated for other cell types.  For example, the 
use of collagenase for liver-derived T cell isolation has little effect on the majority of cell 
surface markers but leads to a reduction in expression of CXCR3 (Shields et al. 1999).  
Incubation of peripheral blood mononuclear cells with collagenase and dispase results in 
reduced expression of CD3, CD4, CD8, αβ and γδ T cell receptors (Abuzakouk et al. 
1996).   The impact of different isolation methods on the surface receptor expression of 
hepatocytes, and their ability to engraft, has not been ascertained, nor has the time 
necessary for any potential recovery in adhesion molecule expression after isolation been 
determined. 
1.4.2 Cell detachment and anoikis 
When hepatocytes are isolated from donor liver tissue, and during the transplantation 
process, hepatocytes are detached from the normal extracellular matrix (ECM).  This may 
cause them to undergo apoptosis due to the loss of the normal survival signals, a process 
known as anoikis.  β1 integrin is known to be important in this process due to the loss of a 
β1 mediated survival signal, normally delivered through binding to RGD (Arg-Gly-Asp) 
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sites on ECM proteins, leading to activation of caspases and subsequent apoptosis 
(Boudreau et al. 1995;Zvibel et al. 2002).  
Treating isolated hepatocytes with the agonistic β1 integrin antibody TS2/16 increases 
their survival (Kocken et al. 1997). This antibody is able to mimic a β1 integrin mediated 
signal, thus inhibiting caspase activation, preventing cell death.  Furthermore, treatment 
with RGD-containing peptides can lead to a dose-dependent increase in survival with a 
1.38-fold increase in cell numbers after 18 hours of culture compared to untreated 
hepatocytes (Pinkse et al. 2005).  However another study found that pre-incubating cells 
prior to transplantation with collagen or fibronectin like polymer (FLP) (both RGD 
containing proteins) led to cell aggregation in vascular spaces (Kumaran et al. 2005) which 
would clearly be detrimental. 
Whether anoikis will be a major problem in clinical practice will depend on the time frame 
between hepatocyte isolation and their subsequent transplantation, and how they are stored 
in the meantime.  Cryopreservation will largely remove this problem, as cells will be 
frozen soon after isolation and only thawed when required for transplant.  However, if 
cells are to be used soon after isolation or cryopreservation is not possible for some reason, 
then they will need to be attached to some form of ECM.  Most assays used to measure the 
activity of isolated cells prior to transplant will also require them to be attached to a 
substrate.  There is evidence that a differentiated phenotype can be maintained in culture 
for several days or longer using specialised culture medium (Pichard et al. 2006).  
Improved metabolic function, demonstrated by markers such as albumin production, 
glucose synthesis and cytochrome P450 function, can be achieved using more complex 
culture systems such as collagen sandwich/3d matrix (Wang et al. 2004;Wen et al. 2009) 
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or gel scaffolds (Wang et al. 2008).  There is also evidence that some aspects of hepatocyte 
function may be better preserved in co-culture with other cell types such as stellate cells 
(Krause et al. 2009).   
However, the effects of culture, the type of ECM used and the method used to detach the 
cells on the outcome of subsequent transplantation needs to be investigated.  The effect on 
subsequent engraftment of treating cells as described above to increase survival is also 
unknown. 
1.4.3 Impact of hepatic ischaemia and blood flow on hepatocyte 
transplantation 
Following hepatocyte transplantation into the portal vein, either directly or via the spleen, 
cells are found in periportal areas and hepatic sinusoids.  In periportal areas cells are 
surrounded by inflammatory infiltrates containing granulocytes, phagocytes and activated 
macrophages resulting in the removal of up to 80% transplanted cells within 24 hours 
(Gupta et al. 1999c).  Therefore the sinusoids in the hepatic lobules provide the optimum 
site for engraftment.  Due to the relatively large size of hepatocytes, leading to temporary 
occlusion of the liver sinusoids by cell emboli, a degree of hepatic ischaemia occurs during 
transplantation.  In the normal liver gamma glutamyl transpeptidase (GGT) is expressed by 
biliary cells only.  GGT is expressed by hepatocytes as a result of liver injury and can be 
used as a marker of hepatic ischaemia.  GGT expression by host hepatocytes can be shown 
as early as 2 hours post transplantation.  This increased expression can be reduced by the 
administration of vasodilators around the time of transplantation (Gupta et al. 2000).  The 
use of vasodilators may also have an effect on the distribution of transplanted hepatocytes 
within the liver.  The administration of nitroglycerine during the transplantation of cells 
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into rat models leads to an increase in transplanted cell entry into liver sinusoids with a 
beneficial effect on cell engraftment (Slehria et al. 2002).  
Hepatic ischaemia has effects on various cell types within the liver, including Kupffer cells 
and stellate cells, and may therefore be important in the context of hepatocyte 
transplantation.  As I will discuss later, the activation of stellate cells may be beneficial for 
hepatocyte engraftment while the activation of Kupffer cells is detrimental.  Hepatic 
ischaemia may also induce changes in growth factor expression.  Ischaemia-
reperfusion/hypoxia has been shown to increase the production of vascular endothelial 
growth factor (VEGF) by hepatocytes (Archambault et al. 2001) and stellate cells 
(Ankoma-Sey et al. 2000), and increased VEGF expression is seen soon after hepatocyte 
transplantation as described later.   
The use of vasodilators is an intervention that could readily be used to aid transplant of 
hepatocytes into humans given that there are several such drugs in regular clinical use 
already.  Exactly which drugs to use, the appropriate dose, the timing of administration of 
the drug in relation to delivery of the hepatocytes and how to avoid potentially detrimental 
systemic side effects requires further animal and clinical study.   
1.4.4  Adhesion to the sinusoidal endothelium during engraftment 
The mechanisms regulating the recruitment of leucocytes into the liver have been 
extensively studied, and although such studies may inform the mechanism of hepatocyte 
recruitment, the process of hepatocyte engraftment is different since the transplanted cells 
must find a niche where they can survive and integrate.  The recruitment of lymphocytes 
from the blood via sinusoidal endothelium to the liver parenchyma has been described 
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(Lalor and Adams 2002) and the molecular basis of this process is partly understood.  
Lymphocyte adhesion is dependent on ICAM-1, VCAM-1 and to a lesser extent VAP-1 
with transmigration being mediated by ICAM-1, VAP-1 and chemokine mediated signals 
(Adams and Eksteen 2006;Lalor et al. 2002;Shetty et al. 2008).   
Some detail of adhesive processes regulating the engraftment of transplanted hepatocytes 
has been described.  Following hepatocyte transplantation in dipeptidyl peptidase IV 
negative (DPPIV-) rats (described later in section 1.5), histochemical staining for DPPIV 
with vinculin immunostaining demonstrates focal adhesion complexes (FAC) at sites of 
contact between transplanted cells and HSEC (Kumaran et al. 2005).  Presumably in order 
for this to occur the movement of transplanted cells through the sinusoid must first be 
arrested with subsequent adhesion to the sinusoidal endothelium.  This supports the idea 
that transplanted cells interact with HSEC and, whilst the movement of hepatocytes from 
the liver sinusoids into the parenchyma is not a physiological process, it is possible that 
transplanted hepatocytes are able to interact with the HSEC via specific pathways 
involving adhesion molecules and chemokine receptors similar to those described above 
for leukocytes.  Alternatively, transplanted hepatocytes may simply become stuck via a 
passive process as a result of their size in relation to that of the sinusoid.  This process has 
been well described in relation to the metastasis of cancer cells to the liver (Vidal-
Vanaclocha 2008). However, even if the initial arrest of cell movement through the 
sinusoid is purely mechanical, there is evidence that specific interactions with the 
sinusoidal endothelium occur thereafter, and similarly such processes have been described 
in the context of tumour metastasis and migration.  For example, proinflammatory 
cytokines such as IL-1β and TNF-α have been shown to up-regulate the expression of 
VCAM-1 on HSEC with a corresponding increase in adhesion of melanoma cells (Vidal-
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Vanaclocha et al. 2000).  The hepatic migration of metastatic breast cancer cells is 
dependent on the chemokine receptor CXCR4 (Muller et al. 2001) and the migration of 
hepatocellular carcinoma depends on the chemokine receptors CCR7 and CXCR4 
(Schimanski et al. 2006a;Schimanski et al. 2006b).  Several other metastatic tumours, such 
as melanoma and colorectal cancer, also express CXCR4 and in colorectal cancer the level 
of CXCR4 gene expression has been shown to be a statistically significant prognostic 
marker (Kim et al. 2006).  CXCL12, the ligand for CXCR4 is highly expressed in the liver.  
Ligand-receptor interactions result in cell adhesion, proliferation and migration.  Currently, 
little is known about how such mechanisms may affect hepatocyte recruitment, but there is 
evidence that integrin-mediated adhesion within the sinusoid may be important.  
Modification of the recipient liver to increase the adhesion of transplanted hepatocytes 
may increase engraftment.  In one study portal infusion of collagen or FLP prior to 
transplant increased hepatocyte engraftment by 2.2 and 3.3 fold respectively compared to 
controls.  FAC were observed more frequently in these rats than in those receiving 
hepatocytes alone (Kumaran et al. 2005).  ECM components infused prior to transplant 
may bind within sinusoids providing extra binding sites for integrins, thus increasing 
adhesion of transplanted hepatocytes and therefore engraftment.  When animals treated 
with prior infusion of FLP received hepatocytes that had been incubated with RGD peptide 
the number of transplanted cells per unit volume of liver decreased by 77% compared to 
animals receiving untreated hepatocytes.  This is presumably due to the blocking of 
integrin binding sites by the RGD peptides.  The treatment of hepatocytes with RGD 
peptides has been shown to significantly reduce binding to fibronectin in vitro although 
there is no effect on their binding to collagen I or collagen IV (Pinkse et al. 2005). 
21 
 
Interestingly there was no significant difference in engraftment in animals which had not 
received prior infusion of ECM components when receiving hepatocytes that had been 
incubated with RGD peptide, suggesting that there are other adhesion pathways involved.  
The decrease in hepatocyte engraftment in animals receiving RGD treated hepatocytes and 
infusion of FLP suggests that these other adhesion pathways are somehow disturbed by the 
infusion of ECM components (Kumaran et al. 2005).   
Many of the potential targets for hepatocyte transplantation will be patients with 
established liver failure.  The liver microenvironment and hence the mechanisms of 
hepatocyte adhesion in such patients may be altered with an effect on hepatocyte 
recruitment.  For example, whilst collagen IV expression is increased in sinusoidal 
endothelium of patients with fulminant liver failure there is a loss of adhesion of 
hepatocytes to collagen coated plates when treated with serum from such patients.  This 
loss of adhesion has been shown to be due a reduction in β1 integrin receptor activity; 
addition of a β1 integrin activating antibody (TS2/16) significantly increases adhesion 
(Newsome et al. 2004).  
Further identification of the specific adhesion molecules and chemokine receptors 
involved in the adhesion of transplanted hepatocytes to and migration across sinusoidal 
endothelium, and how this process changes in different disease states, may allow 
treatments to be developed to increase the expression or activity of specific receptors and 
ligands on both hepatocytes and HSEC in order to increase adhesion and subsequent 
engraftment.    
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1.4.5 Disruption of the sinusoidal endothelium during engraftment 
Having adhered to the sinusoidal endothelium, in order for transplanted cells to engraft 
into the liver they must first enter the space of Disse which separates liver plates from the 
sinusoids.  This requires disruption of the sinusoidal endothelium (Gupta 2002) and has 
been demonstrated in animal models. At 2 hours post transplantation the sinusoidal 
endothelium appears normal.  By 24 hours following transplantation, however, disruption 
of the sinusoidal endothelium and loss of the space of Disse occurs.  At 8 hours following 
transplant VEGF activity can be shown in native hepatocytes adjacent to sinusoidal areas 
as well as some transplanted cells.  VEGF activity then declines and is not seen after 24 
hours post-transplant.  Of note, no VEGF activity is seen in the liver of control animals, 
suggesting that the release of VEGF by both recipient and transplanted cells could be a 
factor in the disruption of sinusoidal endothelium (Gupta et al. 1999c).  Increased VEGF 
expression under hypoxic conditions has been shown to increase the metastatic potential of 
melanoma cells, which may in part be due to an increased vascular permeability allowing 
extravasation into tissues (Rofstad and Danielsen 1999).  Several studies have 
demonstrated the ability of VEGF to increase fenestration and permeability of HSEC 
(Funyu et al. 2001;Yokomori et al. 2003) as well as its role in regeneration of the 
sinusoidal endothelium after liver injury (Sato et al. 2001;Shimizu et al. 2001) supporting 
its possible involvement during hepatocyte transplantation. 
Disruption of hepatic sinusoidal endothelium with the cytotoxic drug doxorubicin leads to 
improved engraftment of transplanted cells into rat liver.  In control animals, intact 
endothelium covered >75% of the sinusoidal area in 95% of hepatic sinusoids, but in rats 
receiving a single dose of doxorubicin there was extensive loss of endothelium with 50-
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75% of the sinusoidal area not covered by endothelium in >60% of sinusoids.  This was 
associated with a several-fold increase in transplanted cells in the liver of rats receiving 
doxorubicin 24 hours prior to transplant compared to control rats (Kim et al. 2005).  The 
use of cytotoxic drugs during hepatocyte transplantation into humans is unlikely to be 
acceptable as most of these drugs have potentially severe systemic side effects as well as 
being hepato-toxic.  The sinusoidal endothelium provides an important barrier function 
regulating the transfer of molecules between the blood in the sinusoid and the space of 
Disse where they come into contact with hepatocytes, and is crucial in regulating the 
passage of other cell types into the liver.  Widespread damage to the sinusoidal 
endothelium, even avoiding the use of cytotoxic drugs, is therefore likely to produce other 
unwanted effects.  Indeed, there is evidence that damage to sinusoidal endothelium is a key 
step in certain types of liver injury (Arii and Imamura 2000;Knolle et al. 1996).  Therefore 
manipulating the endothelial barrier to increase recruitment is a more sensible therapeutic 
strategy than removing it. 
VEGF has already been the subject of various clinical trials, ranging from its use to 
improve coronary perfusion to its inhibition to restrict tumour growth (Ferrara and Alitalo 
1999), and might offer a further treatment option in hepatocyte transplantation to increase 
the permeability of sinusoidal endothelium, thus allowing transplanted cells to engraft 
more readily.  However, whilst an association between hepatocyte transplantation and 
increased local VEGF activity has been demonstrated, there is as yet no evidence of the 
effect on administering exogenous VEGF, or somehow stimulating its release, on 
hepatocyte engraftment.  There is also the potential for a wide range of unwanted effects 
(Epstein et al. 2001) and so further experimentation in animal models is required to 
determine whether this is likely to be a safe treatment in humans.   
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1.4.6 Interactions of transplanted hepatocytes with hepatic stellate cells 
Once through the sinusoidal endothelium, transplanted hepatocytes enter the space of 
Disse where hepatic stellate cells (HSC) are located.  HSCs, which play a major role in the 
development of hepatic fibrosis (Safadi and Friedman 2002), can be activated by Kupffer 
cells, HSEC and hepatocytes (Pinzani and Marra 2001) through the release of various 
inflammatory mediators, such as VEGF (Liu et al. 2009). Activation leads to multiple 
events including HSC proliferation with increased desmin or α-smooth muscle actin 
expression. 
Following hepatocyte transplantation into DPPIV- rats there is a significant increase in 
desmin positive HSC at 24 hours, 3 days and 7 days after treatment.  There are few desmin 
positive HSC in control animals or early (6 hours) post-transplant.  Further, co-localisation 
of desmin positive HSC and DPPIV positive transplanted hepatocytes at 3 days post 
transplantation shows that 64% of transplanted cells are in the immediate proximity of at 
least one desmin positive HSC, suggesting an interaction between the cells (Benten et al. 
2005). Hepatic ischaemia may have a role in HSC activation during hepatocyte 
transplantation, as desmin positive HSC are seen within ischaemic GGT expressing areas.  
Similar findings are also observed following the injection of macroaggregated albumin 
(MAA) particles suggesting that mechanical occlusion of sinusoids leads to a degree of 
HSC activation.  However, animals receiving nitroglycerin (a vasodilator) during 
transplantation, which reduces hepatic ischaemia and GGT expression, also develop a 2.7 
fold increase in desmin positive HSC compared to control rats.  Therefore ischaemia alone 
is not responsible for HSC activation and soluble factors are also likely to play an 
important role (Benten et al. 2005). 
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The activation of HSC during transplantation leads to increased production of several 
factors which may have a beneficial effect on hepatocyte engraftment.  RT-PCR analysis 
of HSC-related genes has shown increased expression of hepatocyte growth factor (HGF), 
basic fibroblast growth factor (bFGF), VEGF and transforming growth factor (TGF) - β1 
within 1 – 6 hours post-transplant.  In addition there is increased expression of TGF β, 
platelet derived growth factor β and TNF α between 6 and 12 hours post-transplant.  
Values returned to near normal thereafter (Benten et al. 2005). 
Following hepatocyte transplant there is also a marked upregulation of matrix 
metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) which are 
produced by HSC following liver injury (Benyon and Arthur 2001). There is markedly 
increased expression of MMP-13, the major interstitial collagenase in the rat, as well as 
MMP-3, which degrades several ECM components, at 12 hours post-transplant.  
Gelatinase A/basement membrane collagenase (MMP-2) and its activator protease, MMP-
14, also increase moderately.  TIMP-1 levels are raised following transplant and peak at 12 
hours.  However, whilst MMP expression returns rapidly to near normal levels, TIMP-1 
expression remains elevated up to 72 hours post-transplant (Benten et al. 2005). 
Hepatocyte transplantation activates cyclooxygenase (cox) pathways with the production 
of prostaglandin-endoperoxidase synthases 1 and 2 leading to the production of 
prostaglandins such as PGE2 which is a significant mediator of tissue inflammation.  
Blocking these pathways with drugs such as Naproxen and Celecoxib leads to an increase 
in hepatocyte engraftment.  However, cox inhibition was not found to have an effect on 
neutrophil or Kupffer cell activity, nor on cytokine-chemokine responses.  Rather, animals 
treated with these drugs showed an increase in desmin positive activated HSC, although 
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the mechanism of HSC activation here is not clear (Enami et al. 2009). The use of drugs 
such as Naproxen and Celecoxib could provide a possible treatment for human recipients.  
Further research into the mechanisms by which HSC activation occurs in this setting and 
the role of prostaglandin pathways may lead to other therapeutic targets.  However, one 
must bear in mind that in diseased liver disease HSC may already be activated.  
Furthermore activated HSC are a key player in the development of liver fibrosis and 
cirrhosis (Li et al. 2008;Wu and Zern 2000).  Clearly in the context of liver disease the 
effect of hepatocyte transplantation on HSC activation may therefore differ, and in the 
healthy liver the promotion of a profibrotic state may not be desirable. 
1.4.7 Engraftment into liver parenchyma and attachment to extracellular 
matrix 
Once the transplanted cells have crossed the sinusoidal endothelium into the space of Disse 
they must then become incorporated into the liver parenchyma.  The upregulation of MMP 
and TIMP by activated HSC may have a role in facilitating entry into the liver parenchyma 
and subsequent remodelling. 
The importance of hepatocyte attachment to extracellular matrix and the consequences for 
the initial survival of cells has already been discussed.  Clearly it is also important that 
once within the recipient liver parenchyma the transplanted hepatocytes attach to the ECM 
in order to survive and spread.  In vitro, up to 70% of seeded rat hepatocytes rapidly attach 
to wells coated with collagen I, collagen IV or fibronectin via β1 integrins.  Antibody 
blocking studies suggest that α1 integrin is the dominant receptor involved (Pinkse et al. 
2005).  There is very little in the literature regarding the expression of adhesion molecules 
on primary hepatocytes, but one study suggests that the integrin repertoire is limited to 
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α1β1, α5β1 and α9β1 heterodimers (Couvelard et al. 1998) which is largely in keeping 
with the above observations. 
The major ECM components in the liver include collagen, glycoproteins such as 
fibronectin, vitronectin, laminin and tenascin as well as proteoglycans such as hyaluronic 
acid (Bedossa and Paradis 2003).  Collagens are the most frequent with types I, III and V 
confined mainly to the portal tract and central vein whereas type IV is associated with 
laminin and entactin forming a low-density basement membrane-like material along the 
sinusoidal wall (Martinez-Hernandez and Amenta 1993). Fibronectin appears to be 
particularly important in the space of Disse (Selden et al. 1999). The α5β1 integrin binds 
fibronectin and osteopontin, α1β1 binds collagen and laminin, and α9β1 binds VCAM, 
tenascin and osteopontin (Humphries et al. 2006).  The relative composition of liver ECM, 
as well as the distribution of adhesion molecules and their receptors is known to alter in 
liver disease.  For example, β1-integrin ligands VCAM-1 and matrix components together 
with the CD44 ligand hyaluronic acid are increased in diseased liver (Crosby et al. 2009). 
Proper integration with host hepatocytes and restoration of normal polarity is critical for 
the maintenance of specialised function.  Unlike the simple polarity of most epithelial 
cells, hepatocytes are organised in plates with several apical and basolateral poles.  The 
apical poles form a continuous network of bile canaliculi and are separated from the basal 
domain or sinusoidal pole, abutting the space of Disse, by tight junctions (Decaens et al. 
2008).  Evidence from animal studies suggests that if transplanted cells survive the 
procedure and make the journey across the sinusoidal endothelium they do indeed become 
integrated into the host liver with restoration of polarisation.  Transplanted hepatocytes 
enter liver plates and form hybrid gap junctions with adjacent host hepatocytes as well as 
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hybrid bile canaliculi within 7 days.  Following the administration of fluorescent bile salt, 
excretion of bile is apparent throughout the liver including hybrid bile canaliculi formed by 
transplanted cells (Gupta et al. 1995).  The actual process by which transplanted cells 
become incorporated into cell plates and regain polarity is not clear.  Continued 
investigation of this final stage of hepatocyte engraftment may provide a further target for 
intervention. 
1.4.8 Immune response and clearance of transplanted cells 
A number of studies have demonstrated the role of inflammatory cells in the clearance of 
transplanted hepatocytes.  Transplanted autologous, as well as allogeneic, hepatocytes 
appear to be recognised as non-self and are destroyed by granulocytes and mononuclear 
cells (Olszewski et al. 1998).  Following transplantation there is an increase in cytokine 
and chemokine gene expression in the liver much of which is secreted by innate immune 
cells including macrophages and neutrophils.  Depletion of these cells prior to hepatocyte 
transplant results in a reduction or normalisation of the expression of most of these genes 
(Krohn et al. 2009). 
Kupffer cells are the resident macrophages of the liver and are likely to play a role in the 
early removal of transplanted hepatocytes.  It is known that ischaemia-reperfusion in the 
liver is a potent activator of Kupffer cells (Serracino-Inglott et al. 2001).  The function of 
Kupffer cells can be examined using techniques such as carbon uptake and 99mTc-sulphur 
colloid incorporation.  Using such techniques it has been demonstrated that following 
infusion into the portal vein, transplanted hepatocytes quickly become surrounded by 
highly activated Kupffer cells (Joseph et al. 2002).   
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Kupffer cell function can be blocked by the use of substances such as gadolinium chloride 
(GdCl3).  Following administration of GdCl3 prior to transplant there is a reduction of up 
to 40% both in the number of Kupffer cells containing carbon particles and in 99msulphur 
colloid accumulation.  In animals treated with GdCl3 it has been found that the number of 
portal vein radicles containing transplanted cells increased from 34% to 66% at 72 hours 
and from 42% to 58% at 7 days compared to control animals.  In addition, the number of 
transplanted cells per portal vein radicle, in periportal sinusoids and subsequently in the 
liver parenchyma was also greater in GdCl3 treated animals.  This translated to a 2–3.8-
fold increase in transplanted cells within the liver parenchyma at 1 day, and this increase 
remained constant at subsequent times after transplantation (Joseph et al. 2002;Krohn et al. 
2009). 
Similarly, neutrophil accumulation in the liver following hepatocyte transplant has been 
demonstrated using myeloperoxidase (MPO) staining.  Depletion of neutrophils with anti-
neutrophil antiserum prior to transplant results in a 3.2 fold increase in cell engraftment 
compared to untreated controls (Krohn et al. 2009). 
The manipulation of the innate immune response in human recipients is perhaps one of the 
most difficult areas to address.  The use of drugs such as GdCl3 is unlikely to be an option 
for patients.  One of the benefits of hepatocyte transplantation is the possibility of avoiding 
life-long immunosuppressive drugs, although the use of such drugs at the time of 
transplantation may be sufficient to reduce initial clearance of transplanted cells, with 
subsequent withdrawal of immunosuppression once engraftment is established.  Further 
research into the mechanisms of hepatic recruitment and activation of neutrophils and 
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Kupffer cells in the context of hepatocyte transplantation may allow the development of a 
more targeted intervention.  
In addition to activation of the innate immune response, transplant of allogeneic 
hepatocytes leads to activation of the adaptive immune system.  Animal studies suggest 
that this is mediated by CD4+ and CD8+ T cells, and that either of these can independently 
initiate an immune reaction (Bumgardner et al. 1999).  The T cell response following 
hepatocyte transplantation does not appear to depend on the CD28/B7 and CD40/CD154 
co-stimulatory pathways which are known to be important in the activation of T cells after 
other allogeneic transplants.  In animal studies, blocking the CD28/B7 pathway did not 
lead to increased survival of hepatocellular allografts.  Blockade of the CD40/CD154 
system, or both together merely increased the time to rejection (Bumgardner and Orosz 
2000) despite the fact that such treatments can result in indefinite survival of other 
allografts such as cardiac or skin (Larsen et al. 1996).  It appears instead that ICAM-
1/LFA-1 interactions are involved.  Blocking this and the CD40/CD154 pathways together 
can result in the survival of transplanted hepatocytes in 100% of treated mice at 60 days 
(Wang et al. 2003).  This could suggest a role for a NK cell mediated process as ICAM-
1/LFA-1 interactions are crucial for NK adhesion to target cells with subsequent activation 
and polarisation of cytotlytic granules (Barber et al. 2004;Gross et al. 2010). 
The differences in the adaptive immune response to transplanted hepatocytes compared to 
other allografts highlight an important area for further research.  The development of 
immunosuppressive treatments targeting this unusual pathway may be critical to reduce the 
hepatocyte rejection although it is likely that manipulation of both the innate and adaptive 
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immune responses will be required to maximise the survival of allogeneic hepatocytes 
(Han et al. 2009). 
1.5 Animal Models of Hepatocyte Transplantation 
Experimental animals that have been humanized by engraftment of human tissue provide 
an opportunity for in vivo study of biological processes that would not otherwise be 
possible (Shultz et al. 2007).  However, the study of human hepatocyte engraftment in 
particular has been limited by the lack of suitable animal models until relatively recently.  
As reviewed below there are differing requirements for animal models to facilitate human 
xeno-transplantation 
In order for the donor hepatocytes to engraft and expand within the recipient liver an 
environment that is permissive to these processes must be provided.  If cells are to be 
transplanted between species, some way of avoiding immune rejection is also required.  
These conditions are usually achieved by using an immunocompromised animal with a 
coexistent severe liver disease.  Until recently most groups have used some form of alb-
uPA mouse.  In many studies, hepatocytes have been transplanted from one animal to 
another of the same species reducing the problem of immune rejection.  However, in this 
situation a means of differentiating donor from recipient hepatocytes is required.  Here, the 
DPPIV- rat has been widely used.   
More recently, other strains of mice have been developed to get round the problems 
associated with the uPA mouse whilst allowing the transplantation of human hepatocytes.  
These include the model described by Krishnan et al (Krishnan et al. 2007) in which they 
successfully transplanted human hepatocytes into non-immunocompromised mice.  This 
32 
 
group developed mice transgenic for the deleted form of human HGF (dHGF).  Human 
albumin levels increased and peaked post-transplant demonstrating sustained engraftment 
in six out of nine transgenic mice.  All six non-transgenic mice showed declining levels of 
human albumin post-transplant with no evidence of engraftment.  Perhaps one of the most 
promising models, however, is the FRG mouse.  These models are described in more detail 
below. 
1.5.1 The uPA mouse 
This transgenic mouse, originally developed to study bleeding disorders (Heckel et al. 
1990), contains an additional copy of urokinase type plasminogen activator (uPA) genes 
under the control of an albumin promoter.  This leads to hypofibrinogenaemia and death 
due to haemorrhage or liver failure.   
The alb-uPA mouse has been combined with several types of immunocompromised mouse 
such as the severe combined immunodeficient (SCID) mouse, the recombination activating 
gene knockout mouse (Rag2-/-) which is depleted of mature B and T lymphocytes or the 
IL-2 receptor common γ-chain knockout mouse (Il2rg-/-) which has impaired B and T cell 
development and a complete lack of NK cell development (DiSanto et al. 1995).  This 
allows for the study of treatment of liver failure in the absence of immune components.    
Reasonable success rates in terms of engraftment levels have been reported following 
hepatocyte transplantation into these animals.  However, uPA mice are problematic to 
work with because there is a narrow time window after birth for transplantation, they are 
difficult to breed and maintain and serial transplantation is not possible (Shafritz 2007).  
Other problems include damage to other organs, particularly the kidneys, which limits long 
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term survival.  This is thought to be related to the production of human complement by 
human hepatocyte repopulated livers (Tateno et al. 2004). 
1.5.2 The DPPIV- rat 
Many of the mechanisms affecting hepatocyte engraftment which have been described in 
this chapter have been investigated using this model.  These rats are a sub-strain of the 
Fischer 344 rat which is deficient in dipeptidyl peptidase IV (DPPIV).  These have proved 
useful hosts for syngeneic transplantation of hepatocytes from DPPIV + rats.  DPPIV 
expression is stable in the transplanted cells allowing them to be easily distinguished from 
the recipient tissue (Thompson et al. 1991). 
1.5.3 FRG mice 
Several groups have used strains of mice deficient in fumarylacetoacetate hydrolase (Fah).  
Fah is an enzyme involved in the tyrosine catabolism pathway.  Its deficiency (type 1 
tyrosinaemia in humans) leads to accumulation of toxic tyrosine metabolites leading to 
severe liver failure.  The administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-
cyclohexanedione (NTBC) inhibits an enzyme upstream in the tyrosine pathway and limits 
the production of these metabolites.  Therefore the timing of liver injury can be 
manipulated and successful engraftment of functioning hepatocytes can be demonstrated 
by the ability to subsequently withdraw treatment with no weight loss or other ill effect for 
the mice. 
Azuma et al (Azuma et al. 2007) attempted to transplant human hepatocytes into Fah-/-
/Rag2-/-/Il2rg-/- (FRG) mice treated with NTBC but were not able to demonstrate 
engraftment in any mice unless they were pre-treated with uPA adenovirus.  However, in 
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mice that had first received uPA adenovirus successful engraftment was achieved and in 
highly engrafted mice (>30% repopulation) their weight stabilised following withdrawal of 
NTBC after two rounds of treatment.  This suggested that transplanted hepatocytes were 
functional and this was confirmed by measuring Fah enzyme activity.  Furthermore it was 
demonstrated that up to four rounds of serial transplantation was feasible.  Bissig et al 
(Bissig et al. 2007) went on to develop a similar model using FRG mice but avoiding the 
need for uPA expression and adenoviral vectors.  Instead they administered intraperitoneal 
nafamostat mesilate, a protease inhibitor, to block the complement system.  In addition 
mice were treated with liposomal clodronate which depletes Kupffer cells. 
There are several advantages of the Fah model over others.  Grompe et al (Grompe et al. 
1995) showed that NTBC abolished neonatal lethality in Fah deficient mice and that the 
extent of liver disease can be controlled by administering and withdrawing NTBC.  The 
mutation in Fah deficient mice is a deletion and so there is no possibility of reversion to 
wild-type by transgene inactivation (Grompe et al. 1993).  Fah deficient mice are easier to 
care for, there is no time limit for transplantation and serial transplantation is possible.  
The use of antibodies to FAH, which is present in the donor human hepatocytes, provides a 
way to readily distinguish transplanted cells from the host murine hepatocytes.  The 
disease caused by the knockout of the FAH gene is very similar to the human form of 
tyrosinaemia which is perhaps one of the likely targets for hepatocyte transplantation in 
humans.  These mice could therefore prove much more useful as a model for hepatocyte 
transplantation and experiments using human hepatocytes and so I initially planned to use 
this model in this investigation. 
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1.5.4 C57BL/6 mice 
The C57BL/6 mouse is an inbred strain of laboratory mouse and is one of the most widely 
used backgrounds for genetically modified mice in the study of human disease (Mekada et 
al. 2009).  It has been used extensively in the study of hepatocyte transplantation 
(Bumgardner et al. 1998;Ponder et al. 1991;Wu et al. 2008) and has been used as a 
background for the generation of FRG mice.  The C57BL/6 mouse has been used with a 
carbon tetrachloride (CCl4) liver injury model by our group and others for the study of 
various types of cell transplantation (Aldridge et al. 2012;Guo et al. 2002;Manuelpillai et 
al. 2012;Zhang et al. 2011).  Wildtype C57BL/6 mice are relatively straight forward to 
care for and lack the complexity of genetic knockout mice.  The CCl4 liver injury model 
provides a model of liver fibrosis/cirrhosis thus allowing the investigation of cellular 
transplantation in the context of diseased liver.  Furthermore, the use of CCl4 provides a 
regeneration stimulus with a selective advantage for transplanted cells to 
proliferate/survive (Oertel and Shafritz 2008). 
1.6 Outline of the Project 
Liver failure represents a high burden of disease and the demand for OLT is increasingly 
greater than the available supply of donor organs.  Alternatives to OLT are therefore 
urgently required.  Hepatocyte transplantation is one such alternative but, despite 
promising results from early laboratory and clinical studies, the long term benefit remains 
limited.  One reason for the lack of sustained clinical benefit appears to be the failure of 
engraftment of transplanted cells in sufficient quantity. 
I am interested in the molecular mechanisms underlying the interaction between 
transplanted hepatocytes and hepatic sinusoidal endothelial cells within the liver sinusoids 
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and how such interactions modulate the engraftment of transplanted hepatocytes into the 
host liver.   
 
The principle aims of my thesis were to: 
1. Optimise a protocol to isolate primary human hepatocytes within the laboratory 
from normal and diseased liver tissue; 
2. Characterise the adhesion molecule and chemokine receptor expression of primary 
human hepatocytes; 
3. Investigate the role of adhesion molecules expressed by primary human 
hepatocytes in regulating adhesion to hepatic sinusoidal endothelium in vitro using 
static and flow-based adhesion assays; 
4. Augment engraftment in vivo by manipulating mechanisms identified in vitro using 
a murine model of hepatocyte transplantation.    
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CHAPTER 2:  METHODS AND MATERIALS 
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2.1 Isolation and Culture of Cells from Human Liver Tissue 
2.1.1 Ethical approval 
All human liver tissue was obtained from Queen Elizabeth Hospital Birmingham or 
Birmingham Children’s Hospital with full approval of the Local Research Ethics 
Committee (reference number 06/Q702/61).  Liver specimens were obtained from liver 
resections, whole explanted livers or donor liver which was either surplus to surgical 
requirements or unsuitable for transplantation.  Written informed consent was obtained 
from all patients or their families.   
2.1.2 Preparation of human tissue 
Cells were isolated from explanted diseased livers from patients with ALD, PBC and PSC 
as well as a variety of other end-stage liver diseases.  Cells were also isolated from tissue 
taken from patients undergoing resection of colorectal cancer liver metastases or benign 
disease such as recurrent cholangitis, focal nodular hyperplasia (FNH) and haemangiomas.  
Donor liver tissue which was surplus to surgical requirements or unsuitable for 
transplantation due to prolonged ischaemic times was also used. 
Following explantation or resection, liver tissue was placed in a sterile bag on ice and 
transported to the laboratory for processing as soon as possible, usually within 1 hour.  
Exceptions to this were when liver tissue became available during late evening or at night, 
in which case specimens were kept sterile on ice and processed immediately the next 
morning.  Another exception was in the case of donor liver tissue; in all cases this was 
initially brought back from the retrieval centre to Queen Elizabeth Hospital or Birmingham 
Children’s Hospital where it was assessed by the transplant team.  The liver was 
maintained in a sterile environment on ice at all times.  If deemed unsuitable for 
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transplantation or surplus to requirements it was then transported to the laboratory for 
processing.   
Liver wedges or slices were cut by a trained pathologist and stored in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Invitrogen Life Sciences, Paisley, UK) at 4°C prior to use.  
Tissue for hepatocyte isolation was generally taken from segments II/III, V/VI, or VII/VIII 
in order provide a wedge of tissue with an intact Glisson’s Capsule except for one cut 
surface.  Tissue was only used for cell isolation if there was no indication of tumour or 
other suspicious lesion in that part of the liver after inspection by the pathologist  in 
conjunction with available preoperative imaging.   
2.1.3 Isolation and culture of primary human hepatocytes 
All tissue culture, cell isolation and preparation of media were carried out in a class II 
biological safety cabinet using aseptic technique. 
2.1.3.1 Preparation of hepatocyte culture medium 
A supplemented serum-free medium based on that developed by Pichard et al. (Pichard et 
al. 2006) was prepared for the culture of hepatocytes after initial plating.  This medium has 
been shown to maintain a hepatocyte phenotype for several weeks. 
Briefly, 500ml Williams E was supplemented with the following (all from Sigma-Aldrich, 
Dorset, UK unless stated otherwise): 
1. 0.02% w/v albumin from bovine serum fraction V 
2. 2µl linoleic acid  
3. 2µl linolenic acid  
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4. 110 units insulin (Invitrogen Life Sciences) 
5. 2.75mg transferrin (Invitrogen Life Sciences) 
6. 3.35µg selenium (Invitrogen Life Sciences) 
7. 20µg dexamethasone  
8. 10µg liver growth factor  
9. 1.225mg cyclic-AMP  
10.  5 international units prolactin  
11.  30ng ethanolamine  
12.  500µg glucagon  
13.  25µg epidermal growth factor  
14.  5 ml penicillin/streptomycin/glutamine solution (PSG, 10000 units/ml penicillin,   
10mg/ml streptomycin, 200mM L-glutamine, Invitrogen Life Sciences) 
15.  1.5ml fungizone solution (Invitrogen Life Sciences) 
The mix of additives was prepared in advance, made up to 25 ml aliquots with Williams E 
medium and stored at -80°C until use. 
2.1.3.2 Preparation of the liver wedge for perfusion 
After cutting, the liver wedge was manually washed through via the exposed vessels on the 
cut surface with cold (4°C) DMEM using a 20ml syringe.  This was to remove any 
remaining blood and to identify two suitable vessels for subsequent perfusion.  The two 
vessels were chosen such as to be of sufficient size for cannulation and to provide 
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maximum perfusion of the wedge.  The latter criterion was judged by observation and 
palpation of the wedge, as well as the ease of perfusion, while perfusing through all the 
available vessels of sufficient size.  Any major vessels not to be used for perfusion were 
oversewn in order to minimise loss of fluids and maintain pressure within the wedge thus 
optimising perfusion.  Two 18 or 20 gauge cannulae (Becton-Dickinson, Oxford, UK) 
were then secured in the chosen vessels and secured by means of a purse string suture 
placed prior to insertion of the cannula (Figure 2.1). 
2.1.3.3 Preparation of perfusion buffers 
Hepatocyte isolations were performed using a modified two-stage collagenase perfusion 
technique originally described in 1969 for the isolation of rat hepatocytes (Berry and 
Friend 1969).  This has since been modified by a number of groups for the isolation of 
human cells (Dorko et al. 1994;Mitry et al. 2003;Pichard et al. 2006). 
The following buffers were prepared in advance using Hank’s Balanced Salt Solution 
without Calcium/Magnesium (HBSS, Invitrogen Life Sciences). 
1. Wash buffer – 500ml HBSS + 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Sigma-Aldrich), pH 7.2. 
2. Chelating buffer – 500ml HBSS + 10mM HEPES, 0.5mM ethylene glycol-bis(2-
aminoethylether)-N,N,N,N-tetraacetic acid (EGTA) (Sigma-Aldrich), pH 7.2. 
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Figure 2.1 Preparation of a liver wedge for hepatocyte isolation 
The photograph shows a liver wedge prepared for perfusion.  The cut surface is shown 
with 2 cannulae inserted into separate vessels and held by means of a purse string suture.  
Several smaller vessels have been oversewn to prevent leakage of the perfusate. 
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Finally, an enzymatic dissociation buffer was prepared immediately prior to use once 
perfusion of the wash buffer had commenced.  The following enzymes were used: 
1. 0.5% w/v Collagenase A (from Clostridium histolyticum, Roche, West Sussex, 
UK) 
2. 0.25% w/v Protease (Dispase® II neutral protease from Bacillus polymyxa, Roche) 
3. 0.125% w/v Hyaluronidase (from bovine testes, Sigma-Aldrich) 
4. 0.05% w/v DNase I (from bovine pancreas, Roche) 
Aliquots of enzymes were removed from storage at -20°C and dissolved in HBSS.  The 
solution was then sterile-filtered using a 0.22μm filter (Millex® Syringe-driven Filter Unit, 
Millipore, Watford, UK) and made up with HBSS to a final volume of 300ml.  This was 
then supplemented with 5mM calcium chloride and 5mM magnesium chloride (both from 
Sigma-Aldrich). 
All buffers were pre-warmed to 37°C in a water bath (Grant Instruments, Cambridgeshire, 
UK) prior to use. 
2.1.3.4 Liver perfusion and isolation of cells 
The liver was placed on a plastic funnel covered with a mesh, which in turn was supported 
over a collection vessel.  Independent perfusion and waste circuits were set up using two 
sets of tubing and a peristaltic pump (Model IP 505DU, Watson-Marlow Ltd, Falmouth, 
UK).  Initially one end of the perfusion tube was placed into the warmed buffer and led via 
the pump to a `y’ connector dividing the tube into two.  These two outlets were connected 
to the cannulae previously inserted into the liver wedge.  One end of the waste tube was 
placed into the collection vessel and led via the pump to a waste vessel (Figure 2.2). 
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Perfusion commenced with 500ml wash buffer at a flow rate of 75ml/min in a non-
recirculating fashion.  This began the warming of the liver to the optimal temperature for 
enzymatic dissociation and ensured that any remaining blood remaining within the 
vasculature was washed out.  Following this, the liver was perfused with 500ml EGTA 
chelating buffer (non-recirculating) in order to disrupt cell-cell and cell-extracellular 
matrix adhesions.  The liver was then perfused with a further 500ml wash buffer in order 
to remove any remaining EGTA which would otherwise inhibit the action of the enzymes 
which require the presence of calcium and magnesium.  The enzyme buffer was then 
placed into the collection vessel beneath the liver, having first removed any remaining 
fluid from the previous buffers.  The waste tubing was clamped and the intake end of the 
perfusion tubing was placed in the collection vessel thus allowing the enzyme buffer to be 
recirculated through the liver.  The liver was then perfused with the recirculating enzyme 
solution using a flow rate of 75ml/min until adequate digestion was achieved.  During this 
time the appearance and texture of the liver was monitored closely.  Perfusion was stopped 
once a digit could be inserted into the liver with minimal force. 
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Figure 2.2 Perfusion of a liver wedge 
The photograph shows a liver wedge connected to the perfusion circuit inside a tissue 
culture hood.  It is being perfused with wash buffer (HBSS + 10mM HEPES) contained in 
the bottle to the right.  The clear tubing from the bottle leads to a pump which delivers 
the wash buffer to the liver wedge via the two cannulae.  The liver is placed upon a sterile 
mesh through which the perfusate drains into the container below where it is pumped to 
waste via the red tube   
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Once perfusion was complete, the cannulae were removed and the liver was placed in cold 
(4°C) DMEM supplemented with 10% v/v heat inactivated foetal calf serum (FCS, 
Invitrogen Life Sciences) and 1% v/v PSG solution in a sterile glass dish.  The liver was 
manually dissociated and the resulting suspension passed through a 250µm followed by 
63µm sterile nylon mesh (John Staniar & Co, Manchester, UK).  The cell suspension was 
then washed three times and the hepatocytes pelleted using low-speed centrifugation (50 × 
g for 5 minutes at 4°C) in supplemented DMEM. 
Cell viability was determined by trypan blue dye (Sigma-Aldrich) exclusion.  If the 
viability was low but the total cell yield was sufficiently high a density gradient 
centrifugation step was performed to improve the yield of viable cells.  An isotonic stock 
solution of Percoll® (GE Healthcare, Buckinghamshire, UK) was prepared by adding 
11ml 10× phosphate buffered saline (PBS) to 99ml Percoll®.  A 30% isotonic Percoll® 
solution was then prepared by combining 15ml stock Percoll® with 35 ml supplemented 
DMEM containing the hepatocytes and centrifuged at 300 × g for 30 minutes at room 
temperature.  Viable hepatocytes are pelleted at the bottom of the tube whilst non-viable 
cells form a layer at the surface and can be easily discarded. 
2.1.3.5 Culture of primary human hepatocytes 
Hepatocytes were plated in Williams E media (Sigma-Aldrich) supplemented with 10% 
v/v FCS and 1% v/v PSG.  Cells were seeded on type I rat tail collagen coated 24 well 
plates (5 × 10
5
 cells/well) or flasks and allowed to adhere for 3 hours.  Seeding density was 
selected to ensure a confluent monolayer.  After this period the media was changed to 
hepatocyte culture medium.  Cells were maintained at 37°C in a humidified 5% CO2 
incubator.  Media was replaced every 24 hours.  For experiments, cells were removed from 
plates/flasks by treating with trypsin/EDTA (Trypsin, 0.05% (1×) with EDTA, Invitrogen 
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Life Sciences) for 2 minutes having removed the media.  Once the cells had detached, the 
media was replaced and the cells washed in PBS at 2000 rpm for 5 minutes. 
2.1.4 Isolation and culture of human hepatic sinusoidal endothelial cells 
All tissue culture, cell isolation and preparation of media was carried out in a class II 
biological safety cabinet using aseptic technique. 
2.1.4.1 Preparation of endothelial culture media 
HSEC were cultured in basal endothelial media (BEM, Invitrogen Life Sciences) 
supplemented with 10% v/v heat inactivated human serum (PAA Laboratories GmbH, 
Pasching, Austria), 1% v/v PSG, 10ng/ml hepatocyte growth factor and 10ng/ml vascular 
endothelial growth factor (both from PeproTech EC Ltd, London, UK). 
2.1.4.2 Isolation of human hepatic sinusoidal endothelial cells 
Slices of liver tissue were placed on a sterile plate and finely chopped using a scalpel.  The 
liver was then placed in a sterile beaker with 20ml PBS and left to digest at 37°C for 30-45 
minutes depending on the texture of the liver.  The resulting digest was then strained 
through a 63µm sterile nylon mesh (John Staniar & Co) mesh and washed four times at 
2000 rpm for 5 minutes in PBS.  After washing the cells were re-suspended in 24ml PBS.  
Percoll® density gradients were prepared as follows: an isotonic stock solution was 
prepared by adding 11ml 10× PBS to 99ml Percoll®; 33% Percoll® was prepared by 
adding 33ml stock to 67ml 1× PBS and 77% Percoll® was prepared by adding 77ml stock 
to 23ml 1× PBS.  3ml 77% Percoll® was layered beneath 3ml 33% Percoll® in each of 8 
15ml conical bottom tubes.  3ml of the cell suspension was then layered onto each of the 
Percoll® gradients and centrifuged at 2000rpm for 25 minutes.  The non-parenchymal cell 
layer was then removed and washed three times in PBS.  The heterogeneous cell 
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suspension was then purified using immunomagnetic selection in order to remove 
contaminating biliary epithelial cells (BEC).  Cells were resuspended in PBS and 
incubated with 10µg/ml mouse anti-human HEA 125 monoclonal antibody (mAb) (Progen 
Biotechnik, Heidelberg, Germany) for 30 minutes at 37°C.  Following washing in PBS, 
cells were re-suspended in cold PBS and incubated with 10µl secondary antibody coated 
magnetic beads (Dynabeads® Sheep-anti Mouse IgG, Invitrogen Life Sciences) at 4°C for 
30 minutes.  BEC were then removed using magnetic selection.  HSEC were then 
positively selected by incubating the remaining cell suspension with 10µl CD31 mAb-
coated magnetic beads (Dynabeads® CD31 Endothelial Cell, Invitrogen Life Sciences) for 
30 minutes at 4°C followed by magnetic selection. 
2.1.4.3 Culture of human sinusoidal endothelial cells 
After isolation, HSEC were cultured in supplemented BEM in 25cm
2
 type I rat tail 
collagen coated flasks.  Cells were maintained at 37°C in a humidified 5% CO2 incubator 
and media was changed every 48 hours.  Once the cells formed a confluent monolayer they 
were transferred to a 75cm
2
 flask.  The media was removed and the cells treated with a 
trypsin replacement enzyme (TrypLE™ Express, Invitrogen Life Sciences).  Once the cells 
were released, media was replaced and the cell suspension washed in PBS at 2000 rpm for 
5 minutes.  The pellet was then re suspended in HSEC media and the cells seeded into a 
75cm
2
 flask.  Cells were then maintained as before and passaged once they became 
confluent using the same procedure and splitting the resulting cell suspension 1:2 or 1:3 
depending on the size of the pellet into further 75cm
2
 flasks.  Cells were used for 
experiments between passage 2 and passage 6. 
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2.2 Culture of Hepatoma Cell Lines 
Huh7.5 cells were a kind gift from Professor Jane McKeating’s group at the Centre for 
Liver Research, University of Birmingham, UK.  HepG2 cells were purchased from ATCC 
(LGC Standards, Teddington, Middlesex, UK).  Cells were maintained in DMEM 
supplemented with 10% v/v FCS, 1% v/v PSG and 1% v/v non-essential amino acids 
(Sigma-Aldrich) in uncoated 75cm
2
 flasks and maintained in a humidified incubator at 
37ºC in 5% CO2.  Cells were passaged once a confluent monolayer was formed.  Media 
was removed and the cells were treated with TrypLE™ Express.  Once the cells were 
released, media was replaced and the cell suspension washed in PBS at 2000 rpm for 5 
minutes.  The pellet was then re-suspended in supplemented DMEM and the cells split 
between 1:3 and 1:8 depending on requirements into further 75cm
2
 flasks.  All tissue 
culture was carried out in a class II biological safety cabinet using aseptic technique. 
2.3 Assessment of Hepatocyte Function 
Albumin and urea synthesis by primary human hepatocytes were used as basic markers of 
hepatocyte function in culture. 
2.3.1 Albumin synthesis 
Albumin synthesis by primary human hepatocytes in culture was confirmed by analysing 
samples of human hepatocyte culture supernatant using a sandwich ELISA kit (Abnova, 
CA, USA) according to the manufacturer’s instructions.  This assay employs a quantitative 
sandwich enzyme immunoassay technique that measures human albumin using a 96-well 
microplate that has been pre-coated with a polyclonal antibody specific for human 
albumin.  Albumin in standards and samples is sandwiched by the immobilized polyclonal 
antibody and a biotinylated polyclonal antibody specific for human albumin, which is 
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recognized by a streptavidin-peroxidase conjugate.  All unbound material is then washed 
away and a peroxidase enzyme substrate is added.  The colour development is stopped and 
the intensity of the colour is measured at 450nm.  Samples were analysed in triplicate and 
the albumin concentration was calculated with reference to a standard curve generated 
using known concentrations of human albumin. 
2.3.2 Urea synthesis 
Urea synthesis by primary human hepatocytes in culture was confirmed by analysing 
samples of human hepatocyte culture supernatant using a QuantiChrom™ Urea Assay Kit, 
(Bioassay Systems, Hayward, CA, USA) according to the manufacturer’s instructions.  
This kit uses a colorimetric quantitative urea determination method adapted from the 
method described by Jung et al (Jung et al. 1975).  A chromogenic reagent forms a 
coloured complex specifically with urea and the intensity of the colour, measured at 520 
nm, is directly proportional to the urea concentration in the sample.  Tissue culture 
supernatant samples were analysed in triplicate and urea concentration was determined 
with reference to a standard concentration using the following formula: 
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 − 𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
 × 𝑛 × [𝑆𝑇𝐷] (𝑚𝑔/𝑑𝑙) 
OD sample, OD blank and OD standard are the optical density values of the sample, 
water and standard respectively; n is the dilution factor; [STD] is 50 mg/dl. 
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2.4 Flow Cytometry 
2.4.1 Labelling of hepatocytes/hepatoma cell lines with antibodies for flow 
cytometry 
Cells were removed from flasks using TrypLE™ Express (cell lines) or trypsin/EDTA 
(primary hepatocytes) as previously described.  Cells were then washed in PBS at 900g for 
5 minutes and re-suspended at 1×10
6
 cells/ml in flow cytometry buffer (PBS supplemented 
with 2% v/v FCS).  100µl (1×10
5
 cells) were then transferred to FACS tubes (Becton-
Dickinson) and incubated with antibodies targeting adhesion molecules and chemokine 
receptors.  Isotype matched control antibodies were also used to determine background 
staining levels.  All antibodies were used at optimal concentrations recommended in the 
manufacturer’s datasheet and incubations were carried out for 30 minutes in the dark at 
4°C.  Details of primary, secondary and isotype matched control antibodies used for flow 
cytometry are shown in Table 2.1.  The cells were then washed twice (2000 rpm, 5 
minutes) to remove unbound antibody.  For antibodies that were not available directly 
conjugated to a fluorescent marker, the cells were then re-suspended in flow cytometry 
buffer and incubated with appropriate conjugated secondary antibody under the same 
conditions as above.  After washing, cells were re-suspended in 500µl flow cytometry 
buffer for analysis.  Data was collected using a CyAn-ADP (Dako Cytomation, UK) and 
analysed using Summit software (Dako Cytomation). 
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Antibody Clone Host Conjugation* Company 
α1-integrin TS2/7 Mouse RPE Serotec 
α2-integrin HAS3 Mouse PE R&D systems 
α3-integrin IA3 Mouse PE R&D systems 
α4-integrin 7.2R Mouse PE R&D systems 
α5-integrin SAM-1 Mouse Alexa Fluor 488 eBioscience 
α6-integrin 450-30A Mouse RPE Serotec 
α7-integrin Polyclonal Rabbit Unconjugated Abcam 
α8-integrin 481709 Mouse PE R&D systems 
α9β1-integrin Y9A2 Mouse Unconjugated Serotec 
α10-integrin Polyclonal Rabbit Unconjugated Millipore 
α11-integrin Polyclonal Rabbit Unconjugated Millipore 
αIIb-integrin M148 Mouse PE Abcam 
αL-integrin B-B15 Mouse PE Abcam 
αM-integrin 44aacb Mouse PE Abcam 
αV-integrin 13C2 Mouse PE Abcam 
αVβ3-integrin 23C6 Mouse PE R&D systems 
αVβ5-integrin P5H9 Mouse PE R&D systems 
αVβ6-integrin 10D5 Mouse Unconjugated Millipore 
β1-integrin P5D2 Mouse PE R&D systems 
β2-integrin 212701 Mouse PE R&D systems 
β3-integrin 256809 Mouse PE R&D systems 
β4-integrin 422325 Mouse Unconjugated R&D systems 
β7-integrin FIB504 Rat PE Abcam 
CCR1 53504 Mouse PE R&D systems 
CCR2 48607 Mouse PE R&D systems 
CCR3 61828 Rat PE R&D systems 
CCR4 205410 Mouse PE R&D systems 
CCR5 45531 Mouse PE R&D systems 
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CCR6 53103 Mouse PE R&D systems 
CCR7 150503 Mouse PE R&D systems 
CCR8 191704 Rat PE R&D systems 
CCR9 112509 Mouse PE R&D systems 
CCR10 314305 Rat PE R&D systems 
CXCR1 42705 Mouse PE R&D systems 
CXCR2 48311 Mouse PE R&D systems 
CXCR3 49801 Mouse PE R&D systems 
CXCR4 44717 Mouse PE R&D systems 
CXCR5 51505 Mouse PE R&D systems 
CXCR6 56811 Mouse PE R&D systems 
Goat anti Mouse IgG H+L Polyclonal Goat PE R&D systems 
Goat anti Rabbit IgG Polyclonal Goat FITC Abcam 
Mouse IgG1  11711 Mouse PE R&D systems 
Mouse IgG2a 20102 Mouse PE R&D systems 
Mouse IgG2b 133303 Mouse PE R&D systems 
Rat IgG2a 54447 Rat PE R&D systems 
Rat IgG2b 141945 Rat PE R&D systems 
Rabbit polyclonal IgG Polyclonal Rabbit Unconjugated Abcam 
 
Table 2.1 Antibodies used for flow cytometry 
The table lists the various primary, secondary and isotype matched control antibodies 
used for flow cytometry.  *RPE - R-phycoerythrin, PE – phycoerythrin, FITC - fluorescein 
isothiocyanate. 
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2.4.2 Labelling of hepatocytes/hepatoma cell lines with a viability marker 
for flow cytometry 
A far red viability marker (LIVE/DEAD® Fixable Far Red Dead Cell Stain Kit, Invitrogen 
Life Sciences) was used to exclude non-viable cells during flow cytometry.  This assay 
uses a dye which reacts with amines on the surface of viable cells and, due to the passage 
of the dye across the compromised membrane, internal as well as surface amines on 
necrotic cells.  This results in bright staining of non-viable cells and relatively dim staining 
of viable cells. 
Cells were removed from flasks using TrypLE™ Express (cell lines) or trypsin/EDTA 
(primary hepatocytes) as previously described.  Cells were then washed in PBS at 2000 
rpm for 5 minutes and re-suspended at 1×10
6
 cells/ml in PBS.  The fluorescent dye was 
prepared according to the manufacturer’s instructions.  The dye was then added to the cell 
suspension (1µl dye per 1ml cell suspension) and incubated on ice for 30 minutes in the 
dark.  The cells were then washed in PBS (2000 rpm for 5 minutes) and then re-suspended 
in flow cytometry buffer for further staining as previously described.  
2.5 RNA Extraction from Cells 
RNA was extracted from cells using a Quiagen RNeasy kit (Quiagen Ltd., Crawley, UK) 
according to the manufacturer’s protocol.  RNA purity was assessed using a Nanodrop 
spectrophotometer (Implen Geneflow).  Purity was assessed using 260/ 280 absorbance 
ratio to give an indication of protein contamination, and samples with a value less than 1.8 
were not used.  RNA was stored at -80°C until use. 
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2.6 Preparation of Cell Lysates 
Following experimental treatment, cells were washed twice in PBS for 5 minutes at 
2000rpm, resuspended in 200µl cell lysis buffer (CelLytic MT supplemented with Protease 
Inhibitor Cocktail, both from Sigma Aldrich) and incubated at 4°C with agitation for 15 
minutes.  The lysate was then centrifuged at 15,000g for 10 minutes at 4°C and the 
supernatant transferred to a cooled micro tube (Eppendorf, Cambridge, UK).  Lysates were 
stored at -80°C until use. 
2.7 Protein Determination Assay 
The protein concentration of cell lysates was determined using an assay based on the 
Sigma Total Protein Kit Micro Lowry, Onishi & Barr Modification (Sigma Aldrich).  A 
1mg/ml bovine serum albumin (BSA; Sigma Aldrich) solution in PBS was made and the 
following standard concentrations were produced using serial dilution: 1000µg/ml, 800 
µg/ml, 600 µg/ml, 400 µg/ml, 200 µg/ml, 0 µg/ml (PBS alone).  20µl BSA standards or 
lysate was added per well in a 96 well plate.  220µl Biuret reagent (Sigma Aldrich) was 
added per well and incubated for 10 minutes at room temperature.  10µl Folin & 
Ciocalteau’s Reagent was then added and incubated for 30 minutes at room temperature.  
The sample plate was then read at 750nm on a plate reader.  A calibration curve was 
plotted using the BSA standards and used to determine the protein concentration of the 
lysates. 
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2.8 Adhesion Molecule Gene Expression by Human Hepatocytes 
and Hepatocyte Cell Lines 
2.8.1 Preparation of cDNA 
RNA was extracted from cells as described above and cDNA was synthesised using an i-
script cDNA Synthesis Kit (Bio-Rad, Hertfordshire, UK) according to the manufacturer’s 
protocols.  Briefly, 4μl of 5x iScript reaction mix and 1μl iScript reverse transcriptase was 
added to a mixture to nuclease free water and RNA (0.25μg/μl) resulting in a reaction 
volume of 20μl in PCR tubes (Thermoscientific).  The complete reaction mixture was 
incubated in a PCR machine (Geneflow TC512) for 5 minutes at 25ºC, 30 minutes at 42ºC 
and 5 minutes at 85ºC.  The cDNA was then stored at -20ºC until use.  Control samples 
were prepared using water substituted for Reverse Transcriptase.   
2.8.2 18s PCR to test for RNA contamination of cDNA samples 
Reverse transcription was carried out using 18S rRNA primers (forward 
GTAACCCGTTGAACCCCATT; reverse CCATCCAATCGGTAGTAGCG) to assess integrity of 
cDNA and to identify any potential RNA contamination.  Hyperladder IV DNA ladder 
(Bioline, London, UK) was used as amplicon length marker.  1μl of cDNA or control 
samples was added to 1μl of ready mixed primers (Sigma), 3μl nuclease free water and 5μl 
of Biomix Red 2× PCR reaction mix (Bioline) in a PCR tube.  7μl of oil was layered over 
the samples to prevent loss of sample due to evaporation and the samples were subjected to 
PCR using the thermal profile shown in Table 2.2.  The PCR product for 18S rRNA was 
visualised on a 2% agarose gel stained with ethidium bromide (10mg/ml, Sigma) using 
standard protocols.  Briefly, 1.4g agarose was dissolved in 70ml 1×Tris-Borate 
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electrophoresis buffer (TBE) prepared using the following reagents (all from Sigma-
Aldrich) as 10×TBE in 1000ml nanopure water: 
: 
1. 0.89M Trisma base 
2. 0.89M Boric acid 
3. 0.5M EDTA disodium salt. 
2µl ethidium bromide was added and the gel allowed to set in a tray.  Samples were loaded 
alongside a lane of Hyperladder IV to indicate the size of the bands and run in 
electrophoresis buffer at 135V for 1 hour.  The gel was removed and photographed on a 
Genegenius Bioimaging System Imaging machine. 
2.8.3 Real time PCR 
Samples were loaded into a TaqMan Custom Array plate (Life Technologies Ltd, Paisley, 
UK) according to the manufacturer’s instructions and subjected to RT-PCR using an 
Applied Biosystems 7900HT Fast Real-Time PCR System (Life Technologies Ltd) and the 
data analysed using SDS software (Life Technologies Ltd). 
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 Temperature (ºC) Time (s) 
Initialisation 95 225 
Denaturing 95 45 
Annealing 55 45 
Extension 72 45 
 
Table 2.2 Thermal profile for 18s PCR 
18s PCR was carried out using the thermal profile detailed in the table (30 cycles) to 
check cDNA integrity and exclude RNA contamination. 
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2.9 Static Adhesion Assay 
2.9.1 Preparation of frozen liver tissue sections 
Tissue blocks were prepared from various types of liver tissue as detailed in 2.1.2.  The 
blocks were then snap-frozen in liquid nitrogen and stored at -80°C prior to sectioning.  
10µm thick sections were cut using a cryostat and placed onto glass microscope slices 
coated with 0.01% v/v poly-L-lysine (Sigma Aldrich) prepared in distilled water.  Sections 
were then fixed in acetone for 5 minutes and stored at -20°C prior to use. 
2.9.2 Stamper-Woodruff assay 
The adhesion of human hepatocytes and hepatoma cell lines to liver tissue was 
investigated using a static adhesion assay based on a technique originally described to 
study leukocyte adhesion (Stamper, Jr. and Woodruff 1976).  This technique has been 
modified in our lab to study the adhesion of various cell types to liver tissue. 
10 µm cryosections cut from human liver tissue were fixed in acetone for 5 minutes, air 
dried and wrapped in foil.  Sections were stored at -80ºC until required for adhesion 
assays.  Frozen liver tissue sections were removed from storage and allowed to warm to 
room temperature for 30 minutes before fixing in acetone for 5 minutes.  The slides were 
then labelled and the section marked circumferentially with a wax pen before being 
moistened with PBS.  The slides were then rested on glass rods on a tray lined with paper 
moistened with distilled water.  Cells were removed from culture, washed in PBS (2000 
rpm, 5 minutes) and resuspended in media.  Function-blocking antibodies or isotype 
matched controls (detailed in Table 2.3) were added and incubated for 30 minutes at 37°C.  
Following incubation the cells were washed again in PBS (2000 rpm, 5 minutes) and 
resuspended in PBS at 1×10
6
/ml.  100µl cell suspension (1×10
5
 cells) was added per 
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section and incubated statically at room temperature for 30 minutes.  The sections were 
then washed gently with PBS to remove non-adherent cells and fixed in acetone for 5 
minutes before washing twice with PBS for 5 minutes.  The sections were then stained 
with Mayers Haematoxylin (VWR International, Lutterworth, UK) for 30s and rinsed in 
tap water for 5 minutes.  Glass cover slips (Leica Microsystems, Milton Keynes, UK) were 
then mounted using Immu-Mount (Thermo Shandon, Runcorn, UK) and left to dry 
overnight.  Sections were then viewed using a light microscope and the number of 
adherent cells in 10 random fields of view was counted.  The total number of adherent 
cells was then expressed as the mean number of cells per high power field of view. 
2.10 Fluorometric ECM Component Adhesion Assay   
Huh 7.5 cells were prepared as for the Modified Stamper-Woodruff assay.  Binding to 
individual ECM components other than hyaluronic acid and VCAM was then assessed 
using an ECM Cell Adhesion Array Kit (Merck Millipore, Massachusetts, USA) according 
to the manufacturer’s instructions.  Briefly, 1×105 cells were added to pre-manufactured 
wells coated with ECM components that were included in the kit and incubated for 1 hour 
at 37ºC.  Wells were then washed to remove unbound cells before adding a lysis/dye 
buffer and incubating at room temperature until lysis was observed (around 20 minutes).  
The labelled cell lysates were then transferred to a new 96 well plate and analysed on a 
plate reader using 485/528nm filters on a plate reader.  Analysis of binding to hyaluronic 
acid and VCAM binding was performed in an identical manner using 96 well plates pre-
coated in the laboratory with hyaluronic acid (2.5mg/ml; Sigma Aldrich) or VCAM-1 
(10µg/ml; R&D Systems). 
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Antibody Clone Host Concentration Company 
β1-integrin P5D2 Mouse 10µg/ml R&D Systems 
α1-integrin 0.T.63 Mouse 10µg/ml Abcam 
αV-integrin 272-17E6 Mouse 10µg/ml Abcam 
Mouse IgG1 isotype control 11711 Mouse 10µg/ml R&D Systems 
Mouse IgG2a isotype control ICIGG2A Mouse 10µg/ml Abcam 
 
Table 2.3 Function blocking antibodies used in static and flow adhesion assays. 
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2.11  Flow Adhesion Assay 
2.11.1 Preparation of microslides 
Plastic multi-channel slides designed for the observation of cells under flow (μ-Slide VI; 
Ibidi GmbH, Martinsried, Germany) were coated with type I rat tail collagen for 2 hours 
and then washed with copious PBS.  HSEC were removed from culture using TrypLE™ 
Express, washed in PBS and resuspended in 400-600μl HSEC media depending on 
confluency.  30μl cell suspension was added to each of the 6 channels of the slide and the 
slide placed at 37°C in a humidified 5% CO2 incubator for 2 hours to allow the cells to 
adhere.  The media was then topped up as required and the cells maintained in the 
incubator until use. 
2.11.2 Stimulation of HSEC 
After 24 hours of culture, and 24 hours prior to the experiment, HSEC were treated with 
pro-inflammatory cytokines.  HSEC media was aspirated from each of the channels in the 
slide and replaced with new media supplemented with TNFα and IFNγ (PeproTech) at a 
concentration of 10ng/ml. 
2.11.3 Preparation of hepatocytes 
Primary human hepatocytes or Huh 7.5 cells were removed from culture as described 
above and incubated with blocking antibodies or isotype matched control (Table 2.3) in for 
1 hour at 37°C.  Cells were then washed and were resuspended in endothelial media 
supplemented with PSG and 0.1% v/v BSA immediately prior to the assay.  
2.11.4 Adhesion assay 
After treatment of the endothelium and/or hepatocytes the slide was placed on a 
microscope stage (Olympus IX50; Olympus, Southend-on-Sea, UK) within an enclosure 
63 
 
regulated at 37°C.  One end of the channel to be examined was connected to a syringe 
driver (Harvard PHD 2000; Harvard Apparatus, Massachusetts, USA) and the other to an 
electronic 2-way valve (Lee Products, Gerrards Cross, UK) using proprietary flow assay 
adaptors (μ-slide VI flow kit; Ibidi) extended with silicone tubing (Fisher Scientific, 
Loughborough, UK).  The syringe driver was set to reproduce a physiological shear stress 
similar to that found in the liver sinusoids of 0.5dynes/cm
2
 and the valve allowed 
switching between the cell suspension and wash buffer.  Wash buffer consisted of 
unsupplemented endothelial media. 
2.12 Hepatocyte Migration across HSEC 
A HSEC monolayer was prepared within a microslide and stimulated with pro-
inflammatory cytokines as described for the flow adhesion assay.  Huh 7.5 were incubated 
with an anti-β1-integrin blocking antibody or isotype matched control as previously 
described and flowed across the HSEC in an identical manner to the flow adhesion assay.  
After five minutes the flow was stopped and the cells were allowed to settle onto the 
HSEC monolayer.  The microslide was then transferred to a JuLi Smart Fluorescent Live 
Cell Imager (Bulldog Bio Inc., NY, USA) at 37°C in a humidified 5% CO2 incubator.  A 
representative field of view was selected and the imager was set up to record an image of 
the field of view once every 2 minutes for 4 hours.  The images were then combined as a 
movie and analysed using ImageJ (Schneider et al. 2012) and the number of Huh7.5 seen 
migrating into/through the HSEC layer was assessed by counting the absolute number of 
migrating cells in a single field of view. 
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2.13 Measurement of Hepatocyte Caspase 3 Activity by Cleaved 
Caspase 3 ELISA 
Cells were incubated in suspension with anti-β1-integrin blocking antibodies or isotype 
matched control for 1 hour at 37 °C.  Cell lysates were prepared and the protein 
concentration determined as previously described.  The protein concentration of the lysates 
was normalised to 1mg/ml and the assay performed according to the manufacturer’s 
instructions using a Pathscan® Cleaved Caspase-3 Sandwich ELISA Kit (Cell Signalling 
Technology, Danvers, USA).  Briefly, 100µl lysate was mixed with 100µl sample diluent 
and 100µl of the diluted lysate was added per well.  The plate was then incubated 
overnight at 4°C.  After washing, 100µl biotinylated caspase 3 rabbit detection antibody 
was added to each well and incubated for 1 hour at 37°C.  Following further washing, 
100µl horseradish peroxidase (HRP)-linked secondary antibody was added to each well 
and the plate incubated for 30 minutes at 37°C.  The plate was washed again and 100µl 
TMB substrate was added to each well and the plate incubated for 10 minutes at 37°C 
before adding 100µl STOP solution to each well.  The 450nm absorbance was then read on 
a plate reader. 
2.14 Assessment of AKT Phosphorylation in Hepatocytes by Western 
Blotting 
2.14.1 Incubation of cells and preparation of lysates 
Hepatocytes were removed from the culture flask using trypsin/EDTA as previously 
described and incubated with anti-β1-integrin blocking antibody or isotype matched 
control for 1 hour at 37°C.  Cell lysates were then prepared using CelLytic MT 
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supplemented with Protease Inhibitor Cocktail as described above.  Protein concentration 
was determined as described above and the concentration corrected to 2mg/ml. 
2.14.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and gel transfer  
An 11% SDS-PAGE gel was made as follows: 
1. 3.7ml nanopure water 
2. 3.7ml 30% (w/v) degassed acrylamide/bis-acrylamide solution (Sigma Aldrich) 
3. 2.5ml gel buffer* 
4. 10% w/v SDS (Sigma Aldrich) 
* Resolving gel buffer – 1.5M Tris(hydroxymethyl)aminomethane hydrochloride (Tris-
HCl; Sigma Aldrich), pH 8.8; stacking gel buffer – 0.5M Tris-HCl, pH 6.8. 
A solution of 10% w/v ammonium persulfate (APS; Sigma Aldrich) in water was 
prepared.  60µl APS and 60µl tetramethylethylenediamine (TEMED; Sigma Aldrich) were 
added to the resolving and stacking gel buffers immediately prior to pouring between gel 
plates. 
A 10× running buffer was made by dissolving the following in 1l nanopure water: 
1. 30.3g Tris-HCl 
2. 144g glycine (Sigma Aldrich) 
3. 10g SDS 
A transfer buffer was made by dissolving the following in 2l nanopure water: 
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1. 28.8g glycine 
2. 6.0g Tris-HCl 
3. 400ml methanol 
4. 1g SDS 
A 5× SDS loading buffer was prepared as follows: 
1. 200mM Tris-HCL solution pH6.8 
2. 20% v/v glycerol (Sigma Aldrich) 
3. 10% w/v SDS 
4. 0.05% w/v bromophenol blue (Sigma Aldrich) 
The gels were placed into PAGE tank with 1× running buffer.  5µl 5× loading buffer was 
added to 20µl of each sample as well as 10µl each of prestained molecular weight markers 
and biotinylated protein marker (both from Cell Signalling Technology)  in an Eppendorf 
and heated for 2 minutes before centrifuging a high speed for 1 minute.  20µl of each 
sample (or 10µl of marker) was then loaded per well and electrophoresis commenced at 
200V for 30 minutes or until the blue dye was near the bottom of the gel.  Gels were then 
transferred to a polyvinylidene difluoride (PVDF) membrane in transfer buffer at 100V for 
1 hour. 
2.14.3 Western blotting 
Western blotting was performed based on manufacturer’s instructions provided with the 
antibodies from Cell Signalling Technology.  A 10×Tris-buffered saline with Tween-20 
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(TBS/T) solution was prepared as 0.2M Tris base, 1.36M sodium chloride (NaCl), 1.0% 
Tween-20 in 1l nanopure water as follows: 
1. 24.2g Tris (Sigma Aldrich) 
2. 80g Sodium Chloride (Sigma Aldrich) 
3. pH adjusted to 7.6 with HC 
Following transfer, the PVDF membrane was washed with 25ml 1× TBS/T for 5 minutes 
at room temperature.  The membrane was then incubated with 10ml blocking buffer (1× 
TBS/T with 5% w/v non-fat dry milk; Marvel, Premier Foods, Hertfordshire, UK) for 2 
hours at room temperature and then washed 3 times for 5 minutes each with 15ml 1× 
TBS/T.  The membrane was next incubated with rabbit anti-human phospho-Akt (Ser473) 
antibody (Cell Signalling Technology) at a 1:1000 dilution in 10ml 1× TBS/T with 5% w/v 
BSA overnight at 4ºC with gentle agitation.  The membrane was further washed 3 times 
with 15ml 1× TBS/T and incubated with HRP-conjugated anti-rabbit IgG secondary 
antibody (1:2000 dilution) and HRP-conjugated anti-biotin antibody (1:1000 dilution)(both 
from Cell Signalling Technology) in 10ml blocking buffer for 1 hour at room temperature 
with gentle agitation.  Finally the membrane was washed three times as before and 
incubated with 10ml LumiGLO Substrate (Cell Signalling Technology) for 1 minute at 
room temperature with gentle agitation.  Excess LumiGLO Substrate was drained and the 
membrane covered with plastic wrap and exposed to x-ray film (Kodak, Rochester, NY, 
USA) for 5 minutes before developing using a Kodak X-Omat 1000 processor.  Images 
were scanned as grey-scale and saved as a TIFF file.  The gel analysis function in ImageJ 
was then used to perform densitometric analysis of bands. 
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2.15 Transfection of Huh 7.5 cells with GFP tagged vinculin and RFP 
tagged actin 
Plasmids containing green fluorescent protein (GFP) tagged vinculin and red fluorescent 
protein (RFP) tagged actin were prepared within our laboratory and were a generous gift 
from Dr Christopher Weston.  24 hours prior to transfection, Huh 7.5 cells were seeded 
into uncoated 6 well plates to achieve approximately 80% confluence on the day of 
transfection (30×10
4
 cells in 2ml media without penicillin/streptomycin per well).  The 
following day Huh 7.5 cells were transfected using Lipofectamine 2000 and Opti-MEM 
media (Life Technologies Ltd) according to the manufacturer’s instructions.  Cells were 
used for experimental purposes 48 hours after transfection. 
2.16 Live Cell Confocal Microscopy to Examine Cytoskeletal 
Rearrangement in Hepatocytes 
Huh 7.5 cells transfected with GFP tagged vinculin and RFP tagged actin were removed 
from the culture flask as previously described and incubated with anti-β1-integrin blocking 
antibody or isotype matched control.  Ibidi µ-slides were prepared as for the flow adhesion 
assays.  Huh7.5 cells were then flowed across the HSEC for 5 minutes and the flow was 
then stopped.  The slide was then transferred to a confocal microscope with a heated 
(37ºC)/5% CO2 stage (Zeiss LSM 780 Zen confocal) and z-stack images were obtained 
using a Plan-ACHROMAT 100x oil immersion objective lens. 
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2.17 Murine Models to Study Engraftment of Transplanted 
Hepatocytes  
2.17.1 C57BL/6 mice 
2.17.1.1 Maintenance of C57BL/6 mice 
C57BL/6 mice were purchased (Taconic, New York, USA) and housed at the University of 
Birmingham Biomedical Services Unit (BMSU).  Mice were maintained under standard 
animal welfare conditions.  Mice were used for experimental work at the age of 6-10 
weeks. 
2.17.1.2 Carbon tetrachloride liver injury model 
Carbon tetrachloride (CCl4) was diluted 1:4 in mineral oil (both from Sigma Aldrich).  6-
10 week old C57BL/6 mice received twice-weekly intraperitoneal injections (1µl/g 
equivalent to 250µl/kg CCl4).  Animals were monitored for any signs of ill health or 
distress and sacrificed using a schedule 1 method if required. 
2.17.1.3 Short term engraftment studies 
Primary human hepatocytes were incubated with blocking antibodies or IgG control as 
required before labelling with carboxyfluorescein succinimidyl ester (CFSE, Sigma 
Aldrich).  Cells were washed twice at 2000rpm for 5 minutes in PBS/0.1% (w/v) BSA and 
resuspended in 2ml.  A 10µM CFSE in PBS/0.1% BSA labelling solution was prepared 
and 2ml were added to the cell suspension to give a final labelling concentration of 5µM 
CFSE.  The solution was mixed gently and incubated at 37°C for 10 minutes in the dark.  
Following incubation, an excess of ice cold culture medium was added and the cells were 
washed three times at 2000 rpm for 5 minutes in cold medium.  The cell suspension was 
rested on ice in the dark for 5 minutes prior to the final wash in order to let un-
70 
 
incorporated CFSE diffuse out of the cells.  The cells were then resuspended at 1×10
7
 
cells/ml in PBS and kept on ice in the dark until use. 
Wild type or CCl4–treated C57BL/6 mice were anaesthetised in an anaesthetic chamber 
using 5% isoflurane with 1-2l/min oxygen.  The mice then received 0.05-0.1mg/kg 
buprenorphine by subcutaneous injection, the abdomen was shaved and the mouse placed 
on the operating table on a warming mat.  Anaesthesia was maintained using a face mask 
with 1.5-3% isoflurane as required and 1-2l/min oxygen.  Depth of anaesthesia was 
monitored by observation of respiratory rate and confirming a lack of response to 
stimulation, in particular the absence of the pedal withdrawal reflex.   
Surgery was performed using sterile technique.  The skin was prepared using Povidone-
Iodine and the mouse covered except for the operative site with a sterile drape.  A midline 
laparotomy was performed, the bowel retracted and the portal vein identified.  1×10
6
 cells 
(100µl of the cell suspension) were injected into the portal vein using a 30G needle (BD 
Microlance 3).  Bleeding from the vein was arrested with pressure using a cotton bud.  The 
mouse was kept under anaesthesia for 15 minutes from the time of injection and then 
culled by cervical dislocation.  The liver was immediately dissected, snap frozen in liquid 
nitrogen and stored at -80°C until processing.  The liver was then cryosectioned (5µm 
slices) and the number of fluorescent hepatocytes per field of view was counted in 40 
random fields of view spread across multiple sections taken from different parts of the 
liver. 
The short term engraftment studies were intended as preliminary studies that would lead 
on to longer-term engraftment models to be carried out in future work.  These experiments 
were designed to investigate a novel mechanism to improve hepatocyte engraftment and 
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there is little published literature in this area on which to base a likely or desired effect size 
and thus undertake a power calculation.  Furthermore, the experimental technique is 
technically challenging and represents a major insult for the mice undergoing surgery, with 
some inevitable loss of animals before completion of the procedure during preliminary 
work to refine the surgical technique of portal vein injection using saline only.  Because of 
this, and the fact that these procedures represented preliminary work only, it was decided 
in consultation with the Veterinary Surgeon and senior staff within the animal facility to 
initially perform 4 procedures on wild type mice and a further 4 procedures on CCl4 treated 
mice before reviewing the results and undertaking further procedures as necessary.  All but 
one of these experiments were successful, resulting in the animals surviving for 15 minutes 
until culling and subsequent demonstration of early hepatocyte engraftment within their 
livers.  One animal in the wild type group did not survive the 15 minute period following 
portal vein injection and was therefore excluded.  However, the data from the remaining 3 
animals revealed a significant effect and so no further procedures were peformed.  We felt 
that this approach was adequate for preliminary work and adhered to the 3 Rs 
(Replacement, Reduction, Refinement) approach to animal research. 
 
2.17.2 FRG mice 
2.17.2.1 Acquisition and breeding of FRG mice 
Two male FRG mice were kindly provided by Markus Grompe’s laboratory, Oregon 
Health and Science University, Oregon, USA.  Female Rag2/Il2rg double knockout mice 
were purchased (Taconic).  The male FRG mice were bred with the female Rag2/Il2rg 
mice by the BMSU, University of Birmingham.  Further breeding using homozygous and 
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heterozygous FRG mice was performed to establish a colony of homozygous triple 
knockout FRG mice. 
2.17.2.2 Genotyping of FRG mice 
DNA was extracted from mouse ear clippings.  Tissue was added to 100µl 50mM NaOH 
and heated to 95°C for 40 minutes with brief agitation after 20 minutes.  8µl 1M Tris-HCl 
(pH 8.0) was then added and the mixture agitated. 
The presence or absence of the FAH, RAG-2 or Il2rg genes was detected by polymerase 
chain reaction (PCR) amplification.  Details of the primers and PCR protocols used are 
shown in Table 2.4.  The PCR products were then subjected to 2% agarose gel 
electrophoresis at 124V for 40 minutes.  Hyperladder IV (Bioline) was used as a marker. 
2.17.2.3 Maintenance of FRG mice 
FRG mice were maintained in the BMSU under standard animal welfare conditions and 
allowed a normal diet with drinking water supplemented with NTBC.  Supplemented 
drinking water was prepared based on instructions provided by the Grompe laboratory.  A 
2mg/ml NTBC stock solution was prepared by dissolving 3g sodium bicarbonate (Sigma 
Aldrich) into 30 ml nanopure (Barnstead Nanopure Diamond, Barnstead International, 
Dubuque, USA) water by heating to 42°C with constant stirring for 2 hours.  The sodium 
bicarbonate solution was added to 220ml nanopure water with 500mg NTBC powder 
(Swedish Orphan Biovitrum, Stockholm, Sweden) and heated to 50°C for 3 hours with 
constant stirring.  The solution was then sterile filtered and stored refrigerated and 
protected from light for up to 3 months. 
To make NTBC drinking water, 250µl red food colouring (Sainsbury’s Supermarkets Ltd, 
London, UK) was added to 1l nanopure water and autoclaved.  The red food colouring was 
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added in order to differentiate the NTBC supplemented water from normal drinking water.  
The autoclaved water was refrigerated overnight before adding 8ml of the 2mg/ml NTBC 
stock solution.  The NTBC drinking water was then delivered to the BMSU where it was 
stored refrigerated and protected from light for up to 2 weeks.  
2.18 Statistical Analysis 
A two-tailed Student’s t-test (paired or unpaired as appropriate) was used to analyse data 
when comparing numerical variables between two groups unless otherwise stated.  All 
statistical analysis was performed using the GraphPad Prism software version 5.  Data 
were considered statistically significant when p<0.05.  Levels of significance were 
expressed as follows: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
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 FAH RAG-2 Il2rg 
Primers Mutant forward:  
GGATTGGGAAGACAATAGCAGGC 
Common Reverse: 
 TTGCCTCTGAACATAATGCCAAC 
Wild type forward: 
TGAGAGGAGGGTACTGGCAGCTAC 
Mutant forward: 
GTTGTGCCCAGTCATAGCCG 
Common Reverse: 
ATTTCAATCGTGTTGTCCCC 
Wild type forward: 
TAAGAGTGGACCTTCCCCTG 
Mutant reverse: 
CCTGCGTGCAATCCATCTTGTTCAAT 
Common forward: 
CTGCTCAGAATGCCTCCAATTCC 
Wild type reverse: 
GATCCAGATTGCCAAGGTGAGTAG 
Reaction 
Mix 
12.5µl 2× Biomix Red 
0.3µl each primer 
2.9µl water  
4µl DNA 
12.5µl 2× Biomix Red 
1.0µl each primer 
2.5µl water 
2µl DNA 
12.5µl 2× Biomix Red 
0.16µl common forward 
0.12µl mutant reverse 
0.24µl wild type reverse 
3.98µl water 
3µl DNA 
PCR  3’ at 94°C + 35×(30” at 94°C, 30” 
at 60°C, 1; at 72°C) + 7’ at 72°C 
5’ at 94°C + 35(45” at 94°C, 45” at 
58°C, 1’ at 72°C) + 5’ at 72°C 
3’ at 94°C + 35×(30” at 94°C, 30” at 
60°C, 1’ at 72°C) + 7’ at 72°C 
 
Table 2.4 Genotyping protocols for FRG mice 
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CHAPTER 3:  OPTIMISATION OF HEPATOCYTE ISOLATION 
FROM NORMAL AND DISEASED LIVERS 
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3.1 Introduction 
Hepatocytes are the major parenchymal cells in the liver and account for 70-80% of the 
total liver cell mass.  As well as being the major structural cells of the liver, hepatocytes 
also form the functional units for liver metabolism and regeneration (Si-Tayeb et al. 2010).  
It is becoming widely accepted that the majority of hepatocyte cell lines, while providing a 
valuable resource for preliminary studies, lack many important aspects of primary cell 
function.  Further, it is unlikely that such cells would be used in the therapeutic setting.  
Therefore the procurement of high quality viable hepatocytes is essential for a range of 
biomedical and pharmaceutical studies.  The use of primary human hepatocytes has gained 
increasing interest for drug development and drug toxicity studies (Li 2007) as well as the 
elucidation of underlying biochemical pathways in liver disease.  Cell therapy is an 
expanding area of research and the potential for primary human hepatocytes to support 
liver function through hepatocyte transplantation shows promise in laboratory and early 
clinical studies.  However, the isolation of human liver cells requires a carefully planned 
logistical network of surgeons, pathologists, technicians and biologists (Knobeloch et al. 
2012).  Furthermore, human liver tissue is a limited resource.  Most studies of hepatocyte 
isolation describe the use of surplus donor tissue made available through liver transplant 
programmes or normal tissue removed during resection of liver tumours (Alexandrova et 
al. 2005;Hughes et al. 2006;Kawahara et al. 2010;Li 2007;Vondran et al. 2008).  However, 
the majority of liver tissue available for research is from explanted diseased liver which 
yields much fewer viable cells.  A means of improving the outcome of hepatocyte isolation 
from diseased liver would allow better use to be made of available liver tissue increasing 
the pool of primary hepatocytes for research purposes.  
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The standard method of human hepatocyte isolation is based on a two-step collagenase 
digestion technique which was first described in 1969 by Berry and Friend for the isolation 
of rat hepatocytes (Berry and Friend 1969).  Several groups have since modified this 
technique for the isolation of human and other animal hepatocytes. 
The procedure involves the initial perfusion of the liver tissue with a warm buffer 
containing EGTA in order to loosen cell-cell junctions and to bring the liver to the 
optimum temperature for enzymatic digestion.  The second step is to perfuse the liver with 
an enzymatic solution containing collagenase to digest the liver parenchyma and release a 
single cell suspension.  Typically several other enzymes are added to this digestion buffer.  
Hyaluronidase is a polysaccharidase that breaks down hyaluronic acid which is found in 
high concentration in connective tissues and within the liver where it is synthesised mainly 
by hepatic stellate cells.  Hepatocytes are then be separated by low speed centrifugation 
which may be followed by a density gradient step to enrich for viable cells. 
3.1.1 Liberase 
Standard collagenase preparations are prepared from bacteria and consist of a mixture of 
collagenases with contaminating proteases, esterases and other enzymes with a somewhat 
variable composition that differs from lot to lot.  Liberase is a relatively new enzyme 
initially developed to improve the outcome of pancreatic islet isolation (Brandhorst et al. 
1999;Linetsky et al. 1995;Linetsky et al. 1997) and comprises purified high specific 
activity collagenases (clostridial collagenase I and collagenase II) blended with high 
specific activity neutral protease (dispase or thermolysin) in an optimal ratio.  Liberase 
blends are also xeno-free which is important for downstream applications.  Little has been 
published on the use of Liberase for human hepatocyte isolation, but it has been shown to 
improve the viability of isolated porcine hepatocytes compared to standard collagenase 
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(Donini et al. 2001).  Here I have investigated the use of Liberase in place of standard 
collagenase in the human hepatocyte isolation protocol in order to improve the outcome of 
human hepatocyte isolation. 
3.1.2 N-acetyl cysteine 
N-acetylcysteine (NAC) is an antioxidant which acts through the replenishment of hepatic 
glutathione stores as well as having direct antioxidant properties (Atkinson 2002) and 
appears to have hepatoprotective effects through a number of mechanisms (Zwingmann 
and Bilodeau 2006).  Animal data suggests that NAC may have a protective effect against 
liver ischaemia/reperfusion injury (Dunne et al. 1994;Fukuzawa et al. 1995;Fusai et al. 
2005) and the use of NAC has recently been shown to improve the viability of human 
hepatocytes isolated from steatotic liver (Sagias et al. 2010).   
Therefore in this chapter I firstly set out optimise human hepatocyte isolation from normal 
and diseased liver tissue for use in subsequent experiments.  The second aim was to 
investigate the effects of the use of Liberase and NAC on the outcome of human 
hepatocyte isolation. 
3.2 Results 
I initially re-established the standard human hepatocyte isolation procedure used 
previously in our laboratory using the collagenase digestion technique to isolate primary 
human hepatocytes.  I then attempted to combine the use of Liberase and NAC in order to 
improve the outcome of human hepatocyte isolation. 
3.2.1 Isolation of human hepatocytes from normal and diseased liver 
Human hepatocyte isolation was initially performed using a standard protocol which had 
been previously employed in our laboratory (Bhogal et al. 2011).  Subsequently, isolations 
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were performed using the modified protocol with the addition of NAC and the substitution 
of Liberase for standard collagenase. 
Hepatocytes were isolated from a variety of different liver diseases including ALD, PBC 
and PSC.  Hepatocytes were also isolated from resections for colorectal metastases (CRM) 
and various sources of normal liver tissue including hepatic resections for benign disease, 
surplus tissue from paediatric transplants (where a large liver may be `cut down’ to a more 
suitable size) and other unused donor tissue.  The latter was mostly obtained from organs 
rejected for transplant due to prolonged ischaemic times and/or extensive steatosis.  When 
preparing the tissue from CRM resections care was taken to keep well away from the 
tumour when taking the wedge for hepatocyte isolation.  Indeed, if there was any doubt as 
to the location of tumours following review of imaging and inspection of the resection then 
no wedge was taken for hepatocyte isolation.  The wedges obtained from CRM resections 
therefore consisted of `normal’ tissue; however as the vast majority of these patients had 
received chemotherapy prior to resection, this group will be considered separately in the 
subsequent analysis and will be described as `resected’.  All other normal tissue will be 
described as `normal’. 
Human hepatocytes were isolated from 65 livers altogether with an overall success rate, 
defined as maintenance of a cells as a confluent monolayer in culture for 48 hours, of 62%.  
Median viability was 60% (range 0-100%) with a median total cell yield of 35 ×10
6
 cells 
(range 0-638 ×10
6
 cells).  The outcome of hepatocyte isolation by liver type is summarised 
in Table 3.1. 
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Liver Type 
Weight of Wedge 
(g) 
Perfusion Time 
(minutes) 
Total Cell Yield 
(×106) 
Viability 
(%) 
Success Rate 
(%) 
Normal (n=17) 132 (56-437) 4 (1-10) 45 (5-638) 78 (0-100) 76 
ALD (n=15) 72 (50-486) 6 (3-11) 24 (0-148) 25 (0-95) 47 
Biliary cirrhosis 
(n=11) 83 (47-117) 5 (3-16) 21(12-283) 86 (5-100) 73 
Resected (n=10) 86 (38-123) 3 (2-3) 99 (18-438) 59 (0-93) 70 
Other (n=12) 78 (46-154) 6 (3-14) 36 (0-185) 19 (0-83) 42 
Total (n=65) 85 (38-486) 5 (1-16) 35 (0-638) 60 (0-100) 62 
 
Table 3.1 Outcome of human hepatocyte isolation from normal and diseased liver 
tissue. 
This table summarises the yield, viability and success rate obtained after hepatocyte 
isolation from various different types of liver tissue.  Data expressed as median (range).  
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3.2.2 Morphology of primary human hepatocytes in culture 
Primary human hepatocytes isolated from normal and diseased liver had a similar 
appearance to that previously reported by us and others (Bhogal et al. 2011;Laba et al. 
2005).  Figure 3.1 shows the morphology of hepatocytes isolated from normal liver tissue 
at different time points after isolation.  On initial plating cells appeared rounded and phase 
bright, but during the next 24 hours, cells gradually flattened out forming a confluent 
monolayer and demonstrating a typical cuboid or polygonal appearance with many cells 
being binucleate.  This morphology was maintained in culture for at least 1 week. 
3.2.3 Comparison of hepatocyte isolation using the original and new 
protocols 
Human hepatocytes were isolated from 30 consecutive liver specimens using the original 
protocol.  Hepatocytes were then isolated from a further 30 consecutive liver specimens in 
an identical manner except for the addition of NAC to the EGTA-containing buffer and the 
substitution of Liberase for standard collagenase (new protocol). 
The underlying disease of the tissues used for cell isolation is shown in Table 3.2 and 
included PBC or PSC, ALD, tissue removed during colorectal metastasis resection and 
normal or donor tissue.  A number of baseline factors related to the liver tissue used for 
isolation in the two groups are shown in Table 3.3.   
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Figure 3.1 Morphology of human hepatocytes isolated from liver tissue. 
Representative example of primary human hepatocytes isolated from normal donor liver 
tissue showing typical morphological changes: (a) 1 hour after plating the cells are 
rounded and phase bright; (b) after 48 hours a confluent monolayer has formed.  The 
hepatocytes have flattened out becoming phase dark.  The typical cuboid/polygonal 
appearance is seen with many cells possessing two nuclei. 
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These include patient age and gender, Model for End-Stage Liver Disease (MELD) and 
United Kingdom End-Stage Liver Disease (UKELD) scores, delay from the time of liver 
explant/resection (or, for donor/normal tissue, from the time that the liver arrived at Queen 
Elizabeth Hospital, Birmingham) until commencement of perfusion and the weight of the 
wedge used for isolation.  Of note there was no significant difference in either the disease 
category or any of the variables between the two groups, with the exception of time delay 
which was significantly longer in the original protocol group (median 4 hours vs. 2 hours, 
p=0.007). 
3.2.3.1 The effect of protocol modification on the perfusion time and 
Percoll use 
Although the isolation procedure itself remained unchanged other than the modifications 
being studied, the duration of perfusion (enzymatic digestion) and use of Percoll density 
gradient centrifugation varied depending on the nature of the particular liver specimen and 
the initial cell yield and viability as described above.  I therefore investigated the effect of 
the new protocol on these factors and the results are summarised in Table 3.4.  The new 
protocol necessitated a slightly longer perfusion time than the original protocol (median 
4.5 vs. 3.0 minutes, p=0.028).  However, there was no difference in the frequency with 
which the Percoll step was required (p=0.792).  Further, where Percoll was used, the initial 
cell yield prior to Percoll was similar with the new protocol compared to the original 
protocol (median 256×10
6
 vs. 275×10
6
, p=0.728) as was viability (median 19% vs. 18%, 
p=0.839), suggesting that the same criteria were applied for its use.
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Disease Original protocol New Protocol 
Biliary cirrhosis (primary biliary cirrhosis 
or primary sclerosing cholangitis 
5 7 
Alcoholic liver disease 6 8 
Resected tissue 6 4 
Normal 2 1 
Donor tissue 8 5 
Other 3 5 
 
Table 3.2 Source of liver tissue for human hepatocyte isolation. 
Liver tissue from a similar variety of diseases was used for hepatocyte isolation in each of 
the study groups with no significant difference in the range of diseases or number of 
samples between each group (p=0.77). 
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Factor Original protocol New Protocol p-value 
Age (Years) 57.5 (38.0 - 65.8) 56.5 (45.0 - 62.0) 0.997 
Gender (Male)# 18 (60.0%) 17 (56.7%) 0.600 
UKELD 56.5 (50.3 - 58.8) 54.5 (49.3 - 59.8) 0.494 
MELD 18.0 (12.8 - 21.3) 14.5 (9.3 - 19.0) 0.254 
Delay (Hours) 4.0 (2.0 - 19.0) 2.0 (1.0 - 3.0) 0.007* 
Weight Of Wedge (g) 83.5 (58.3 - 125.1) 88.7 (67.5 - 107.3) 0.502 
 
Table 3.3 Baseline factors of tissue used for human hepatocyte isolation.   
Data are displayed as median (quartiles) with p-values from Mann-Whitney Tests to 
compare protocols, unless stated otherwise.  Analyses were also repeated parametrically, 
where applicable, and returned comparable results.  #Data displayed as n (%) and p-
values from Fisher’s Exact Tests.  *Significant at p<0.05. 
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Factor Original Protocol New Protocol p-value# 
Perfusion Time (Min) 3.0 (2.5 - 6.1) 4.5 (4.0 - 6.0) 0.028* 
Percoll Used# 13 (43.3%) 11 (36.7%) 0.792 
Cell yield (×106)before Percoll 275 (77.5-474.8) 256 (115.0-317.5) 0.728 
Viability before Percoll 18% (11.3%-32.5%) 19% (13.0%-26.0%) 0.839 
 
Table 3.4 The effect of the isolation protocol on perfusion time and Percoll use.   
Data for perfusion time are displayed as median (quartiles) with p-values from Mann-
Whitney Tests to compare protocols, unless stated otherwise.  Analyses were also 
repeated parametrically and returned comparable results.  #Data displayed as n (%) and 
p-values from Fisher’s Exact Tests.  *Significant at p<0.05 
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3.2.3.2 The effect of protocol modification on the outcome of 
hepatocyte isolation 
The next stage was to compare a number of key outcomes between the two protocols.  For 
continuous variables, comparisons between the groups were performed using Mann-
Whitney tests, with Fisher’s Exact test used for binary outcomes.  In addition to this, the 
analyses were repeated using general linear models or binary logistic regression, as 
appropriate, in order to adjust the p-values to account for the fact that the delay differed 
significantly between protocols.  These results are summarised in Table 3.5.  Initial 
viability and cell yield (before Percoll) and final viability and cell yield (following Percoll 
where it was used) are reported.  No effect was found on the initial or final cell yield.  
However, the new protocol resulted in significant increases in both initial (p=0.007) and 
final (p=0.043) viability, with the median values rising from 10% to 25% and 48% to 70% 
respectively.  In addition to this, the final viable cell yield/g tissue showed a significant 
increase (p=0.003), with the median rising from 7.3x10
4
 in the original protocol to 
28.3x10
4
 in the new protocol.  Success rates also increased significantly (p=0.037), from 
12/30 (40.0%) under the original protocol, to 21/30 (70.0%) with the new protocol.  After 
adjustment to account for the difference in the average delay between the protocols, the 
effect of the protocol on final viability ceased to be significant (p=0.063).  However, all 
other variables found to be significant in univariate analysis remained so after adjustment 
for the delay.   
The effect of protocol modification on hepatocyte isolation from liver tissue of different 
disease types is summarised in Table 3.6.  There was an improvement in outcome for all 
liver tissue types but the greatest benefit was seen with ALD and resected liver tissue.  For 
ALD liver, the median final viable cell yield increased to 9.83 x10
4 
with the new protocol 
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from 0.26 x10
4 
with the old protocol (p=0.04).  The success rate also significantly 
improved to 63% using the new protocol whereas no isolations from ALD tissue 
performed using the old protocol resulting in maintenance of a confluent monolayer in 
culture for 48 hours (p=0.03).  For resected tissue, the median final viable cell yield 
increased to 61.88 x10
4 
with the new protocol from 9.48 x10
4 
with the old protocol 
(p=0.02).  The success rate increased from 33% to 100% although this did not reach 
statistical significance. 
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Factor Original Protocol New Protocol 
Unadjusted 
p-value# 
Adjusted 
p-value§ 
Initial Yield/g Tissue 
105.1 
(28.2 - 400.8) 
125.0 
(41.5 - 277.6) 
0.775 0.872 
Initial Viability 
10.0% 
(0.0% - 31.3%) 
25.0% 
(14.5% - 56.3%) 
0.007* 0.015* 
Final Cell Yield (x106) 
29.0 
(12.4 - 104) 
42.5 
(15.9 - 119.4) 
0.478 0.236 
Yield Cells/ 
g Tissue (x104) 
27.5 
(18.9 - 134.1) 
48.5 
(16.2 - 114.4) 
0.654 0.289 
Final Viability 
48.0% 
(0.0% - 80.0%) 
70.0% 
(23.2% - 83.1%) 
0.043* 0.063 
Final Viable Cell 
Yield 
/g Tissue (x104)  
7.3 
(0.0 - 20.5) 
28.3 
(8.2 - 70.2) 
0.003* 0.001* 
Success 
12 
(40.0%) 
21 
(70.0%) 
0.037* 0.014* 
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Table 3.5 The effect of protocol modification on initial (before Percoll) and final (after 
Percoll) cell yield and viability and overall success.   
Data are displayed as median (quartiles) for continuous variables, and n (%) for binary 
outcomes.  #p-value from a Mann-Whitney or Fisher’s Exact test for continuous and 
binary outcomes respectively.  §p-value from a General Linear Model or Binary Logistic 
Regression, for continuous and binary outcomes respectively, after adjustment for the 
effect of the time delay.  *Significant at p<0.05 
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Disease Type 
Final Viable Cell Yield/g Tissue (x104) Success 
Old Protocol New Protocol Old Protocol New Protocol 
ALD 
0.26 
(0.00-0.90) 
9.83* 
(3.51-31.61) 
0% 63%* 
Biliary Cirrhosis 
10.59 
(5.48-20.34) 
29.12 
(17.23-85.78) 
60% 71% 
Resected 
9.48 
(0.00-20.39) 
61.88* 
(52.26-97.54) 
33% 100% 
Normal/Donor 
11.52 
(4.88-24.76) 
16.57 
(9.31-38.55) 
60% 83% 
 
Table 3.6 The effect of the isolation protocol on the final viable cell yield and success 
rate of hepatocyte isolations from different types of liver tissue. 
Data are displayed as median (quartiles) for continuous variables.  *Significant at p<0.05. 
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3.2.3.3 The function of hepatocytes isolated using the original and new 
protocols 
Albumin and urea concentration were analysed in tissue culture supernatants from normal, 
PBC/PSC and ALD hepatocytes at days 1, 3, 5 and 7 in order to evaluate metabolic 
function of isolated hepatocytes.  Albumin synthesis by hepatocytes isolated from normal, 
PBC/PSC or ALD liver tissue using the modified protocol was maintained for at least 1 
week in culture (Figure 3.2).  Underlying liver disease was found to have a significant 
effect on albumin synthesis (p<0.001, Table 3.7) with synthesis by normal hepatocytes 
significantly higher than both ALD and PBC/PSC (both p<0.001).  There was no 
significant difference between the albumin measurements of ALD and PBC/PSC 
hepatocytes (p=0.187).   
I next compared albumin synthesis by hepatocytes isolated using the new and original 
protocols (Table 3.8).  There was no significant difference in albumin values for ALD 
tissue (p=0.053).  However, for the other two tissue types, significant changes were 
detected.  For hepatocytes isolated from normal tissue, the geometric mean albumin 
measurements increased from 220 under the old protocol to 379 with the new protocol 
(p<0.001).  For PBC/PSC, on the other hand, the new protocol caused a significant 
reduction in albumin, from 226 under the old protocol, to 207 under the new one 
(p=0.012). 
Urea synthesis by hepatocytes isolated from normal, PBC/PSC or ALD liver tissue using 
the modified protocol was maintained for at least 1 week in culture (Figure 3.3).  Tissue 
type was found to have a significant effect on urea measurements (p=0.002, Table 3.9).  
The average ALD urea measurements were significantly lower than both normal (p=0.006) 
and PBC/PSC (p=0.002).  There was no significant difference between the urea 
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measurements of normal and PBC/PSC hepatocytes (p=0.778).  I next compared urea 
synthesis by hepatocytes isolated using the new and original protocols (Table 3.10).  The 
results showed no significant difference in urea values between the two protocols for ALD 
tissue types (p=0.159).  However, significant increases were brought about by the new 
protocol for both normal and PBC/PSC tissue (p=0.001 and 0.002 respectively). 
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Figure 3.2 Albumin synthesis by primary human hepatocytes isolated from normal and 
diseased liver.   
Albumin concentration in tissue culture supernatants was used as a measure of albumin 
synthesis by human hepatocytes in culture.  Solid lines represent new protocol; broken lines 
represent original protocol.  Data are displayed as the geometric mean of 3 samples taken at 
days 1, 2, 3 and 7 of culture. 
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Tissue 
Type 
Geometric Mean 
(95% CI) 
Tukey's HSD p-Value vs. 
ALD Normal PBC/PSC 
ALD 176 (159-195) - <0.001* 0.187 
Normal 368 (326-415) <0.001* - <0.001* 
PBC/PSC 199 (180-221) 0.187 <0.001* - 
 
 
Table 3.7 Albumin concentration in tissue culture supernatants from normal and 
diseased liver isolated using the new protocol. 
Albumin concentration was used to compare albumin synthesis by human hepatocytes 
isolated from different types of liver tissue using the new protocol.  Hepatocytes isolated 
from normal tissue synthesised significantly more albumin than those isolated from ALD 
or PBC/PSC tissue.  *Significant at p<0.05. 
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Tissue Type 
Geometric Mean (95% CI) 
p-value Original Protocol New Protocol 
ALD 161 (150-173) 178 (166-191) 0.053 
Normal 220 (208-233) 379 (355-404) <0.001** 
PBC/PSC 226 (216-235) 207 (198-216) 0.012** 
 
 
Table 3.8 Albumin concentration in tissue culture supernatants isolated using the new 
and original protocols.   
Albumin synthesis by human hepatocytes isolated using the original and new protocols 
was compared.  Albumin synthesis by hepatocytes isolated from normal tissue was 
significantly improved under the new protocol.  There was also a trend towards an 
improvement in albumin synthesis by hepatocytes isolated from ALD tissue although 
those isolated from PBC/PSC tissue showed a small but significant decrease in albumin 
synthesis under the new protocol.  **Significant after Bonferroni Correction for 3 
comparisons (p<0.0167). 
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Figure 3.3 Urea synthesis by primary human hepatocytes isolated from normal and diseased liver.   
Urea concentration in tissue culture supernatants was used as a measure of urea synthesis by 
human hepatocytes in culture.  Solid lines represent new protocol; broken lines represent original 
protocol.  Data are displayed as the geometric mean of 3 samples taken at days 1, 2, 3 and 7 of 
culture. 
 
98 
 
Tissue 
Type 
Geometric Mean 
(95% CI) 
Tukey's HSD p-Value vs. 
ALD Normal PBC/PSC 
ALD 5.6 (4.3-7.2) - 0.006* 0.002* 
Normal 10.7 (8.3-13.8) 0.006* - 0.778 
PBC/PSC 12.0 (9.3-15.4) 0.002* 0.778 - 
 
 
Table 3.9 Urea concentration in tissue culture supernatants from normal and diseased 
liver isolated using the new protocol.   
Urea concentration was used to compare urea synthesis by human hepatocytes isolated 
from different types of liver tissue using the new protocol.  Hepatocytes isolated from 
normal or PBC/PSC tissue synthesised significantly more urea than those isolated from 
ALD tissue.  *Significant at p<0.05. 
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Tissue Type 
Geometric Mean (95% CI) 
p-value Original Protocol New Protocol 
ALD 5.0 (4.1-6.1) 6.0 (5.0-7.3) 0.159 
Normal 5.7 (4.7-6.7) 10.3 (8.8-12.1) 0.001** 
PBC/PSC 6.5 (5.2-8.2) 13.6 (10.8-17.2) 0.002** 
 
 
Table 3.10 Urea concentration in tissue culture supernatants isolated using the new and 
original protocols. 
Urea synthesis by human hepatocytes isolated using the original and new protocols was 
compared.  There was no significant difference for hepatocytes isolated from ALD tissue, 
but urea synthesis by hepatocytes isolated from normal and PBC/PSC tissue was 
significantly increased using the new protocol.  **Significant after Bonferroni Correction 
for 3 comparisons (p<0.0167). 
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3.3 Discussion 
Our group previously published a study of hepatocyte isolation from over 100 liver 
specimens of which 54% were from cirrhotic, end-stage liver diseases showed for the first 
time that viable functioning hepatocytes may be routinely isolated from diseased liver 
(Bhogal et al. 2011).  In that series, our overall success rate was 51% with a median 
viability of 40%.  Whilst we successfully isolated cells from all types of liver disease, we 
showed that ALD livers produced the poorest results and that cells isolated from ALD 
livers had inferior metabolic function in terms of albumin and urea synthesis.  Further, we 
showed that time delay between hepatectomy/explant and the commencement of perfusion 
influenced the likelihood of success.   
Whilst the results from our previous series were encouraging, the viability achieved fell 
short of that achieved by groups using more favourable tissue and in nearly half the cases 
the outcome was not successful.  I therefore set about improving the viability and cell yield 
focussing on the use of Liberase and NAC as other studies in the literature suggested they 
may be of benefit.  Donini et al (Donini et al. 2001) investigated the outcome of 
hepatocyte isolation from 14 porcine livers randomly assigned to standard collagenase or 
Liberase.  Mean cell viability in that study was extremely high even without the use of 
Liberase (90%), most probably due to the fact that livers were retrieved from normal 
healthy pigs and perfused in situ with a cold preservation solution before immediate 
progression to hepatocyte isolation.  Liberase significantly increased mean viability to 
95% although there was no effect on cell yield.  Sagias et al (Sagias et al. 2010) isolated 
hepatocytes from 10 severely steatotic (>60%) livers with two specimens from each liver 
being randomly assigned to standard collagenase digestion or the same digestion technique 
with the addition of NAC.  Use of NAC significantly increased mean viability from 66% 
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to 81% as well as the mean viable cell yield from 1.10×10
6
 cells/g tissue to 2.59×10
6
 
cells/g tissue. 
 I decided to combine the use of both Liberase and NAC at the same time in an attempt to 
optimise the impact on hepatocyte isolation.  As liver tissue is in high demand within our 
laboratory for the isolation of various other cell types, I was unable to randomise tissue 
from the same liver to each of the two protocols.  However, my approach has enabled me 
to produce the largest series to date investigating the use of Liberase and NAC and, to the 
best of my knowledge, the only series to use both in combination.  Furthermore, I know of 
no other study describing the use of these reagents to isolate human hepatocytes from a 
wide range of diseased and cirrhotic livers.  My data confirm that the use of Liberase and 
NAC in combination significantly improves the outcome of human hepatocyte isolation 
from normal and diseased liver in terms of both viable cell yield and overall success rate. 
The time delay until the start of the isolation procedure was significantly shorter in the new 
protocol group and this is likely to reflect improvements that have been made to the 
arrangements for collecting liver specimens from the hospital and their subsequent 
processing.  These improvements occurred during the period when I performed the first 
few isolations included in the study; the median delay to processing for the second half of 
the old protocol group (specimens 16-30) was 2 hours, the same as for the new protocol 
group.  Despite this there was no trend to improved outcomes during the first 30 patients 
(old protocol), suggesting that an improvement in time delay alone was not responsible for 
the improved outcome with the new protocol.  This is further demonstrated by the fact that 
even after adjusting for this difference in time delay between the two groups the outcomes 
were still significantly improved.  Similarly, the lack of any trend towards improving 
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outcomes within the first 30 isolations suggests that learning curve was not an important 
factor in the observed improvements in the success of hepatocyte isolation. 
The enzyme perfusion time required for digestion with the new protocol was slightly 
longer than with the old protocol.  Perfusion time is not pre-determined, rather perfusion 
continues until adequate tissue digestion is achieved.  As such it is a function of both the 
nature of the liver tissue being digested and the specific enzyme cocktail being used.  
Although there was no significant difference in the range of liver disease types used 
between the two groups overall, there was possibly more cirrhotic liver in the new protocol 
group (slightly more biliary cirrhosis and ALD liver).  I also suspect that Liberase has a 
gentler action than standard crude collagenase preparations and may require a longer time 
to act.  Indeed, other authors have reported longer digestion times for other tissues such as 
pancreas (Georges et al. 2002) and ovary (Dolmans et al. 2006) when using Liberase 
compared to standard collagenase. 
The decision to use Percoll is somewhat subjective and in my experience always results in 
a loss of cells over and above what would be expected given the initial cell viability and 
yield.  Therefore I only use this step when there are a large number of cells with very low 
viability.  The fact that Percoll use was similar between the two groups suggests I was 
consistent in the application of criteria for its use and that differential use of Percoll does 
not account for the improvement seen with the new protocol.   
The fact that I have shown an improvement in overall success rate, which I defined as the 
maintenance of cell adhesion and morphology for 48 hours, as well as viable cell yield is 
important.  Many experimental protocols require cells to be plated down and maintained in 
culture for a period of time and so an increased yield of viable cells which then fail to 
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attach in culture would be of limited benefit.  Further, hepatocytes are known to undergo 
anoikis or detachment-related cell death (Pinkse et al. 2004;Rosner et al. 2002), and so 
failure to attach will quickly render isolated hepatocytes useless.  Even if used 
immediately for cell transplantation, it seems likely that such cells would be less able to 
survive and engraft (Zvibel et al. 2002).  It has been shown that establishment of a 
confluent monolayer is critical for maintenance of the differentiated hepatocyte phenotype 
(Greuet et al. 1997) and so I used the presence of absence of a confluent monolayer, rather 
than attempting to quantify adhesion, in order to determine success.  A 48 hour culture 
period was a pragmatic choice that would be likely to provide sufficient time for 
downstream experiments or use of the hepatocytes for transplantation without the loss of 
phenotype associated with prolonged culture. 
It is interesting that the new protocol did not result in an increase in total cell yield.  The 
previous studies of NAC or Liberase in hepatocyte isolation also reported no increase in 
absolute cell yield (Donini et al. 2001) or only reported an increase in viable cell yield 
(Sagias et al. 2010).  It is therefore likely that the beneficial effects of both these agents are 
exerted mainly through an improvement in viability, and indeed, it is difficult to see how 
the antioxidant and hepatoprotective actions of NAC might improve absolute cell yield.  
Obtaining a high cell yield depends on sufficient tissue digestion, and I continue enzyme 
perfusion until the liver can be easily manually dissociated rather than setting a fixed 
perfusion time for all types of liver.  I believe that this approach already maximises the 
absolute cell yield obtained, but that the continued exposure of the hepatocytes to enzymes 
during this time is detrimental.  Therefore it is likely that an improved enzyme preparation 
that is less damaging to individual cells will improve final viability and viable cell yield 
but not the overall number of cells obtained. 
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In this study I confirmed our previous findings that hepatocytes isolated from ALD liver 
generally have poorer metabolic function compared to those isolated from normal or 
PBC/PSC liver.  This may be due to the fact that many ALD patients had advanced 
cirrhosis or it may reflect toxicity effects secondary to alcohol.  The metabolic function of 
hepatocytes isolated using the new protocol was similar to that of hepatocytes isolated 
using the original protocol for ALD hepatocytes and generally improved for normal and 
PBC/PSC hepatocytes.  Whilst PBC/PSC hepatocytes showed a lower average albumin 
synthesis, this result is perhaps explained by the higher albumin values for PBC/PSC 
hepatocytes isolated using the original protocol during the first 48 hours of culture; by day 
7 the values for both groups were similar.  There are of course many other aspects of 
hepatocyte function that I have not investigated and I have not attempted to show 
maintenance of the complete hepatocyte phenotype in culture.  However, these results are 
encouraging as they suggest that the improved overall success rate and viable cell yield do 
not occur at the expense of metabolic function.  It is also of note that the greatest 
improvement in metabolic function was seen in hepatocytes isolated from normal liver 
tissue, and it is these that are most likely to be used for clinical purposes and are preferred 
for laboratory investigation. 
In conclusion, I have shown that the combined use of NAC and Liberase for the isolation 
of human hepatocytes from normal and diseased liver results in a higher success rate and 
viable cell yield.  Furthermore, metabolic function is maintained for up to 1 week in 
culture and is improved compared to hepatocytes isolated without NAC and Liberase.  The 
routine use of NAC and Liberase should greatly increase the availability of primary human 
hepatocytes both for research and clinical applications. 
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CHAPTER 4:  EXPRESSION OF ADHESION MOLECULES AND 
CHEMOKINE RECEPTORS BY PRIMARY HUMAN 
HEPATOCYTES AND HEPATOCYTE CELL LINES 
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4.1 Introduction 
During hepatocyte transplantation, the transplanted cells enter the liver sinusoids from 
where they must cross the sinusoidal endothelium in order to engraft within the liver 
parenchyma.  Part of this process may be purely mechanical, whereby the relatively large 
hepatocytes become lodged within the small diameter sinusoids.  However, there is 
evidence from animal models that a specific interaction between the transplanted 
hepatocytes and the sinusoidal endothelial cells occurs.  Therefore understanding the 
mechanisms involved in the adhesion of hepatocytes to HSEC may uncover a potential 
target for manipulation in order to improve engraftment.  
4.1.1 Adhesion Molecules 
Cell adhesion molecules (CAMs) are proteins present on the surface of cells that are able 
to interact with ligands on the surface of other cells or with extracellular matrix proteins 
thereby regulating cellular adhesion.  Most CAMs are transmembrane proteins with 
cytoplasmic, transmembrane and extracellular domains.  The cytoplasmic domain interacts 
with the cell cytoskeleton and the extracellular domain binds to other cell adhesion 
molecules or extracellular matrix.  There are several families of CAMs including integrins, 
cadherins, selectins,  and the immunoglobulin superfamily cell adhesion molecules 
(Albelda and Buck 1990).  Integrins are a large family of receptors which are particularly 
important in mediating cell-ECM interactions and will be discussed further.  Cadherins are 
widely expressed molecules mainly located in adherens junctions that form calcium-
dependent homophilic cell-cell interactions and are crucial for tissue morphogenesis 
during development (Halbleib and Nelson 2006).  They may be further divided into several 
subgroups.  The classical cadherins include E-cadherin (found in epithelial tissue), N-
cadherin (found on neurons) and P-cadherin (found in the placenta).  The other subgroups 
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include the desmosomal cadherins, protocadherins and atypical cadherins (Nollet et al. 
2000).  Selectins are carbohydrate-binding molecules found on endothelial cells (E-
selectin), leukocytes (L-selectin) and platelets (P-selectin) which are involved in cellular 
trafficking in the immune system (Ley 2003).  Adhesion molecules of the immunoglobulin 
superfamily include neural cell adhesion molecule (NCAM), activated leukocyte cell 
adhesion molecule (ALCAM), intercellular cell adhesion molecule-1 (ICAM-1), platelet 
endothelial cell adhesion molecule (PECAM) and vascular cell adhesion molecule 
1(VCAM-1) (Wai et al. 2012).  They are characterised by the presence of 
immunoglobulin-like domains and mediate calcium-independent adhesion through binding 
to other immunoglobulin-like domains of the same structure on adjacent cells (homophilic 
adhesion) or through interaction with integrins and carbohydrates (heterophilic adhesion) 
(Barclay 2003).   
I decided to concentrate on investigating integrin expression as integrins form a large 
group of adhesion molecules which are expressed on many cell types.  Previous studies 
reported that hepatocytes express a small number of functional integrins.  Animal 
experimentation suggests that integrins may have a role in hepatocyte engraftment into the 
liver during transplantation and it has previously been shown that recruitment of 
lymphocytes to the liver is dependent on molecules such as VCAM-1 and ICAM-1 which 
are expressed by HSEC and which bind integrins.  In addition I also decided to investigate 
chemokine receptor expression.  Chemokines are small 8-12kd cytokines that bind to GPR 
couple receptors to trigger migraton responses and activation of integrin mediated 
adhesion through intergrin clustering and conformational activation.  They play a crucial 
role in the recruitment of leucocytes to tissues including the liver as well as metastasis of 
tumour cells. 
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4.1.1.1 Integrins 
The integrins are a superfamily of adhesion molecules which are expressed on almost 
every cell type and mediate cell-cell and cell-matrix interactions (Hogg and Leitinger 
2001;Sonnenberg 1993).  Integrins are αβ heterodimeric type 1 transmembrane receptors.  
In humans there are 18α and 8β subunits which combine to form 24 different heterodimers 
(Humphries et al. 2006;Takada et al. 2007).  Integrins may become activated through 
clustering on the cell surface, which increases the avidity of molecular interactions, or 
through conformational changes leading to increased affinity for the ligand (Campbell and 
Humphries 2011). 
The α- and β-integrin subunits have distinct domain structures, with the extracellular 
domains of each subunit contributing to the ligand binding site.  The sequence arginine-
glycine-aspartic acid (RGD) has been identified as a general integrin-binding motif, but 
different integrins also have specific protein ligands.  These may be extracellular matrix 
proteins such as collagen or fibronectin, or other adhesion molecules such as VCAM-1 or 
ICAM-1 (Humphries et al. 2006;Takada et al. 2007).   
Integrin binding not only supports cell adhesion but is also crucial for embryonic 
development, tissue repair, host defence and haemostasis (Harburger and Calderwood 
2009).  The linkage between the short cytoplasmic integrin domains and the intracellular 
cytoskeleton allows transmission of force across the plasma membrane (Calderwood et al. 
2000;Evans and Calderwood 2007).  Integrins are able to transmit chemical signals from 
outside into the cell (termed outside-in signalling) and are also able to regulate their 
affinity for extracellular ligands via conformational alterations in response to signals 
impinging upon the cytoplasmic tails (termed inside-out signalling) (Calderwood 
2004;Hynes 2002;Miranti and Brugge 2002). 
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4.1.1.2 Chemokine receptors 
Chemokines are a group of at least 46 small (8-14kDa) structurally related molecules 
expressed by a variety of cell types.  Their name derives from their ability to induce 
chemotaxis (chemotactic cytokines) and they play a pivotal role in inflammatory processes 
and immunity (Zlotnik et al. 2006;Zlotnik and Yoshie 2000).  Chemokines may be divided 
into two major groups based on the presence (CXC chemokines) or absence (CC 
chemokines) of an amino acid between two N-terminal cysteine residues.  Two further 
classes of chemokines have also been described: CX3C has 3 amino acids between the first 
two N terminal cysteine residues and C chemokines which lack cysteine residues one and 
three (Zlotnik and Yoshie 2000).  Chemokines function through binding to G-protein 
coupled receptors that have seven transmembrane spanning domains.  Binding of 
chemokines to chemokine receptors leads to dissociation of the coupled heterotrimeric G 
proteins into α and βγ subunits.  These G protein subunits act as second messengers 
leading to calcium influx and activation of protein kinases.  Effects include the activation 
of chemotaxis through actin-dependent processes, upregulation of adhesion molecules and 
a wide range of other functions (Horuk 2001).  Chemokine receptors are named in a 
similar manner to chemokines according to the type of chemokine they bind. 
Thus in this chapter I investigate the surface expression of integrins and chemokine 
receptors by primary human hepatocytes. 
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4.2 Results 
4.2.1 Optimisation of Methods for Flow Cytometric Analysis of Primary 
Human Hepatocytes and Hepatocyte Cell Lines 
In order to optimise my protocols for flow cytometric analysis of human hepatocytes and 
hepatocyte cell lines I initially looked at the surface expression of a small panel of 
common integrin subunits that I felt were likely to be expressed.  This included integrins 
that have been previously reported to be expressed by hepatocytes, which are expressed by 
other epithelial cell types or have been shown to be important in the adhesion of other non-
leukocyte cells in the liver.  This included the following integrins: α1, α2, α3, α4, α5, α6, 
α9 β1, αVβ3, αVβ5, β1, β2, β3, β4.  Antibodies to individual integrin subunits were used 
when available.  Figure 4.1 shows representative side scatter/forward scatter plots of Huh 
7.5 cells with high surface expression of β1 integrin detected using a PE-conjugated 
antibody.   
For the analysis of primary human hepatocytes a viability marker was also used in light of 
my previous findings regarding cell viability (Table 3.1) to ensure that non-viable cells 
were not included.  Representative flow cytometry plots showing high surface expression 
of β1 integrin by primary human hepatocytes are shown in Figure 4.2.  The percentage 
surface expression and MFI values for the integrins listed above for Huh 7.5 and Hep G2 
hepatoma cell lines are shown in Figure 4.3 and for primary human hepatocytes in Figure 
4.4. 
Integrin expression by primary human hepatocytes was limited with only α1 and β1 
subunits expressed at high levels.  There were also low levels of α2 and α9 but this was 
somewhat variable between experiments The hepatoma cell lines expressed a slightly 
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wider range of integrins on their surface with moderate to high expression of α2, β4 and 
αVβ5 in addition to α1 and β1.   
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Figure 4.1 Typical flow cytometric analysis of surface expression of integrins by 
hepatoma cell lines showing β1 integrin expression by Huh 7.5 cells  
Illustrative plots for Huh 7.5 cells are shown: (a) typical side scatter/forward scatter plot 
with gate around cell population; (b) gating on pulse width to exclude doublets; (c) β1 
integrin (red peak) compared to IgG isotype control (grey peak). 
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Figure 4.2 Flow cytometric analysis of integrin surface expression by freshly isolated 
primary human hepatocytes.   
Illustrative plots are shown: (a) typical side scatter/forward scatter plot; (b) gating on 
pulse width to exclude doublets; (c) PE-conjugated IgG isotype control; (d) cells labelled 
with the viability marker only showing two distinct populations with dim (viable) and 
bright (dead) fluorescence in the APC channel; (e) cells labelled with the viability marker 
and a PE-conjugated anti-β1 integrin antibody. 
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Figure 4.3 Optimisation of flow cytometric analysis of integrin expression by Huh 7.5 
and Hep G2 cell lines. 
This graph shows the expression of a limited panel of integrins by (a) Huh 7.5 and (b) Hep 
G2 cells.  Data shown are % expression and median fluorescence intensity for indicated 
integrin subunits.  Data expressed as the mean and standard error of 3 experiments.  
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Figure 4.4 Flow cytometric analysis of integrin expression by primary human 
hepatocytes.   
This graph shows the expression of a limited panel of integrins by primary human 
hepatocytes.  Data shown are % expression and median fluorescence intensity for 
indicated integrin subunits.  Data expressed as the mean and standard error of at least 3 
experiments. 
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4.2.2 Surface Expression of Adhesion Molecules/Chemokine Receptors on 
Primary Hepatocytes 
Following the initial optimisation experiments, freshly isolated primary human 
hepatocytes were analysed for surface expression of a wider range of integrin subunits 
including α7, α8, α10, α11, αIIb, αL, αM, αV, αVβ6, and β7.  These were chosen as 
previous literature suggests that they are potential partners of the subunits already 
identified as being expressed during the optimisation experiments or because they bind 
ligands/ECM components known to be expressed by the liver or HSEC.  In addition, a new 
antibody to α5 was used as it had become evident from other work in our laboratory that 
the previously used antibody was not working.  Hepatocytes were also analysed for the 
surface expression of chemokine receptors CCR 1-10 and CXCR 1-7.  Staining was 
performed with PE conjugated antibodies where available or an unconjugated antibody 
followed by a PE conjugated secondary antibody.  Antibody-labelled samples were 
compared with respective IgG controls.  A far red viability marker (detected on the APC 
channel) was also included to ensure that only viable cells were analysed. 
4.2.2.1 Surface expression of integrin subunits 
Primary human hepatocyte integrin surface expression data is shown in Figure 4.5.  
Primary hepatocytes express high levels of α1 (89%; MFI 52), αV (77%; MFI 20) and β1 
(87%; MFI 47), moderate expression of α5 (30%; MFI 12), α7 (44%; MFI 20), α10 (39%; 
MFI 30), α11 (39%; MFI 37) and αM (54%; MFI 17) and low levels of α2 (16%; MFI 9), 
αIIb (13%; MFI 7), α9β1 (16%; MFI 5) and αVβ3 (7%; MFI 6) .  
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Figure 4.5 Flow cytometric analysis of integrin surface expression by primary human 
hepatocytes.   
Following initial optimisation experiments, primary human hepatocytes were analysed for 
expression of a large panel of integrin subunits.  Data shown are the mean ± standard 
error of at least 3 experiments expressed as % expression and median fluorescence 
intensity. 
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Figure 4.6 Flow cytometric analysis of chemokine receptor surface expression by 
primary human hepatocytes.   
Chemokine receptor expression by primary human hepatocytes was analysed by flow 
cytometry.  Data shown is the mean ± standard error of at least 3 experiments expressed 
as % expression and median fluorescence intensity. 
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4.2.2.2 Surface expression of chemokine receptors 
Primary human hepatocyte chemokine receptor surface expression data is shown in Figure 
4.6.  Chemokine receptor expression by primary human hepatocytes was limited with only 
moderate expression of CCR4 (40%; MFI 77), CCR5 (31%; MFI 24) and CXCR3 (25%; 
MFI 19). 
4.2.3 Surface Expression of Adhesion Molecules/Chemokine Receptors on 
Hepatoma Cell Lines 
Huh 7.5 and Hep G2 cells were stained for surface expression of integrin subunits and 
chemokine receptors using PE conjugated antibodies where available or an unconjugated 
antibody followed by a PE conjugated secondary antibody.  Antibody labelled samples 
were compared with respective IgG controls. 
4.2.3.1 Surface expression of integrin subunits 
Both cell lines expressed a similar repertoire of integrins to primary human hepatocytes, 
with α1, α2, α7, α10, α11, αIIb, αM, αV, αVβ5, β1 and β4 and integrins expressed.  Whilst 
the same integrins were expressed by both cell lines, the levels of expression differed 
slightly.  Huh 7.5 cells expressed high levels of α1 (89%; MFI 42), α2 (80%; MFI 26), α10 
(81%; MFI 17), αIIb (97%; MFI 47), αV (100%; MFI 167), β1 (91%; MFI 82) and αVβ5 
(72%; MFI 22), moderate levels of α7 (44%; MFI 44) and α11 (54%; MFI 15) and low 
levels of α5 (24%; MFI 9), (αM (26%; MFI 8) and β4 (23%; MFI 8) (Figure 4.7).  Hep G2 
cells expressed high levels of α2 (90%; MFI 41), α10 (62%; MFI 22) αIIb (92%; MFI 52), 
αV (85%; MFI 154) and β1 (94%; MFI 45), moderate levels of α1 (50%; MFI 10), α7 
(41%; MFI 44), α11 (52%; MFI 16), αV β5 (60%; MFI 13) and β4 (46%; MFI 9) and low 
levels of α5 (20%; MFI 7) and αM (23%; MFI 10) (Figure 4.8).  
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4.2.3.2 Surface expression of chemokine receptors 
As with integrin expression, hepatocyte cell lines expressed a wider range of chemokine 
receptors than primary hepatocytes but expression levels varied between the two different 
cell lines.  Huh 7.5 cells expressed high levels of CCR4 (95%; MFI 47), moderate levels of 
CCR 5 (35%; MFI 44), CCR10 (30%; MFI 21) and CXCR3 (27%; MFI 18) and low levels 
of CCR3 (19%; MFI 22) and CXCR1 (10%; MFI 21) (Figure 4.9).  Hep G2 cells 
expressed moderate levels of CCR4 (49%; MFI 90), CCR5 (32%; MFI 28) and CXCR3 
(24%; MFI 15) and low levels of CCR3 (6%; MFI 3), CCR9 (6%; MFI 3) and CCR10 
(18%; MFI 15) (Figure 4.10). 
4.2.4 Adhesion Molecule Gene Expression by Primary Human Hepatocytes 
and Huh 7.5 Cells 
RNA was obtained from primary human hepatocytes isolated from normal liver tissue and 
Huh7.5 cells.  cDNA was synthesised and subjected to RT-PCR using a TaqMan Custom 
Array.  A list of genes investigated and the adhesion molecules which they encode is 
shown in  
 
Table 4.1.  Primary human hepatocytes expressed all the genes tested (Figure 4.11) while 
Huh7.5 gene expression was more limited with no expression of ITGA3, ITGA4, ITB2, 
ITGAD, ITGAX, HEPACAM, CLEC4M, CD209 or SELP (Figure 4.12). 
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Figure 4.7 Flow cytometric analysis of integrin surface expression by Huh 7.5 cells.   
Following initial optimisation experiments, Huh 7.5 cells were analysed for expression of 
a large panel of integrin subunits.  Data shown is the mean ± standard error of at least 3 
experiments expressed as % expression and mean fluorescence intensity. 
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Figure 4.8 Flow cytometric analysis of integrin surface expression by Hep G2 cells.   
Following initial optimisation experiments, Hep G2 cells were analysed for expression of a 
large panel of integrin subunits.  Data shown is the mean ± standard error of at least 3 
experiments expressed as % expression and mean fluorescence intensity. 
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Figure 4.9 Flow cytometric analysis of chemokine receptor surface expression by Huh 
7.5 cells.   
Chemokine receptor expression by Huh 7.5 cells was analysed by flow cytometry.  Data 
shown is the mean ± standard error of at least 3 experiments expressed as % expression 
and mean fluorescence intensity. 
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Figure 4.10 Flow cytometric analysis of chemokine receptor surface expression by Hep 
G2 cells.   
Chemokine receptor expression by Hep G2 cells was analysed by flow cytometry.  Data 
shown is the mean ± standard error of at least 3 experiments expressed as % expression 
and mean fluorescence intensity. 
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Gene Molecule 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase (housekeeping gene) 
ITGA1 α1 integrin 
ITGA2 α2 integrin 
ITGA3 α3 integrin 
ITGA4 α4 integrin 
ITGA5 α5 integrin 
ITGA6 α6 integrin 
ITGA7 α7 integrin 
ITGA8 α8 integrin 
ITGA9 α9 integrin 
ITGA10 α10 integrin 
ITGA11 α11 integrin 
ITGB1 β1 integrin 
ITGB2 β2 integrin 
ITGB3 β3 integrin 
ITGB4 β4 integrin 
ITGB5 β5 integrin 
ITGB6 β6 integrin 
ITGB7 β7 integrin 
ITGB8 β8 integrin 
ITGAL αL integrin 
ITGAM αM integrin 
ITGAD αD integrin 
ITGAX αX integrin 
ITGAV αV integrin 
ITGAE αE integrin 
ITGA2B αIIb integrin 
EPCAM epithelial cell adhesion molecule 
HEPACAM hepatocyte cell adhesion molecule 1 
HEPACAM2 hepatocyte cell adhesion molecule 2 
BCAM basal cell adhesion molecule 
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Gene Molecule 
VCAM1 vascular cell adhesion molecule 1 
PECAM1 platelet/endothelial cell adhesion molecule 1 
ICAM1 intercellular adhesion molecule 1 
ICAM2 intercellular adhesion molecule 2 
ICAM3 intercellular adhesion molecule 3 
ICAM4 intercellular adhesion molecule 4 
AOC3 vascular adhesion protein 1 (VAP-1) 
CD44 CD44 
CDH1 epithelial cadherin (E-cadherin) 
CDH2 neural cadherin (N-cadherin) 
CDH17 liver-intestine cadherin (LI-cadherin) 
CLEC4M liver/lymph node-specific intercellular adhesion molecule-3-grabbing non-
integrin (L-SIGN) 
CD209 dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) 
SELP P-selectin 
 
 
Table 4.1 List of adhesion molecule genes investigated by PCR of human hepatocyte 
and Huh 7.5 cDNA. 
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expression relative to GAPDH (2
-dCT)
GAPDH
ITGA1
ITGA2
ITGA3
ITGA4
ITGA5
ITGA6
ITGA7
ITGA8
ITGA9
ITGA10
ITGA11
ITGB1
ITGB2
ITGB3
ITGB4
ITGB5
ITGB6
ITGB7
ITGB8
ITGAL
ITGAM
ITGAD
ITGAX
ITGAV
ITGAE
ITGA2B
EPCAM
HEPACAM
HEPACAM2
BCAM
VCAM1
PECAM1
ICAM1
ICAM2
ICAM3
ICAM4
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Figure 4.11 PCR analysis of adhesion molecule gene expression by primary hepatocytes. 
Gene expression by primary human hepatocytes isolated from normal liver tissue for a 
variety of adhesion molecules was analysed by PCR and compared to GAPDH.  Data are 
expressed as the mean and SE of 3 experiments. 
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Figure 4.12 PCR analysis of adhesion molecule gene expression by Huh 7.5 cells 
Gene expression by Huh 7.5 for a variety of adhesion molecules was analysed by PCR and 
compared to GAPDH.  Data are expressed as the mean and SE of 3 experiments. 
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4.3 Discussion 
4.3.1 Integrin expression by primary human hepatocytes isolated from 
normal and diseased human liver 
There is currently little data in the literature concerning integrin expression by human 
hepatocytes, with the majority of work investigating hepatocyte adhesion having been 
performed using rat or murine cells.  However the few studies that have focussed on 
human tissue suggest that human hepatocytes express only a limited repertoire of integrin 
subunits.  Couvelard et al (Couvelard et al. 1998) investigated the changes in integrin 
expression during liver development using immunohistochemistry.  Foetal hepatocytes 
stained strongly for the β1 subunit with moderate staining for α1, α5, α6 and α9.  However, 
mature hepatocytes only showed weak staining for the β1 and α1 subunits and moderate 
staining for α5 and α9.  Staining for the α6 subunit was lost altogether after 16-25 weeks 
gestation (Couvelard et al. 1998).  Several studies have investigated changes in integrin 
surface expression by hepatocytes in diseased liver and shown that expression of some 
integrin subunits may be upregulated compared to normal liver.  Nejjari et al examined 
liver tissue from patients with chronic hepatitis C and demonstrated increased expression 
of α1, α5 and β1 integrins and de novo induction of α2 and α6 expression.  The α9 subunit 
was also present but levels were similar in normal and diseased liver (Nejjari et al. 2001).  
Other studies have shown de novo expression of α2 and α6 in cirrhosis and hepatocellular 
carcinoma (HCC) (Le et al. 1997), and α3 and α6 in inflammatory liver diseases (Volpes et 
al. 1991).  
My results confirm that human hepatocytes are able to express α1, α2, α5, α9 and β1 
integrins at varying levels although I was not able to demonstrate significant expression of 
α6 integrin.  However, I demonstrate a much wider range of integrin expression on 
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hepatocytes than previously described in the published literature.  In particular, in addition 
to high levels of α1 and β1 subunits, αV was also very highly expressed.  There was also 
expression of α7, α10, α11, αIIb and αM integrins which, to the best of my knowledge, has 
not been previously described.  The αV subunit is able to dimerise with several β subunits 
including β1 forming αVβ1, a fibronectin receptor (Zhang et al. 1993).  Whilst αVβ5 was 
also highly expressed by cell lines, it was not expressed by primary hepatocytes, nor were 
αV αVβ3 or αVβ6.  α7 integrin is expressed mainly in skeletal and cardiac muscle and 
combines to form α7β1 integrin which is a laminin receptor (Mayer et al. 1997).  α10 and 
α11, along with α1 and α2, dimerise with β1 forming collagen receptors (Springer and 
Dustin 2012).  Integrin αIIb is only known to associate with β3 forming a fibrinogen 
receptor which is expressed on platelets and plays a crucial role in coagulation (Bledzka et 
al. 2013).  The αM subunit associates with β2, known as complement receptor 3 (CR3), 
and is a leukocyte integrin with a wide range of ligands including several ECM 
components (Li 1999).  The presence of these subunits on the surface of both primary 
hepatocytes and hepatocyte cell lines in the absence of the corresponding β subunits has a 
number of possible explanations.  It is possible that the αIIb and αM subunits are both also 
able to associate with β1 but that this is yet to be reported.  Alternatively, it may be that, 
for some reason, certain cells express integrin subunits which do not have a partner or that 
hepatocytes do indeed express β2 and β3 integrin but that these particular subunits are 
especially sensitive to the isolation process or the process of removing cells from culture.  
Finally, it is possible that the antibodies used are not specific and generated falsely positive 
results. 
There are several reasons why my results may differ from those of previous studies.  
Firstly, the majority of studies published to date used frozen or fixed tissue sections and 
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immunohistochemical staining.  The process of enzymatic dissociation of liver tissue, the 
isolation of hepatocytes and their subsequent handling may have an effect on surface 
expression of adhesion molecules causing either upregulation of expression or cleaving the 
molecule from the cell surface resulting in loss of expression.  Such effects have been 
demonstrated in our laboratory with other cells such as mesenchymal stem cells (Garg et 
al. 2014)  The analysis of a suspension of a single cell type by flow cytometry is also likely 
to produce slightly different results to those obtained by studying staining on whole liver 
sections. 
The use of primary human hepatocytes for the purpose of hepatocyte transplantation 
necessitates their isolation from liver tissue.  The method of delivery is likely to be as a 
cell suspension of freshly isolated, cultured or cryopreserved hepatocytes.  Therefore the 
expression data obtained from freshly isolated cells/cells recently removed from culture 
are likely to reflect the situation in which hepatocytes would be used in clinical practice 
and are therefore relevant for investigating the adhesive mechanisms involved in 
engraftment of transplanted hepatocytes. 
4.3.2 Chemokine receptor expression by primary human hepatocytes 
isolated from normal and diseased liver 
Under normal physiological conditions hepatocytes are not required to home to the liver 
from the circulation, and so there is unsurprisingly little in the literature regarding 
hepatocyte migration to the liver and the potential role of chemokines and chemokine 
receptors. 
Hepatocyte migration has, however, been studied in the context of liver regeneration.  For 
example, Ma et al showed that following injury to a hepatocyte monolayer, basic fibroblast 
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growth factor (bFGF) promotes wound repair by stimulating proliferation and migration of 
hepatocytes (Ma et al. 1999).  Furthermore, following hepatocyte transplant into the 
spleen, hepatocytes migrate to the liver where they integrate into hepatic parenchyma 
(Ponder et al. 1991).  However, such studies have not demonstrated a definite role for 
chemokine receptors. 
There are several studies in the literature describing the expression and role of particular 
chemokine receptors by hepatocytes.  CXCR1 and CXCR2 are thought to be involved in 
the regulation of hepatocyte proliferation and regeneration following 
ischaemia/reperfusion injury (Clarke et al. 2011;Kuboki et al. 2008) and HIV can cause 
hepatocyte death by signalling through CXCR4 (Vlahakis et al. 2003).  Interestingly I 
found none of these receptors on primary hepatocytes or cell lines, except for low levels of 
CXCR1 expression by Huh 7.5 cells.  Similarly, the receptors that were expressed on my 
primary human hepatocytes (CCR4, CCR5 and CXCR3) have not been reported in the 
literature.  These chemokine receptors are associated with lymphocytes with CCR4 
expressed at higher levels on Th2 lymphocytes and some regulatory T cells while CCR5 
and CXCR3 are expressed by memory effector T cells and Th1 lymphocytes (Bonecchi et 
al. 1998).  One possible explanation for this previously unreported expression is that the 
freshly isolated hepatocytes were contaminated by other cell types including lymphocytes 
that survived the isolation process.  However, this does not explain why these receptors 
were also expressed by the cell lines, and if the hepatocytes used for analysis were indeed 
contaminated then one might expect expression of other lymphocyte-associated chemokine 
receptors.  Another explanation as suggested with integrin expression is that the isolation 
process and/or underlying liver disease alter chemokine receptor expression.  Further, it is 
quite possible that nobody has actually investigated chemokine receptor expression by 
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human hepatocytes and so the presence of CCR4, CCR5 and CXCR3 on the surface of 
hepatocytes has gone unnoticed until now.  
4.3.3 Integrin and chemokine receptor expression by hepatocyte cell lines 
The hepatoma cell lines expressed a similar range of integrins to primary hepatocytes with 
the addition of αVβ5 and β4 which were not expressed at all by primary cells.  Similarly, 
both cell lines expressed the same chemokine receptors as primary cells but with the 
addition of CCR3, CCR10 (both cell lines), CXCR1 (Huh 7.5) and CCR9 (HepG2).   
Both cell lines differed somewhat from primary hepatocytes in terms of chemokine 
receptor expression.  Whilst the integrin expression of both cell lines was similar, Huh 7.5 
cells most closely reflected the levels of expression by primary hepatocytes.  Furthermore, 
I found Huh 7.5 cells easier to handle and maintain in culture compared to HepG2 cells 
which tended to form clumps and were less suited to further planned experiments.  I 
therefore decided to select the Huh7.5 hepatoma cell line for all further preliminary 
functional studies, where necessary, in place of hepatocytes. 
4.3.4 Adhesion molecule gene expression 
I analysed hepatocyte gene expression for a wide range of different adhesion molecules 
including the full repertoire of known integrin subunits as well as various CAMs, 
cadherins and selectins all of which are known to be expressed by other epithelial cell 
types, have ligands known to be expressed in the liver or by HSEC or are involved in the 
recruitment of other cell types into the liver.  The gene expression profile of Huh 7.5 cells 
was different to that of primary hepatocytes in that several genes were not expressed by 
Huh 7.5 and those that were expressed were generally expressed at a lower level than in 
primary cells.  These differences are likely to reflect the difference between primary cells 
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and a cell line but may also be a result of contamination by other cell types of the primary 
cells which were freshly isolated from whole liver tissue.   
The integrin gene expression data backs up my surface expression data, and although I 
have not been able to investigate all of the other adhesion molecules further, this data 
provides a useful resource for future studies.  Ideally to gain a complete picture of the 
adhesion molecule profile of primary human hepatocytes flow cytometric analysis for 
surface expression as well as gene expression analysis would be performed for all 
candidate adhesion molecules as well as chemokine receptors. 
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CHAPTER 5:  DEFINING THE FUNCTIONAL ROLE OF ADHESION 
MOLECULES EXPRESSED BY HUMAN HEPATOCYTES IN 
THEIR ADHESION TO LIVER TISSUE AND SINUSOIDAL 
ENDOTHELIUM IN VITRO AND IN VIVO 
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5.1 Introduction 
During hepatocyte transplantation, hepatocytes arriving in the liver must travel from the 
sinusoidal blood across the sinusoidal endothelium in order to engraft within the liver 
parenchyma.  As discussed in the main introduction, the exact mechanisms underlying this 
process so far remain unclear.  It is possible that hepatocytes interact with HSEC through 
cell-cell adhesion interactions modulated by specific adhesion molecules.  Alternatively, it 
is also possible that hepatocytes become mechanically lodged within the sinusoid with 
subsequent damage to or remodelling of the endothelium and exposure of the underlying 
matrix to which they are able to adhere.  As discussed in section 1.4.4, evidence from 
animal studies suggest that specific interactions with HSEC may be at least partly involved 
with both integrin-mediated and non-integrin mediated adhesion pathways likely to be 
important.   
Integrins are crucial for leukocyte recruitment to liver through binding to ligands such as 
VCAM-1 and ICAM-1 expressed on HSEC (Adams and Eksteen 2006;Lalor et al. 
2002;Shetty et al. 2008) and our group has recently demonstrated a role for β1 integrin in 
the recruitment of human mesenchymal stem cells (MSCs) to injured liver (Aldridge et al. 
2012).  Chemokine receptors are also essential for leukocyte migration and, as discussed 
previously, may have a role in the recruitment of epithelial cells including breast cancer 
metastases and melanoma to tissue. 
Having demonstrated surface expression of a range of integrins and chemokine receptors 
by primary human hepatocytes I therefore decided to concentrate the next stage of my 
investigation on their possible role in hepatocyte engraftment from the sinusoid into the 
liver.  As the β1 integrin subunit was the only β subunit demonstrated at high levels on the 
surface of primary hepatocytes, I decided to focus on this subunit as well as α1 and αV 
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integrins due to the similarly high levels of expression.  Because I also detected chemokine 
receptors on primary human hepatocytes at low to moderate levels I decided to investigate 
their role in adhesion also.  In order to quickly ascertain any role for chemokine receptors I 
decided to use pertussis toxin (PTX) to inhibit G-protein signalling resulting from 
activation of chemokine receptors (Goldman et al. 1985).  
5.2 Results 
5.2.1 Static Adhesion of Hepatocytes to Normal and Diseased Liver Tissue 
and Extracellular Matrix Components 
5.2.1.1 Adhesion to liver tissue 
The adhesion of Huh 7.5 cells to normal and various types of diseased liver tissue was 
compared using modified Stamper-Woodruff assays.  Adhesion to liver parenchyma and 
portal tract areas was quantified separately.  The mean number of cells adhering to 
parenchymal and portal tract areas of different types of liver tissue is shown in Figure 5.1.  
There was no significant difference in the mean number of cells adherent per field of view 
between the various diseases, nor between parenchymal and portal areas of the same 
disease. 
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Figure 5.1  Static adhesion of Huh 7.5 cells to liver tissue in a modified Stamper 
Woodruff assay.   
The adhesion of Huh 7.5 cells to parenchymal and portal tract areas of different types of 
liver tissue is shown.  The data are shown as the mean number of cells adherent per high 
power field of view and is the mean and standard error of 4 experiments. 
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5.2.1.2 The effect of integrin blockade on the adhesion of hepatocytes 
to liver tissue 
Function blocking antibodies to α1 and β1 integrins, the two major subunits expressed by 
primary human hepatocytes, were used to investigate their contribution to adhesion of Huh 
7.5 cells to liver (Figure 5.2).  Blockade of the α1 integrin subunit significantly reduced 
adhesion (percentage of IgG control) to normal (46.6% ± 9.1, p=0.01), PBC (47.4% ± 
12.0, p=0.02), ALD (30.6% ± 3.2, p=0.0002) and NASH (40.6% ± 6.0, p=0.002) liver 
parenchyma.  Adhesion to portal tract areas was also significantly reduced in ALD (26.8% 
± 7.6, p=0.002) and AIH (26.8% ± 9.4, p=0.004) livers with α1 integrin blockade.  
Blockade of the αV integrin subunit significantly reduced adhesion to normal (47.1% ± 
6.0, p=0.003), AIH (41.2% ± 10.2, p=0.01) and ALD (36.5% ± 10.2, p=0.01) liver 
parenchyma and normal (48.6% ± 10.9, p=0.02) and NASH (51.5 ± 13.2, p=0.04) portal 
tract areas.  Blockade of the β1 integrin subunit had little effect except on AIH liver where 
adhesion to parenchyma was significantly reduced (45.7% ± 8.4, p=0.008).   
5.2.1.3 The effect of chemokine receptor blockade using PTX on the 
adhesion of hepatocytes to liver tissue 
Huh 7.5 cells were incubated with PTX to block chemokine receptor signalling in order to 
establish any role for chemokine receptors in the adhesion of hepatocytes to liver tissue 
(Figure 5.3).   
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Figure 5.2  Static adhesion assay of Huh7.5 to liver tissue with integrin blockade.   
This figure shows the effect of α1, αV and β1 integrin blockade on the adhesion of Huh 
7.5 cells to normal and diseased liver tissue.  Adhesion is expressed as % of IgG control.  
Data shown are the mean and standard error of 4 experiments.  * P<0.05 paired two-
tailed t test. 
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Figure 5.3  Static adhesion assay of Huh7.5 to liver tissue with PTX treatment 
This figure shows the effect of PTX treatment on the adhesion of Huh 7.5 cells to normal 
and diseased liver tissue.  Adhesion is expressed as the mean and standard error number 
of cells per field of view for Huh 7.5 treated with PTX and media only (control).  * p<0.05, 
**p<0.01 paired two-tailed t test. 
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PTX treatment did not reduce the adhesion of Huh 7.5 cells to any of the normal or 
diseased tissue.  However, for PBC tissue PTX treatment resulted in an increase in the 
mean number of cells bound per field of view compared to media only treated cells from 
9.4 ± 2.7 to 18.1 ± 1.9 in parenchymal areas (p=0.008) and 12.9 ± 1.1 to 26.1 ± 2.3 in 
portal tract areas (p=0.009).  Similarly, PTX treatment increased the mean number of 
adherent cells bound to parenchymal areas of NASH liver from 9.4 ± 1.6 to 15.7 ± 0.9 
(p=0.02).  
5.2.1.4 Adhesion to extracellular matrix 
The adhesion of Huh 7.5 cells and primary hepatocytes to extracellular matrix components 
was investigated using a fluorometric assay with binding to matrix proteins compared to a 
BSA control.  For Huh 7.5 cells there was a statistically significant increase in binding to 
collagen types I, II and IV, fibronectin, laminin, tenascin and vitronectin compared to 
control but no significant difference when comparing adhesion between the different ECM 
proteins (Figure 5.4).  Adhesion to VCAM-1 and hyaluronic acid (HA) was also 
investigated but was not significantly different to the control. 
The adhesion of primary hepatocytes to ECM components was similarly investigated.  
There was generally much less binding of primary human hepatocytes to all ECM proteins 
compared to Huh 7.5 cells and no significant adhesion demonstrated to any of the ECM 
components compared to BSA control in this assay (Figure 5.5). 
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Figure 5.4  Static adhesion of huh 7.5 cells to ECM proteins/HA and VCAM-1.   
Adhesion to ECM was assessed using a fluorometric assay kit (ECM proteins) and 
immobilised HA/VCAM-1.  (a) Adhesion to all ECM proteins was significantly greater than 
to the control (p<0.05) but there was no significant difference in adhesion to different 
ECM proteins.  (b) There was no significant adhesion to HA or VCAM-1.  Data shown are 
the mean and standard error of 4 experiments. 
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Figure 5.5 Static adhesion assay of primary hepatocytes to ECM proteins.   
Adhesion to ECM was assessed using a fluorometric assay kit.  There was no significant 
adhesion to any of the ECM components compared to BSA.  Data shown are the mean 
and standard error of 3 experiments. 
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5.2.2 Adhesion of hepatocytes to hepatic sinusoidal endothelium under 
flow 
5.2.2.1 Optimisation of the flow adhesion assay for primary human 
hepatocytes and Huh 7.5 cells 
Huh 7.5 and primary hepatocytes were flowed over hepatic sinusoidal endothelial cells 
which had been treated for 24 hours with TNF-α and IFN-γ.  Occasional brief tethering 
interactions were seen but the rolling adhesion characteristic of leukocytes and some other 
cell types was not observed.  Under standard flow conditions, no primary hepatocytes and 
only very small numbers of Huh 7.5 cells were captured from flow and remained firmly 
adherent to the endothelium (not shown). 
The assay was modified by pausing the flow for a period of time once a stable flow of cells 
across the endothelium had been established.  Flow was then recommenced using wash 
buffer and the number of cells remaining adherent after 5 minutes of washing was counted.  
As observed in the static assay to ECM components, primary human hepatocytes were less 
adherent than Huh 7.5 cells.  A 2 minute pause allowed sufficient Huh 7.5 cells to adhere 
for further blocking studies; primary hepatocytes required a longer 5 minute pause in order 
to obtain a similar number of adherent cells (Figure 5.6).  I therefore used this modified 
flow adhesion assay for further experiments, with a 2 minute pause for Huh 7.5 and a 5 
minute pause for primary human hepatocytes. 
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Figure 5.6  Modification of flow assay to allow hepatocytes to adhere to hepatic 
sinusoidal endothelium. 
Flow was paused in order to allow cells to adhere to the endothelium.  A 2 minute pause 
was sufficient for Huh 7.5 cells while a pause of 5 minutes was required to achieve a 
similar level of adhesion of primary hepatocytes.  Data shown are the mean and standard 
error of 3 experiments. 
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5.2.2.2 The role of integrins in the maintenance of hepatocyte adhesion 
under flow to hepatic sinusoidal endothelium  
Huh 7.5 cells were incubated with function blocking anti-α1, anti-αV and anti-β1 integrin 
antibodies in order to assess the role of these subunits in the adhesion of hepatocytes to 
HSEC (Figure 5.7).  Blocking of α1-integrin had no effect on Huh 7.5 adhesion to HSEC 
(mean percentage of cells remaining adherent after wash 68% ± 6 with IgG control vs. 
69% ± 4. with α1 block, p=0.86).  Blocking of αV integrin increased adhesion to HSEC 
with the mean percentage of cells remaining adherent after wash increasing to 69% ± 5 
compared to 30% ± 10 with IgG control (p=0.04).  Similarly, β1 integrin blockade also 
increased adhesion from a mean of 54% ± 8 to 77% ± 6 (p=0.0006). 
I was interested to find that blocking the αV and β1 integrin subunits consistently 
increased the adhesion of Huh 7.5 cells to HSEC under flow.  I therefore repeated these 
experiments with primary hepatocytes (Figure 5.8).  Blocking of αV integrin had no effect 
on the adhesion of primary hepatocytes to HSEC (mean percentage of cells remaining 
adherent after wash 22% ± 1 with IgG control vs. 19% ± 3 with αV block; p=0.34).  
However, as with Huh 7.5 cells, β1 integrin blockade increased the percentage of cells 
remaining adherent after wash from a mean of 13% ± 4 to 31% ± 6 (p=0.031). 
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Figure 5.7  The effect of integrin blockade on the maintenance of Huh 7.5 cell adhesion 
to HSEC under flow. 
Huh 7.5 were incubated with blocking antibodies to integrin subunits prior to flowing 
over HSEC.  α1-integrin blockade had no effect on adhesion (a); blockade of the αV-
integrin (b) and β1-integrin (c) subunit increased adhesion to HSEC.  Data shown are the 
mean and standard error of at least 3 experiments (dots represent individual 
experiments).  * p<0.05; *** p<0.001. 
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Figure 5.8  The effect of integrin blockade on the maintenance of primary human 
hepatocyte adhesion to HSEC under flow. 
Primary human hepatocytes were incubated with blocking antibodies to integrin subunits 
prior to flowing over HSEC.  αV-integrin blockade had no effect on adhesion (a); blockade 
of the β1-integrin subunit (b) increased adhesion to HSEC.  Data shown are the mean and 
standard error of at least 3 experiments (dots represent individual experiments).  * 
p<0.05. 
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5.2.2.3 Blocking of RGD-binding domains and activation of integrins 
does not affect the adhesion of hepatocytes to HSEC under flow 
To further assess the role of integrins in the adhesion of hepatocytes to HSEC under flow I 
performed a series of further flow adhesion experiments using Huh 7.5 cells.  Firstly I 
investigated the effect of RGD peptide to block integrin binding.  During incubation with 
synthetic RGD peptides, RGD-binding integrins present on the cell surface bind the 
synthetic peptide thereby interfering with subsequent integrin-mediated adhesion (Villard 
et al. 2006).  There was no significant difference in the number of cells remaining adherent 
when comparing those treated with RGD peptide (mean 44% ± 5.6) to those treated with a 
scrambled RGD (sRGD, control) peptide (34% ± 4) (p=0.12, Figure 5.9). 
I next used various activating agents to attempt to increase integrin binding.  Manganese 
chloride (MnCl2) induces integrin activation most likely by stabilising an active 
conformational state (Bazzoni and Hemler 1998).  Phorbol 12-myristate 13-acetate (PMA) 
is a protein kinase C (PKC) activator that promotes adhesion by targeting downstream 
events following ligand binding without significantly affecting the affinity of the receptor 
for the ligand (Bazzoni and Hemler 1998;Liu et al. 2002).  Incubation of Huh 7.5 cells 
with MnCl2 had no effect on adhesion under flow (control cells mean 73% ±16 vs treated 
cells mean 71% ± 12, p=0.79), nor did treatment with PMA (control cells mean 73% ±16 
vs treated cells mean 75% ±18, p=0.46) (Figure 5.10).   
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Figure 5.9  The effect of RGD peptides on the adhesion of Huh 7.5 cells to HSEC under 
flow 
Huh 7.5 cells were incubated with RGD peptide to block potential RGD-binding integrins 
prior to flowing over HSEC.  Incubation with RGD peptide had no effect on adhesion 
compared to cells incubated with a scrambled RGD peptide (control).  Data shown are the 
mean and standard error of 3 experiments (dots represent individual experiments). 
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Figure 5.10  The effect of MnCl2/PMA treatment on the adhesion of Huh 7.5 cells to 
HSEC under flow 
Huh 7.5 cells were incubated with the integrin activating agents MnCl2 or PMA in an 
attempt to increase adhesion to HSEC under flow.  Neither agent increased adhesion 
compared to control (media only) cells.  Data shown are the mean and standard error of 
3 experiments (dots represent individual experiments). 
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Lastly, I incubated Huh 7.5 cells with the anti-β1-integrin antibody TS2/16.  This is a β1-
integrin activating antibody which is thought to induce an active conformation by forcing 
shape change (Byron et al. 2009).  There was no difference in the adhesion of cells treated 
with the TS2/16 antibody (mean 51% ± 11) compared to untreated cells (mean 42% ± 9) 
(p=0.41, Figure 5.11). 
5.2.2.4 The increased adhesion of hepatocytes treated with β1-integrin 
blocking antibody to HSEC under flow is maintained at a variety of antibody 
concentrations and incubation times. 
I was surprised by the finding that β1-integrin blockade resulted in increased hepatocyte 
adhesion to HSEC under flow and therefore decided to investigate whether altering the 
concentration of the antibody or the length of incubation time might alter the effect and 
block adhesion.  I firstly performed a titration experiment with Huh 7.5 cells across a range 
of antibody concentrations from 1ng/ml to 100ng/ml (Figure 5.12).  All antibody 
concentrations within the range tested resulted in a significant increase in Huh 7.5 
adhesion compared to isotype matched control.  The increase in adhesion compared to 
isotype matched control was greater with increasing antibody concentration, with the 
highest concentration (100ng/ml) resulting in a mean percentage of cells remaining 
adherent of 102% ± 5 compared to 56% ± 5 with isotype matched control.   
I then went on to perform a time course experiment using the standard concentration of 
antibody (10ng/ml) with incubation times ranging from 10 minutes to 4 hours (Figure 
5.13).  A 1 hour incubation time appeared to result in the greatest adhesion in the flow 
assay (mean 83% ± 2). 
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Figure 5.11  The effect of the TS2/16 antibody on the adhesion of Huh 7.5 cells to HSEC 
under flow 
Huh 7.5 cells were incubated with the β1-integrin activating antibody TS2/16 prior to 
flowing over HSEC.  Treatment with TS2/16 had no effect compared to cells treated with 
an isotype matched control.  Data shown are the mean and standard error of 4 
experiments (dots represent individual experiments). 
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Figure 5.12  Investigating the effect of anti-β1-integrin antibody concentration on  
maintenance of Huh 7.5 cell adhesion under flow 
Huh 7.5 cells were incubated with a β1-integrin blocking antibody at a range of 
concentrations.  All concentrations in antibody resulted in a significant increase in 
adhesion to HSEC under flow compared to IgG control.  Data shown are the mean and 
standard error of 3 experiments (dots represent individual experiments).  Pairs of groups 
were compared using a paired t test with Bonferroni Correction for multiple comparisons.  
** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 5.13  Time course analysis of Huh 7.5 cells incubated with an anti-β1-integrin 
blocking antibody 
Huh 7.5 cells were incubated with a β1-integrin blocking antibody with incubation times 
ranging from 10 minutes to 4 hours.  A 1 hour incubation time resulted in the greatest 
percentage of cells remaining adherent under flow compared to shorter or longer 
incubation times.  However the differences between incubation times were not 
significant after Bonferroni Correction.  Data shown are the mean and standard error of 3 
experiments (dots represent individual experiments). 
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5.2.2.5 The increased adhesion of anti-β1-integrin treated hepatocytes 
to HSEC under flow is unrelated to TNFα/IFNγ HSEC stimulation and is not 
due to FC receptor interactions  
I next examined two further factors that might have an effect on my unexpected finding of 
increased hepatocyte adhesion following β1-integrin blockade.  Firstly, I repeated the flow 
adhesion assays with Huh 7.5 but without the prior stimulation of HSEC using TNF α and 
INF γ.  β1-integrin blockade still improved adhesion of Huh 7.5 cells to HSEC under flow 
with a mean percentage remaining adherent of 72% ± 9 compared to 46% ± 8 for IgG 
treated cells (p=0.03, Figure 5.14). 
I next wanted to exclude the possibility that the increased adhesion seen with anti-β1-
integrin treated cells was due to FC receptor-antibody interactions.  In order to do this I 
first treated Huh 7.5 cells and the HSEC with a FC receptor blocking reagent prior to 
incubation of the Huh 7.5 cells with the anti-β1-integrin antibody or isotype matched 
control.  Again, β1-integrin blockade resulted in increased adhesion (mean 73% ± 7) 
compared to IgG (mean 56% ±7) (p=0.03, Figure 5.15). 
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Figure 5.14  The effect of β1-integrin blockade on the adhesion of Huh 7.5 cells to 
unstimulated HSEC 
Huh 7.5 cells pre-treated with either a β1-integrin blocking antibody or isotype matched 
control were flowed over unstimulated HSEC.  The percentage of anti-β1-integrin treated 
Huh 7.5 cells remaining adherent under flow was higher compared to those treated with 
an isotype matched control.  Data shown are the mean and standard error of 3 
experiments (dots represent individual experiments).  * p<0.05. 
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Figure 5.15  The effect of a FC receptor blocking reagent on the increased adhesion of 
Huh 7.5 with β1-integrin blockade 
Flow adhesion assays were repeated using anti-β1-integrin or IgG treated Huh 7.5 cells 
following incubation of the Huh 7.5 and HSEC with a FC receptor blocking reagent.  This 
had no effect on the previously demonstrated findings of increased adhesion with anti-
β1-integrin treated cells.  Data shown are the mean and standard error of 3 experiments 
(dots represent individual experiments).  * p<0.05. 
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5.2.2.6 HSEC stimulation with TNF/IFN has no effect on binding of IgG 
or anti-β1-integrin treated hepatocytes to endothelium under flow 
Having shown that prior stimulation of HSEC using TNF α and INF γ had no effect on the 
improved adhesion under flow seen with β1-integrin blockade, I investigated whether 
HSEC stimulation had any effect on the number of cells remaining adherent for both IgG 
and anti-β1-integrin treated cells.  For IgG treated cells, a mean of 46% ± 8 remained 
adherent to unstimulated HSEC compared to a mean of 43/5 ±9 to stimulated HSEC 
(p=0.97).  For anti-β1-integrin cells, a mean of 72% ± 9 remained adherent to unstimulated 
HSEC compared to 72%±9 to stimulated HSEC (p=0.84) (Figure 5.16). 
5.2.2.7 The role of chemokine receptors in the adhesion of hepatocytes 
to hepatic sinusoidal endothelium under flow 
Huh 7.5 cells were incubated with PTX in order to inhibit G-protein signalling and 
therefore block any possible chemokine receptor interactions that may be involved in their 
adhesion to HSEC under flow.  PTX block had no effect on the adhesion of Huh 7.5 cells 
to HSEC with a mean of 63% ± 5 PTX-treated cells remaining adherent after wash 
compared to 63% ± 3 untreated cells (p=0.96, Figure 5.17). 
5.2.3 The effect of β1-integrin blockade on the transmigration of 
hepatocytes through HSEC 
Having established that β1-integrin blockade of hepatocytes leads to an increase in the 
numbers remaining adherent under flow after washing in the flow-based adhesion assays, I 
decided to investigate whether hepatocytes were able to migrate through a HSEC 
monolayer and, if so, whether this increased adhesion led to an increased number of cells 
migrating.  Huh 7.5 cells which had been incubated with an anti-β1-integrin blocking 
antibody or isotype matched control were perfused across HSEC and then the flow was 
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stopped allowing them to settle onto the HSEC layer.  A single field of view was then 
recorded in order to observe transmigration.  After 1 hour cells were observed to start 
migrating into or through the HSEC monolayer (Figure 5.18).  A greater number of anti-
β1-integrin treated cells were seen to migrate compared to IgG treated cells (mean 35.7 ± 
5.2 vs. mean 17.0 ± 1.5, p=0.03). 
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Figure 5.16  The effect of HSEC stimulation with TNF/IFN on the adhesion of IgG and 
anti-β1-integrin treated hepatocytes to HSEC under flow 
Flow adhesion assays were repeated using anti-β1-integrin or IgG treated Huh 7.5 cells 
over both unstimulated HSEC and HSEC stimulated with TNF α and INF γ to investigate 
whether HSEC stimulation had any overall effect on the proportion of cells remaining 
adherent under flow.  Data shown are the mean and standard error of 3 experiments 
(dots represent individual experiments). 
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Figure 5.17  The effect of PTX to block chemokine receptor interactions on the adhesion 
of Huh 7.5 cells to HSEC under flow. 
Huh 7.5 cells were incubated with PTX to block chemokine receptor interactions.  This 
had no effect on their ability to adhere to HSEC under flow.  Data shown are the mean 
and standard error of 3 experiments (dots represent individual experiments). 
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Figure 5.18  Transmigration of hepatocytes across hepatic sinusoidal endothelium 
Huh7.5 cells treated with anti-β1-integrin or IgG control were flowed over a HSEC 
monolayer.  (a) After 1 hour cells were observed to start migrating into or through the 
HSEC monolayer (red circle).  (b) Higher numbers of anti-β1-integrin-treated cells were 
seen to migrate through the HSEC layer than isotype matched control-treated cells.  Data 
expressed as the mean and standard error of 3 independent experiments (dots represent 
individual experiments).  *p<0.05  
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5.2.4 The effect of β1-integrin blockade on the engraftment of human 
hepatocytes into a murine liver 
In order to study the effects of β1-integrin blockade on hepatocyte engraftment in vivo I 
transplanted human hepatocytes into wild type or CCl4 treated mice.  Hepatocytes were 
initially treated with anti-β1-integrin blocking antibody or isotype matched control and 
fluorescently labelled prior to infusion into the portal vein.  After 15 minutes the mice 
were culled and the livers frozen then sectioned. 
On examination of the liver sections, brightly fluorescent cells were clearly seen against 
the dim green autofluoresence of the murine liver.  Some cells were found to be within or 
closely associated with a vessel whereas others appeared to be more distant from vessels. 
β1-integrin blockade of primary human hepatocytes significantly increased their 
engraftment into murine liver.  In wild type mice, the mean number of transplanted cells 
per field of view increased from 0.66 ± 0.14 (IgG treated cells) to 1.56 ± 0.18 (anti-β1-
integrin treated cells, p=0.017).  In CCl4 injured mice, the mean number of transplanted 
cells per field of view increased from 0.71 ± 0.20 (IgG treated cells) to 1.86 ± 0.44 (anti-
β1-integrin treated cells, p=0.038). 
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Figure 5.19  Engraftment of human hepatocytes in murine liver  
Primary human hepatocytes were incubated with anti-β1-integrin antibody or IgG 
control.  The cells were then fluorescently labelled and injected into the portal vein of 
uninjured or CCl4 injured wild type mice which were culled after 15 minutes.  Livers were 
snap frozen and cryosectioned for examination.  (a) Anti-β1 integrin and (b) IgG control 
treated CFSE-labelled hepatocytes are clearly seen against background autofluoresence 
following intraportal injection into mouse liver.  Significantly more fluorescent cells were 
seen in the livers of (c) uninjured and (d) CCl4 injured mice.  Date expressed as mean and 
standard error of at least 3 experiments (dots represent individual experiments), *p<0.05  
c 
d 
uninjured 
CCl4 injured  
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5.3 Discussion 
5.3.1 Adhesion of hepatocytes to liver tissue/ECM under static conditions 
Having demonstrated a range of integrin and chemokine receptor expression by primary 
human hepatocytes I set out to investigate their role in the adhesion of hepatocytes under 
static conditions as well as under flow.  Due to the number of experiments I needed to 
perform and the unpredictable nature of hepatocyte isolation I decided to use the Huh 7.5 
cell line for all initial experiments.  The more important findings were then confirmed 
using primary cells. 
I initially examined adhesion under static conditions to liver tissue sections and 
immobilised ECM components.  Here I used a variety of liver diseases and ECM 
components as our group and others have previously shown differential expression of 
adhesion molecules, chemokines and ECM components in liver disease with consequent 
effects on cell recruitment.  For example, α1, α5, α6 and β1 integrins and ICAM-1 are 
upregulated in fibrosis related to chronic hepatitis C (Nejjari et al. 2001).  A distinct 
pattern of chemokine expression is seen in patients with ALD (Afford et al. 1998) and 
CXCR3 ligands expressed on HSEC mediate T cell recruitment in liver injury (Curbishley 
et al. 2005;Oo et al. 2010;Oo et al. 2012).  In fibrotic liver disease there are changes in 
both the quantity and composition of ECM components with accumulation of collagens, 
fibronectin, laminin and hyaluronan amongst others resulting from increased synthesis and 
reduced degradation due to overexpression of tissue inhibitors of matrix 
metalloproteinases (TIMPs) (Arthur 2000;Bataller and Brenner 2005;Benyon and Iredale 
2000).  I therefore felt it was important to determine whether hepatocytes would 
preferentially adhere to tissue from a specific type of liver disease or to specific ECM 
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components particularly as perhaps the greatest benefit of hepatocyte transplantation 
would be treating patients with pre-existing liver disease.   
Huh 7.5 cells were able to adhere to liver tissue sections  but interestingly there was no 
difference in the numbers that adhered to tissue from normal and different types of liver 
disease.  This may be due to a lack of requirement for specific adhesion pathways for these 
cells, which readily adhere in culture to uncoated flasks.  Alternatively, it may be that the 
required specific mechanisms important for their adhesion to liver tissue were functional in 
all the sections and were not altered by the presence of any particular liver disease.  This is 
backed up by the finding that Huh 7.5 cells adhere to individual ECM components better 
than BSA control, suggesting that adhesion to ECM, presumably through integrins, is 
important.  Huh 7.5 cells express a range of integrins allowing them to bind to ECM 
proteins present in normal and diseased liver.  My integrin expression data suggest that the 
reason for the lack of specificity for any particular ECM component may be that Huh 7.5 
cells express all the integrin subunits required for adhesion to the ECM components tested: 
collagens are bound by α1β1, α2β1, α10β1 and α11β1; fibronectin is bound by αVβ1; 
tenascin is bound by α2β1; laminin is bound by α1β1, α2β1, α7β1 and α10β1; and 
vitronectin is bound by αVβ5 (Humphries et al. 2006).  I also examined adhesion to 
immobilised VCAM-1 and hyaluronic acid because our group has previously shown that 
VCAM-1 and CD44 which can bind hyaluronic acid are important for the recruitment of 
other cells such as human mesenchymal stem cells into injured liver (Aldridge et al. 2012).  
The fact that there was no increased binding to VCAM-1 compared to control is not 
surprising given that Huh 7.5 cells lack the VCAM-1 binding integrins (αDβ2, α9β1, α4β7, 
α4β1).  Similarly, the lack of binding to hyaluronic acid suggests these cells do not express 
CD44 consistent with previous studies that report that human hepatocytes in normal and 
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cirrhotic liver do not express CD44 although expression has been reported in 
hepatocellular carcinoma (Cruickshank et al. 1999;Mathew et al. 1996;Seelentag et al. 
1995).  Having demonstrated Huh 7.5 binding to ECM components I decided to repeat this 
experiment with primary human hepatocytes.  Interestingly there was no significant 
adhesion to any of the ECM components compared to BSA control despite primary human 
hepatocytes expressing the necessary integrins.  I suspect that this may be due to a lack of 
sensitivity of the experimental technique combined with the fact that, in my experience, a 
large proportion of hepatocytes often fail to attach in culture without optimal conditions.  
Most protocols for hepatocyte culture, including my own, require initial plating in media 
containing serum which is changed to serum free media after several hours; this process 
was not possible during this assay.  
I next investigated the effect of blocking the 3 major integrin subunits I had identified as 
being expressed on the surface of primary human hepatocytes.  Blockade of the α1 or αV 
integrins resulted in some reduction in adhesion to most types of liver tissue tested, 
although the exact pattern varied depending on disease.  Interestingly, the results from 
normal and NASH liver looked almost identical with a significant reduction in adhesion to 
parenchymal and portal areas with αV-integrin block and parenchymal areas only with α1-
integrin block.  Whether these differences in the blocking effect of anti α1/αV antibodies 
might relate to specific patterns of ECM deposition in different diseases is unclear from 
the literature.  Most likely the differences relate to limitations of the assay and variations in 
cells and tissue samples outside my control.  However, it does seem likely that α1- and 
αV- integrins are important.  Blockade of α1- integrin has been previously shown to block 
rat hepatocyte adhesion to collagen I and IV and also to liver sections (Kocken et al. 
1997;Pinkse et al. 2004).  It is possible that αVβ5, which is expressed highly by Huh 7.5 
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cells, is involved in their adhesion although this is unlikely to be relevant to primary cells 
where I have not been able to demonstrate αVβ5 integrin expression although I did detect 
the αV chain by flow cytometry and RT-PCR.  Indeed, normal hepatocytes are thought not 
to express any αV-integrins, although they are expressed in hepatocellular carcinoma 
(Nejjari et al. 2002).   
β1-integrin blockade only resulted in a significant reduction in adhesion to parenchymal 
areas of AIH liver with no effect on adhesion to other liver types.  This was most 
surprising as numerous studies have reported a role for β1-integrin in hepatocyte adhesion.  
Rat hepatocytes treated with an anti-β1-integrin antibody show loss of attachment to 
isolated collagen I and IV, laminin and fibronectin as well as both vessel walls and 
parenchymal areas of liver sections (Kocken et al. 1997;Pinkse et al. 2004).  The 
impairment of adhesion seen after cryopreservation of human hepatocytes appears to be 
partly due to a down-regulation of β1-integrin expression with a direct correlation between 
loss of β1-integrin and attachment (Terry et al. 2007).  Serum from patients with fulminant 
hepatic failure leads to a down-regulation in human hepatocyte β1-integrin activity with 
loss of cellular adhesion; this effect is prevented when hepatocytes are treated with a β1-
integrin activating antibody (Newsome et al. 2004).  I had therefore expected β1-integrin 
blockade to significantly reduce adhesion in these experiments.  However, in the absence 
of expression of other β subunits that are known to associate with α1- and αV- integrins, I 
suspect that α1β1 and αVβ1 are important for hepatocyte adhesion.  It is also possible that 
integrins which I have demonstrated to be expressed at lower levels but have not tested in 
these experiments, such as α10β1 and α11β1, may also contribute.  The extensive previous 
literature describing a role for β1-integrin in hepatocyte adhesion, albeit mainly focussing 
on non-human hepatocytes, as well as the fact that I did see a reduction in binding to AIH 
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liver, is highly suggestive that β1-integrins are involved in human hepatocyte adhesion.  I 
therefore hypothesise that some other, as yet undetermined factor, is preventing the 
significant reduction in hepatocyte adhesion with β1-integrin block described elsewhere.  
Possible mechanisms for this include the presence of other adhesion pathways that may be 
upregulated in response to blocking β1-integrin.  It is also possible that the particular 
antibody used does not function well in this particular assay, but I feel this is unlikely as 
our group has used the same antibody at the same concentration to successfully block 
adhesion of other cell types such as mesenchymal stem cells in similar experiments. 
Finally I used PTX to block chemokine receptor signalling in order to demonstrate any 
possible role for chemokine receptors in adhesion to liver tissue.  PTX block did not result 
in any reduction in adhesion suggesting that chemokine receptors do not contribute to 
hepatocyte adhesion to liver tissue; conversely adhesion was significantly increased in 
some experiments.  Why this might be is unclear and may relate to mechanisms not 
involving chemokine receptors.  Similar effects of PTX have been described with other 
cell types.  For example, myelomonocytic cells show increased adhesion to vitronectin 
when exposed to PTX, possibly through binding to CD14 on the cell surface leading to 
increased activity of urokinase-type plasminogen activator receptor (uPAR) which is also a 
vitronectin receptor that promotes cell adhesion and migration (Li and Wong 2000;Madsen 
et al. 2007;Wong et al. 1996).  Hepatocytes are known to express CD14 (Pan et al. 
2000;Su et al. 1999) and it is possible that PTX may enhance hepatocyte adhesion through 
a similar pathway. 
5.3.2 Adhesion of hepatocytes to HSEC under flow 
I next moved on to look at hepatocyte adhesion to HSEC under flow.  My initial 
optimisation experiments showed that neither primary human hepatocytes or Huh 7.5 cells 
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showed the characteristic cascade of initial capture with tethering/rolling interactions prior 
to firm adhesion as seen with lymphocytes (Lalor and Adams 1999).  Indeed, negligible 
numbers of cells were able to adhere to endothelium under flow.  This is not surprising as 
these cells would not normally migrate through the vasculature.  Work in our laboratory 
investigating human mesenchymal stem cell recruitment to liver demonstrated similar 
findings which led us to develop a modified flow assay technique whereby flow is paused 
for a period of time to allow initial adhesion (Aldridge et al. 2012).  Flow is then 
recommenced, thus washing away cells which are not firmly adherent.  Adhesion can then 
be quantified as the percentage of cells present per field of view while the flow is stopped 
that remain adherent once flow is restarted.  As discussed previously, it is likely that 
human hepatocytes become mechanically lodged to some extent within the liver sinusoids 
following intraportal infusion.  I therefore feel that my modified flow adhesion assay better 
resembles the in vivo environment with the stopping of flow modelling the 
slowing/lodging of cells within the sinusoids.  
Once again I concentrated on the 3 most highly expressed integrins on primary human 
hepatocytes and, using Huh 7.5 cells initially, established that α1-integrin did not appear to 
have a role in hepatocyte adhesion to HSEC under flow.  Similarly, PTX toxin block had 
no effect on adhesion suggesting that chemokine receptors are not involved in adhesion to 
HSEC.  This was expected given that hepatocytes did not appear to undergo the 
tethering/rolling under flow seen with leucocytes during which time chemokine signals 
lead to activation of integrins which in turn permit firm adhesion.  However, I was then 
surprised to find that blocking αV- or β1-integrin significantly increased adhesion to 
HSEC.  Because this finding was unexpected I repeated the experiments with primary 
hepatocytes.  Whilst αV-integrin blockade no longer had any effect, β1-integrin blockade 
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again significantly increased adhesion.  As discussed in Chapter 1, there is little in the 
literature describing the interaction between hepatocytes and HSEC other than animal data 
suggesting that integrin mediated pathways may be important.  It is possible that some of 
the integrins expressed at lower levels by hepatocytes are involved, or that hepatocytes 
express ligands for integrins present on HSEC.  Alternatively other non-integrin adhesion 
molecules which I have not investigated may be more important for adhesion in this 
context.   
Why β1-integrin blockade should increase adhesion was unclear and I wanted to satisfy 
myself that this was a true finding.  I therefore performed a series of experiments 
demonstrating that the effect of β1-integrin blockade persisted with lower or higher 
antibody concentrations and different antibody incubation times.  Next, I repeated the 
experiment with unstimulated HSEC and again showed increased adhesion with anti-β1-
integrin treated hepatocytes compared to IgG control.  Lastly, as HSEC are also known to 
express β1-integrin and both HSEC and hepatocytes have FC receptors then I also wanted 
to exclude the possibility of the antibody binding β1-integrin on hepatocytes and 
subsequently binding HSEC via FC receptors or vice-versa.  However, addition of a FC 
receptor blocking agent did not reverse the increased adhesion seen with β1-integrin 
blockade.  Furthermore, if the effect seen with β1-integrin blockade was due to FC 
receptor binding then it would be expected that a similar effect would have been seen with 
anti α1- and αV-integrin antibodies.  I was therefore confident that β1-integrin blockade of 
primary human hepatocytes does increase their adhesion to HSEC under flow.   
5.3.3 Transmigration of human hepatocytes through HSEC 
Increasing adhesion of hepatocytes to sinusoidal endothelium would be of little benefit if 
this did not translate into increased engraftment into the liver.  I therefore went on to 
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question whether hepatocytes, having adhered to HSEC, would transmigrate through an 
HSEC layer and whether β1-integrin blockade might also increase the number 
transmigrating.  I used the same technique as for the modified flow adhesion assay up until 
the point when the flow was paused and the cells settled onto the HSEC monolayer when 
the microslide was transferred to a JuLi Cell Analyser in order to capture transmigration.   
Between 1 and 4 hours, cells were seen to move into the HSEC monolayer, and 
significantly more cells were seen to move when they were pre-treated with anti-β1-
integrin blocking antibody compared to those treated with IgG control.  Presumably this is 
due to the increase in initial adhesion to HSEC which I have demonstrated in the preceding 
experiments, although it is possible that signalling as a result of the β1-integrin blocking 
antibody also results in a more migratory phenotype through other mechanisms.  Whether 
the movement seen represented migration into or transmigration across the HSEC 
monolayer is not clear from this assay.  However, it is clear from animal experiments, as 
outlined in the introduction chapter, that hepatocytes are able to transmigrate into the liver 
parenchyma from the hepatic sinusoids.  Taken together with the results of this experiment 
I hypothesised that β1-integrin blockade would increase transmigration across HSEC into 
the liver.  
5.3.4 Engraftment of human hepatocytes in murine liver 
Many groups have demonstrated that human hepatocytes are able to successfully engraft of 
human in murine liver.  As such models are well established and the techniques involved 
relatively straight forward I felt that a murine model would be ideal to investigate the 
effect of β1-integrin blockade on engraftment of human hepatocytes in vivo.  I initially 
selected the FRG mouse and successfully established a colony within our animal facility.  
This mouse, a model of human Tyrosinaemia Type 1, has several advantages as described 
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in the introduction.  However, despite the successful use of this model for human 
hepatocyte transplantation reported by other groups, I found considerable variability in the 
ability of FRG mice to tolerate general anaesthesia and surgery.  After discussion with our 
veterinary surgeon I therefore opted to use a different model. 
The C57BL/6 mouse has been used extensively for murine to murine hepatocyte transplant 
experiments.  Our group has also used this mouse model for previous work including 
developing a CCl4 liver injury model and have successfully transplanted human 
mesenchymal stem cells into both CCl4 injured and non-injured mice by intraportal 
injection (Aldridge et al. 2012).  I therefore chose this model and transplanted anti-β1-
integrin or IgG treated hepatocytes into both injured and non-injured mice.  I chose a 15 
minute end point as I wanted a long enough period to allow cells to travel throughout the 
liver and for cells that failed to bind successfully within the sinusoids to be washed away.  
However, importantly it was also short enough that mice could be easily maintained in a 
stable condition under general anaesthesia. 
When analysing the livers following hepatocyte transplantation I wanted to ensure as far as 
possible that the results were representative of the situation in the whole liver.  Therefore 
sections were taken from several positions within different lobes of the liver and fields of 
view were selected randomly from several different sections.  I only wanted to count 
transplanted cells that were truly adherent or trapped within vessels/sinusoids and therefore 
rejected any fields of view where there were large clumps of cells or debris, or where the 
liver parenchyma was damaged. 
Individual fluorescent cells were seen throughout the livers of all mice following 
transplantation of CFSE-labelled human hepatocytes.  Many cells appeared to be within or 
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close to a vessel, although smaller numbers appeared to be within the parenchyma.  The 
overall numbers of cells seen in any field of view were small.  However, when one 
considers the relatively small number of cells transplanted (1×10
6
 cells) and the volume of 
one field of view of a 5µm section compared to that of the whole mouse liver, the numbers 
appear appropriate.  Interestingly, in keeping with my in vitro findings, more transplanted 
hepatocytes were found in the livers of mice receiving anti-β1-integrin treated cells 
compared to those receiving IgG-treated cells.  This was true for both wild type and CCl4 
injured mice suggesting that liver fibrosis is not a barrier at least to the early stages of 
hepatocyte engraftment following intraportal infusion.  It is possible that the presence of a 
degree of liver injury may be beneficial to initial engraftment due to the cytokine effects 
leading to upregulation or differential expression of adhesion molecules in disease states.  
Indeed, slightly higher numbers of IgG and anti-β1-integrin treated hepatocytes were seen 
in CCl4 treated livers than wild type although this did not reach statistical significance.  
There is one report in the literature of similar findings following transplantation of Brown 
Norway rat hepatocytes into immunocompromised Lewis rats.  At day 2 following 
intraportal infusion of 1×10
7
 untreated hepatocytes, 2.39% ± 0.27% of the transplanted 
hepatocytes were found in the liver parenchyma.  Following infusion of hepatocytes 
treated with an anti-β1-integrin antibody, 36.31% ± 8.15% of transplanted hepatocytes 
were found in the recipient liver at day 2 representing a significant (p<0.001) increase in 
survival  (Kocken et al. 1997).    
In conclusion, I have demonstrated in this chapter that although β1-integrins are likely to 
have an important role in human hepatocyte adhesion, incubation with anti-β1-integrin 
blocking antibodies alone has a minimal effect on adhesion under static conditions.  
However, pre-treatment of isolated human hepatocytes with an anti-β1-integrin antibody 
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increases their ability to remain adherent to sinusoidal endothelium under flow and results 
in an increase in early engraftment of human hepatocytes in murine liver following 
intraportal infusion.  The underlying mechanisms as yet remain unclear. 
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CHAPTER 6:  INVESTIGATING THE MECHANISMS UNDERLYING 
THE EFFECT OF Β1-INTEGRIN BLOCKADE ON HUMAN 
HEPATOCYTE ADHESION AND ENGRAFTMENT 
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6.1 Introduction 
The work described in the previous chapters led me to focus on β1-integrin and the effects 
of β1-integrin blockade on human hepatocyte adhesion and engraftment into liver.  Rather 
than blocking adhesion of human hepatocytes, treatment with anti-β1-integrin antibodies 
confers an increased ability to remain adherent to sinusoidal endothelium under flow, 
improves migration across HSEC and leads to higher numbers of cells retained within 
murine livers following transplant by intraportal infusion.  The mechanism by which 
blocking a molecule classically described as an adhesion molecule might lead to increased 
adhesion is not immediately clear.   
The phenomenon of anoikis, or detachment-related cell death, has been demonstrated in 
isolated hepatocytes and is one of the stumbling blocks to successful hepatocyte 
transplantation (Zvibel et al. 2002).  Treatment of rat hepatocytes with anti-β1-integrin 
antibodies increases their survival (Kocken et al. 1997;Pinkse et al. 2004).  It has been 
suggested that this occurs through the activation of integrin-linked kinase (ILK) and 
subsequent phosphorylation of protein kinase B/Akt (Pinkse et al. 2005).   
Activation of integrin related signalling pathways and improved survival of isolated 
primary human hepatocytes through the prevention of anoikis could potentially go some 
way to explain the improvement in adhesion and engraftment observed following anti-β1-
integrin treated hepatocytes.  I therefore investigated whether anti-β1-integrin antibodies 
result in activation of a cell survival signalling pathway in human hepatocytes.  
6.1.1 Anoikis 
For most cells, their position within tissue is crucial to their function and that of the organs 
of which they are part.  Integrins on the cell surface are able to interact with ECM and 
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form a link with the cytoskeleton activating signalling cascades and influencing responses 
to other stimuli (Lee and Juliano 2004;Shattil et al. 2010).  If cells lose their usual cell-
ECM interactions, a specific form of caspase-dependant apoptosis, known as anoikis, 
occurs (Frisch and Ruoslahti 1997).  Thus anoikis provides a means by which `misplaced’ 
cells may be eliminated; overcoming anoikis is a crucial step in the development of 
malignancy allowing tumour cells to disseminate throughout the body (Guadamillas et al. 
2011). 
Anoikis is not a single specific pathway leading to cell death; rather, different cells 
respond to loss of adhesion to ECM via a diverse range of signalling mechanisms.  Anoikis 
progresses via the interplay of two different apoptotic signalling pathways which 
ultimately converge on the activation of caspases (Gilmore 2005).  These two pathways, 
termed the intrinsic and extrinsic pathways, are summarised in Figure 6.1.  The intrinsic 
pathway may be triggered by intracellular signals, such as DNA damage and endoplasmic 
reticulum stress through the action of pro-apoptotic regulator proteins of the B cell 
lymphoma-2 (Bcl-2) family, including Bcl-2-associated death promoter (Bad), Bcl-2-
associated X protein (Bax), Bcl-2-interacting domain (Bid) and Bcl-2-interacting mediator 
of cell death (Bim).  These lead to mitochondrial permeabilisation and release of pro-
apoptotic factors such as cytochrome c and second mitochondria-derived activator of 
caspases/direct inhibitor of apoptosis binding protein with low pI (Smac/DIABLO) with 
subsequent assembly of the so-called apoptosome and caspase activation.  The extrinsic 
pathway is initiated by the binding of ligands to death receptors of the tumour necrosis 
factor receptor (TNFR) superfamily such as Fas receptor, TNFR1 and TNF-related 
apoptosis inducing ligand (TRAIL) receptors.  This results in the formation of the death-
189 
 
inducing signalling complex (DISC) which in turn leads to caspase activation (Chiarugi 
and Giannoni 2008;Guadamillas et al. 2011;Paoli et al. 2013). 
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Figure 6.1  The extrinsic and intrinsic apoptotic pathways 
Anoikis, or detachment-related cell death, occurs through the activation of two apoptotic 
pathways.  In the extrinsic pathway, engagement of death receptors such as TNFR1, Fas 
and TRAIL receptors leads to formation of the death-inducing signalling complex (DISC).  
The interaction of DISC with adaptor proteins such as the Fas-associated death domain 
(FADD) results in the activation of caspase-8 and downstream executioner caspases.  In 
the intrinsic pathway, activation of the pro-apoptotic BH3-only group of the Bcl-2 protein 
family leads to translocation of Bax/Bak to the outer mitochondrial membrane where 
their oligomerisation creates a channel resulting in cytochrome c release.   
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BH3-only activators (e.g. Bid, Bim) directly promote Bax/Bak oligomerisation whilst 
sensitizers (e.g. Bad, Bmf) block the anti-apoptotic effects of Bcl-2.  Cytochrome c 
together with caspase-9 and apoptosis protease activating factor (Apaf) form the 
apoptosome which results in downstream caspase activation.  Caspase-8 activation may 
also cleave Bid to a truncated form (t-Bid) which also promotes mitochondrial 
cytochrome c release, thereby linking the intrinsic and extrinsic pathways. 
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6.1.2 Caspases 
Caspases are a family of proteases with a critical role in cell death and inflammation.  
Those involved in cell death may be divided into two groups: initiator caspases (caspase-8 
and -9) exist as inactive procaspase monomers that are activated by dimerization brought 
about by upstream signalling events; executioner caspases (caspase-3, -6 and -7) are 
produced as inactive dimers which are activated through cleavage by initiator caspases and 
subsequently other activated executioner caspases (McIlwain et al. 2013). 
Caspase-3 in particular is a key protease in mammalian cell death and is activated by a 
variety of agents that induce apoptosis.  Many of the typical hallmarks of apoptosis are 
dependent on caspase-3 and it is indispensable for chromatin condensation and DNA 
fragmentation during cell death (Nicholson et al. 1995;Perry et al. 1997;Porter and Janicke 
1999).  Caspase-3 activity has been demonstrated in hepatocytes subjected to a variety of 
apoptotic stimuli and is therefore a useful marker of hepatocyte apoptosis (Kubota et al. 
2004;Li et al. 2003;Tapalaga et al. 2002) and I therefore selected caspase-3 activity to use 
as a more specific marker of apoptosis in human hepatocytes along with a more generic 
flow cytometry viability marker.  
6.1.3 The PKB/Akt signalling pathway and cell survival 
Protein kinase B or Akt (PKB/Akt) is a serine/threonine kinase which has a key role in cell 
survival, metabolism, motility and the cell cycle.  Three members of the family have been 
identified in mammals, termed PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3 (Fayard et al. 
2005;Manning and Cantley 2007).  PKB/Akt is a downstream target for phosphoinositide 
3-kinase (PI-3K) which may be activated by insulin or other growth factors, G-protein 
coupled receptor stimulation or integrin signalling (Foster et al. 2003;Wymann et al. 
2003).  PI-3K activation  results in the generation of second messengers which in turn 
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allows the translocation of PKB/Akt to the plasma membrane from the cytoplasm.  Once at 
the plasma membrane, PKB/Akt undergoes phosphorylation at threonine 308 (Thr308) by 
phosphoinositide-dependent kinase-1 (PDK-1) (Alessi et al. 1997) and serine 473 
(Ser473).  Ser473 phosphorylation may occur via a variety or mechanisms including 
mammalian target of rapamycin (mTOR) complex 2 (mTORC2), DNA-dependent protein 
kinase (DNA-PK), ILK or by autophosphorylation (Delcommenne et al. 1998;Feng et al. 
2004;Sarbassov et al. 2005;Toker and Newton 2000).  Phosphorylation of both residues is 
required for maximal PKB/Akt activity (Alessi et al. 1996). 
Activation of the PKB/Akt signalling pathway promotes cell survival through direct action 
on mediators of apoptosis (such as Bad and caspase-9), regulation of transcription factors 
associated with pro- and anti-apoptotic genes and interactions with metabolic pathways 
such as the inhibition of glycogen synthase kinase 3 (GSK3) (Song et al. 2005). 
6.1.4 Activation of the PKB/Akt pathway by integrin ligation 
Integrins do not possess any intrinsic enzymatic activity and so integrin signalling depends 
on the recruitment of various associated signalling proteins (Harburger and Calderwood 
2009;Schiller et al. 2011).  ILK is one such protein that has been studied extensively.  ILK 
is recruited to β1 and β3 integrins and thought to influence various processes including 
cytoskeletal rearrangement, cell polarisation, spreading and migration, and cell 
proliferation and survival (Attwell et al. 2000;Hannigan et al. 2005;Hannigan et al. 
1996;Widmaier et al. 2012).  It has been demonstrated that ILK may have a role in 
phosphorylation of PKB/Akt on Ser473 (Troussard et al. 2003) and, as mentioned above, 
ILK has been suggested as a possible link between β1-integrin and PKB/Akt.  However, 
the exact nature of ILK signalling remains unclear; whilst many earlier studies reported 
ILK to be a serine/threonine kinase it lacks several highly conserved motifs present in 
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most kinases and more recent evidence suggests that ILK lacks true kinase activity 
(Wickstrom et al. 2010;Widmaier et al. 2012).  Other authors suggest that, rather than 
acting as a true kinase and directly phosphorylating PKB/Akt, it may act as an adapter 
protein that activates another kinase or inhibits a S473 phosphatase (Lynch et al. 1999).  
Other intermediate proteins that have been shown to be involved in β1-integrin signalling 
include focal adhesion kinase (FAK) and Src family kinases but it has been shown that β1-
integrin may induce PKB/Akt phosphorylation independently of these pathways (Velling 
et al. 2004).  β1-integrin may also modify PKB/Akt signalling through activation of 
phosphatases such as protein phosphatase 2A (PP2A) (Pankov et al. 2003).  
Due to the uncertainty surrounding the role of ILK and the mechanism by which integrin 
ligation leads to PKB/Akt activation, I decided to focus on investigating PKB/Akt 
phosphorylation directly in order to ascertain whether this pathway is activated in human 
hepatocytes following ligation by anti-β1-integrin antibodies. 
6.2 Results 
6.2.1 Human hepatocytes treated with anti-β1-integrin antibodies show 
increased viability 
Primary human hepatocytes were incubated in suspension for 1 hour with anti-β1-integrin 
antibodies or isotype matched control antibody before labelling with a viability marker for 
flow cytometry.  Hepatocytes treated with anti-β1-integrin antibodies showed a small but 
significant increase in viability compared to those treated with IgG control (mean viability 
24.9% ± 3.3 vs. 21.4% ± 3.4; p=0.01); similar findings were demonstrated with Huh 7.5 
cells although the viability in both groups was much higher than for primary hepatocytes 
(mean viability 85.4% ± 1.6 vs. 79.1% ± 2.2; p=0.02) (Figure 6.2 a, b). 
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To confirm the findings, primary hepatocytes and Huh 7.5 cells were treated in a similar 
manner with anti-β1-integrin antibodies or isotype matched control and viability assessed 
using trypan blue dye exclusion.  Again, viability was significantly higher following anti-
β1-integrin antibody treatment for both primary hepatocytes (mean viability 49.7% ± 3.8 
vs. 36.3% ± 5.8; p=0.03) and Huh 7.5 cells (mean viability 75.8% ± 6.2 vs. 58.4% ± 4.2; 
p=0.01).    
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Figure 6.2 The effect of anti-β1-integrin antibodies on hepatocyte viability measured by 
flow cytometry 
Primary hepatocyte and Huh 7.5 viability was assessed by flow cytometry using a cell 
viability marker.  Incubation of (a) primary hepatocytes and (b) Huh 7.5 with anti-β1-
integrin antibodies led to a small but significant increase in mean viability compared to 
those incubated with isotype matched control.  Date expressed as mean and standard 
error of at least 3 experiments (dots represent individual experiments), *p<0.05.  
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Figure 6.3 The effect of anti-β1-integrin antibodies on hepatocyte viability measured by 
trypan blue dye exclusion 
Primary hepatocyte and Huh 7.5 viability was assessed using trypan blue dye exclusion.  
Incubation  of (a) primary hepatocytes and (b) Huh 7.5 with anti-β1-integrin antibodies 
led to a small but significant increase in mean viability compared to those incubated with 
isotype matched control.  Date expressed as mean and standard error of 3 experiments 
(dots represent individual experiments), *p<0.05.  
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6.2.2 Treatment of human hepatocytes with anti-β1-integrin antibodies 
results in a reduction in caspase-3 activity 
Caspase-3 activity was then measured in lysates of hepatocytes or Huh 7.5 cells s 
incubated for 1 hour in suspension with anti-β1-integrin antibodies or isotype matched 
control.  Caspase-3 activity as indicated by cleaved caspase 3 ELISA was significantly 
reduced in hepatocytes that had been treated with anti-β1-integrin antibodies (mean 
absorbance 1.37 ± 0.28 vs. 1.90 ± 0.36, p=0.02).  Caspase-3 activity was similarly reduced 
in Huh 7.5 cells (mean absorbance 1.672 ± 0.24 vs. 1.943.± 0.26, p=0.002) (Figure 6.4 a, 
b). 
6.2.3 Treatment of human hepatocytes with anti-β1-integrin antibodies 
results in activation of the protein kinase B/Akt pathway 
Western blotting was used to evaluate PKB/Akt phosphorylation in hepatocytes treated 
with anti-β1-integrin antibodies compared to those treated with IgG control.  Total Akt 
levels were constant across experiments; however, phosphorylated Akt levels were 
increased in hepatocytes treated with anti-β1-integrin antibodies (mean relative density 3.5 
± 0.73; p=0.03) suggesting that this treatment does lead to Akt activation within human 
hepatocytes (Figure 6.5). 
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Figure 6.4 The effect of anti-β1-integrin antibodies on hepatocyte caspase-3 activity 
Caspase-3 activity was measured by cleaved caspase-3 ELISA of hepatocyte lysates from 
(a) primary hepatocytes and (b) Huh 7.5 cells treated with anti-β1-integrin antibodies.  
Data expressed as mean and standard error of ≥3 independent experiments (dots 
represent individual experiments).  *p<0.05, **p<0.01.   
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Figure 6.5 The effect of anti-β1-integrin antibodies on AKT signalling in primary human 
hepatocytes 
Cell lysates were made form primary human hepatocytes following incubation with anti-
β1-integrin antibodies or isotype matched control and the protein concentration 
normalised.  Total and phosphorylated AKT were measured by Western Blot.  
Representative blots (two replicates) are shown for (a) total AKT and (b) phosphorylated 
AKT.   
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6.2.4 Human hepatocytes treated with anti-β1-integrin antibodies and 
allowed to adhere to HSEC demonstrate cytoskeletal reorganisation  
I next investigated the interaction between hepatocytes and HSEC in vitro.  Huh 7.5 cells 
transfected with GFP-vinculin and RFP-actin were incubated with anti-β1-integrin 
antibodies or isotype matched control and subsequently layered over an HSEC monolayer.  
Confocal microscopy was used to obtain images of individual Huh 7.5 cells once they had 
settled onto the HSEC.  Huh 7.5 cells that had been pre-treated with anti-β1-integrin 
antibodies showed filamentous actin projections.  Far fewer projections were seen with 
IgG control treated cells.  Anti-β1-integrin treated cells also clearly demonstrated the 
formation of multiple discrete areas of actin/vinculin co-localisation at the point of contact 
between the Huh7.5 and HSEC suggesting the formation of focal adhesions/adherens 
junctions (Figure 6.6).  
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Figure 6.6 Action of anti-β1-integrin antibodies on hepatocyte cytoskeleton 
Huh7.5 cells were transfected with plasmids containing GFP tagged vinculin and RFP 
tagged actin.  The transfected cells were then allowed to adhere to a HSEC monolayer 
and imaged using confocal microscopy.  Representative images with GFP and RFP 
colocalisation at the level of the interface with underlying HSEC are shown (100X 
magnification).  (a) Huh7.5 pre-treated with anti-β1-integrin antibodies appeared to be 
spreading and showed filamentous projections and discrete areas of actin and vinculin 
colocalisation.  (b) Cells treated with isotype matched control showed fewer projections 
and far less colocalisation of actin and vinculin.    
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6.3 Discussion 
6.3.1 Hepatocyte survival 
The importance of attachment to ECM for hepatocyte survival is well described, and β1-
integrin in particular has been found to play a crucial role in hepatocytes.  Rat hepatocytes 
cultured on polyhydroxyethylmethacrylate (polyHEMA) coated plates to prevent 
attachment rapidly show more extensive DNA fragmentation, a  hallmark of apoptosis, 
than those cultured on ECM components.  However, when hepatocytes that have been pre-
incubated with anti-β1-integrin antibodies are cultured on polyHEMA there is a marked 
reduction in DNA fragmentation.  Even when cultured on different ECM components to 
which hepatocytes are able to adhere, such as collagen, laminin and fibronectin, hepatocyte 
DNA fragmentation was evident within 5 hours of plating.  However, no DNA 
fragmentation was detected up to 24 hours after plating in hepatocytes that had been pre-
treated with anti-β1-integrin antibodies and cultured on ECM components (Pinkse et al. 
2004).  Furthermore, freshly isolated rat hepatocytes incubated with anti-β1-integrin 
antibodies showed a reduction in caspase-3 immunostaining compared to untreated 
hepatocytes (20.1±3.4% vs 39.8±3.9%, P<0.02), again suggesting a reduction in apoptosis 
(Pinkse et al. 2005).    
My data confirms that the findings previously demonstrated in rat hepatocytes are 
replicated in human hepatocytes.  I have demonstrated an increase in viability of human 
hepatocytes cultured in suspension with anti-β1-integrin antibodies.  It is interesting that 
viability of primary hepatocytes was much lower in both the IgG and anti-β1-integrin 
groups compared to Huh 7.5 cells undergoing the same treatment.  This is likely to reflect 
the fragility of primary hepatocytes especially when removed from culture flasks, with the 
necessary subjection to enzymes, and kept in suspension for a prolonged period.  Huh 7.5 
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cells, however, are a cell line derived from hepatocellular carcinoma and are likely to have 
a degree of anoikis resistance.  Absolute viability also varied for both primary hepatocytes 
and Huh7.5 cells in control and treatment groups between experiments.  This was also the 
case in the flow adhesion assays described earlier, and likely reflects lot-to-lot variation in 
the quality of cells and the imprecise nature of certain steps in the experimental procedure 
such as removing cells from the culture flask.   
The difference in viability between anti-β1-integrin treated and control cells, although 
significant, was small.  However, repeating the experiment with both primary and Huh 7.5 
cells using an alternative method of viability assessment produced similar results, and so I 
believe the difference to be real.  Further, I have demonstrated reduced caspase-3 activity 
in isolated hepatocytes treated with anti-β1-integrin antibodies demonstrating a definite 
effect on the apoptotic pathway.  Together these findings suggest that a similar β1-integrin 
mediated survival mechanism operates in human hepatocytes to that demonstrated 
previously in rat hepatocytes.  One aspect that I have not studied here is the length of 
incubation with anti-β1-integrin antibodies, instead keeping to 1 hour which I used as a 
standard incubation time for all experiments.  It is quite possible that longer incubation 
times may have revealed a greater difference in viability between anti-β1-integrin and 
isotype matched control treated cells.  However, time course experiments described in 
5.2.2.4 did not reveal an increase in hepatocyte adhesion to HSEC under flow with anti-
β1-integrin antibody incubation times up to 4 hours compared to incubation for 1 hour.  
Therefore it is possible that only a small difference in viability may contribute to the 
differences in adhesion, migration and engraftment described in previous chapters.  
Alternatively, it may be that the effect on viability of the anti-β1-integrin antibody is 
unrelated to the effects seen in earlier studies. 
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6.3.2 PKB/Akt signalling 
The PKB/Akt signalling pathway is well known to have a crucial role in cell survival and 
the anti-apoptotic and regenerative effects of PKB/Akt are important in hepatocyte 
survival and liver regeneration as well as the development of tumours such as HCC.  
Indeed, following partial hepatectomy, PKB/Akt is markedly activated and active 
PKB/Akt is essential for liver regeneration (Haga et al. 2009;Hong et al. 2000).  
Conversely the use of drugs such as fenofibrate, a fibric acid derivative with lipid-lowering 
activity, can be limited due to hepatic toxicity due to caspase dependent hepatocyte 
apoptosis resulting from the inhibition of PKB/Akt phosphorylation (Kubota et al. 2005).  
Fenofibrate may also suppress the growth of human HCC by blocking PKB/Akt activation 
(Yamasaki et al. 2011) whereas activation of PI-3K/PKB/Akt signalling with a drive 
towards cell survival mediates resistance to certain therapeutic agents for HCC (Chen et al. 
2011). 
My finding of an increase in PKB/Akt Ser473 phosphorylation following treatment of 
hepatocytes with anti-β1-integrin blocking antibodies suggests that the PKB/Akt signalling 
pathway is activated in human hepatocytes by β1-integrin and that anti-β1-integrin 
blocking antibodies are able to mimic the signal that is normally delivered through 
interaction with ECM.  The improvement in hepatocyte viability that I have demonstrated 
following incubation with anti-β1-integrin blocking antibodies is likely to result from 
PKB/Akt activation and subsequent modulation of the apoptotic pathway and thus 
prevention of anoikis.  
PKB/Akt signalling has previously been identified as a likely mechanism for β1-integrin 
mediated survival in several cell types.  Treatment of rat hepatocytes cultured on 
polyHEMA with anti-β1-integrin antibodies results in a significant increase in the 
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proportion of hepatocytes expressing Ser473 phosphorylated PKB/Akt (assessed by 
immunostaining) compared to untreated hepatocytes (80% vs 20%; P<0.05) (Pinkse et al. 
2005).    Treatment of embryonic hippocampal neurons with an integrin-activating peptide 
derived from laminin (EIKLLIS) protects the cells from apoptosis and results in increased 
PKB/Akt activity.  The effect is blocked by co-incubation with a PI-3K inhibitor or an 
anti-β1-integrin antibody (Gary et al. 2003).  The fact that in that study a β1-integrin 
antibody completely abolished any increase in PKB/Akt activity following integrin 
activation suggests that the specific clone of blocking antibody is important.  A number of 
different anti-β1-integrin antibodies are available; in the hippocampal neuron study, a 
polyclonal antibody was used.  Pinkse et al treated rat hepatocytes with a hamster anti-rat 
monoclonal antibody (clone not specified) whilst I used a mouse anti-human β1-integrin 
antibody clone P5D2.  A study of human lung fibroblasts found that treatment with the β1-
integrin activating antibody TS2/16 in suspension culture resulted in an increase in 
PKB/Akt phosphorylated at Ser473.  Interestingly, the authors state that this was inhibited 
when cells were pre-treated with the P5D2 anti-β1-integrin antibody although they do not 
show the data in the paper (Nho et al. 2005).  It is possible that the use of two anti-β1-
integrin antibodies together blocks the pro-survival effect of the P5D2 antibody; indeed, 
previous work by the same group suggested that the P5D2 anti-β1-integrin antibody 
treatment of fibroblasts, both attached and in suspension, leads to an increase in in Ser473 
phosphorylation of PKB/Akt (Tian et al. 2002).  
In addition to an increase in Ser473 phosphorylated PKB/Akt, Pinkse et al also reported an 
increase in ILK activity following treatment of rat hepatocytes with anti-β1-integrin 
integrin antibody and suggested that anti-β1-integrin integrin antibodies exert an effect on 
cell survival by activating ILK which in turn phosphorylates PKB/Akt on Ser473 (Pinkse 
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et al. 2005).  However, the study offered no proof that ILK was directly responsible for 
PKB/Akt phosphorylation and it is quite possible that ILK activation is a separate 
phenomenon to the activation of PKB/Akt with phosphorylation of the latter occurring 
through a different mechanism.  Nonetheless, ILK appears to have a role in survival 
signalling in hepatocytes; depletion of murine hepatocyte ILK results in increased 
apoptosis and caspase-3 activity compared to normal hepatocytes in culture and hepatitis 
in vivo.  Reintroduction of ILK reverses this effect.  However, PKB/Akt phosphorylation 
is not affected by the loss of ILK from hepatocytes suggesting that ILK does indeed act 
through a different pathway (Gkretsi et al. 2007).  Conversely, Gary et al confirmed a 
possible role for ILK in PKB/Akt phosphorylation in their study of hippocampal neurons.  
Following transfection of cells with a kinase-dead ILK, integrin activation using EIKLLIS 
had no effect on levels of phosphorylated PKB/Akt where as a large increase was seen in 
untransfected neurons or neurons transfected with wild-type ILK (Gary et al. 2003).  
Similarly, knock down of ILK expression using small interfering RNA (siRNA) leads to a 
reduction of PKB/Akt phosphorylation and increases the level of apoptosis in fibroblasts 
(Nho et al. 2005). 
In summary, whilst the exact mechanism and the possible role of ILK in promoting 
PKB/Akt phosphorylation either directly or indirectly is uncertain, my data lend support to 
the hypothesis that anti-β1-integrin antibodies improve hepatocyte survival by activating 
the PKB/Akt pathway.  
6.3.3 Cytoskeletal reorganisation 
The Rho family of GTPases are a group of small signalling proteins that have a major role 
in cytoskeletal reorganisation.  Integrin-mediated adhesion results in the activation FAK 
and formation of an active FAK-Src complex and activation of subsequent signalling 
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pathways resulting in the regulation of several Rho-GTPases (Huveneers and Danen 
2009).  Key members of the Rho GTPase family involved in cell migration and cell-
cell/cell-ECM adhesion include RhoA, which can modulate actin polymerisation, and Rac 
and Cdc42 which are involved in the formation of filopodia and lamellipodia, the actin 
cytoskeletal projections present on mobile cells (Bustelo et al. 2007;Etienne-Manneville 
and Hall 2002;Price et al. 1998).  β1- and β3-integrin are particularly important in Rho-
GTPase activation and may differentially activate RhoA and Rac/Cdc42, with the 
overexpression of β1- integrin in Chinese hamster ovary cells leading to enhanced 
Rac/Cdc42 activity and lamellipodia formation (Miao et al. 2002).  β1-integrin ligation has 
been shown to result in activation of these pathways with effects on processes such as 
melanoma invasion (Nakahara et al. 1996;Nakahara et al. 1998) and migration of 
pancreatic cancer cells (Shields et al. 2012).  In hepatocytes, Cdc42 may have a key role in 
establishment of cell polarity (Hua et al. 2012) and hepatocyte proliferation during liver 
regeneration (Cimica et al. 2005;Yuan et al. 2009).  Hepatocytes from rats fed with an 
ethanol-containing diet show impaired cell spreading and attachment possibly due to a loss 
of Rac and Cdc42 activation (Schaffert et al. 2006;Tuma et al. 1999;Xu et al. 1992).  ILK 
is also able to activate Rac and Cdc42 ultimately resulting in actin cytoskeleton 
remodelling and promotion of cell spreading and migration (Boulter et al. 2006;Filipenko 
et al. 2005). 
My confocal microscopy data suggest that hepatocytes treated with anti-β1-integrin 
antibodies undergo reorganisation of the cytoskeleton when allowed to adhere to a HSEC 
monolayer.  Discrete areas of actin/vinculin colocalisation may represent sites of adhesion 
between hepatocytes and endothelium or underlying matrix, with the enhanced spreading 
and generation of filopodia-like protrusions indicating a more migratory phenotype.   
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In conclusion, in this chapter I have demonstrated that treatment of human hepatocytes 
with anti-β1-integrin antibodies results in an increase in cell viability and most likely 
occurs through activation of the PKB/Akt signalling pathway leading to suppression of 
anoikis.  Anti-β1-integrin treated hepatocytes also appear to have an enhanced spreading 
and migratory phenotype compared to untreated cells.  A possible mechanism for this is 
through FAK/Src and ILK signalling with subsequent activation of Rho GTPases and 
cytoskeletal rearrangement.   
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CHAPTER 7:  OVERVIEW 
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7.1 Overview 
7.1.1 Hepatocyte isolation 
The aim of the first part of this thesis was to re-establish the technique of hepatocyte 
isolation from human liver tissue within our laboratory.  However, it soon became clear 
that the outcome of human hepatocyte isolation from the range of diseased liver tissue 
available within the laboratory was not ideal.  Although we were able to isolate viable 
hepatocytes from a range of different types of normal and diseased liver tissue, the success 
rate of the technique and the viability obtained were modest (Bhogal et al. 2011).  Huh 7.5 
cells proved useful for optimising initial experiments and for experiments where the use of 
primary cells would have been extremely challenging.  However, I felt it was important, 
where possible, to confirm results obtained with the Huh 7.5 cell line using primary 
hepatocytes and that this would add strength to the data.  Therefore a significant part of the 
work presented here describes an attempt to improve the outcome of hepatocyte isolation 
from human liver tissue in order to obtain sufficient numbers of viable cells for 
experimental purposes. 
Most laboratory research involving hepatocytes makes use of rat or murine hepatocytes, 
and there is very little literature available describing techniques for human hepatocyte 
isolation.  However, two small studies looking separately at the use of NAC and Liberase 
showed that these reagents offer some improvement in the outcome of hepatocyte isolation 
(Donini et al. 2001;Sagias et al. 2010).  Taken together with other studies concerning the 
mechanisms of action of NAC and the effect of Liberase on the isolation of other cell 
types, this suggested to me that their use in combination may improve the outcome of 
human hepatocyte isolation.  I therefore developed an isolation protocol that included 
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NAC and Liberase and compared outcomes with the standard protocol that had been in use 
up until now in our laboratory. 
The new protocol resulted in a significant improvement in the outcome of hepatocyte 
isolation from normal and diseased human liver tissue.  I was able to greatly increase the 
success rate of hepatocyte isolation, meaning that the isolation process resulted in viable 
cells that would attach in culture and were therefore useful for experimental purposes.  I 
also showed that two basic measures of hepatocyte function, urea and albumin synthesis, 
were as good as or better than that seen with hepatocytes isolated using the old protocol.  
Clearly there are many further aspects of hepatocyte function that warrant investigation, 
but these findings suggest that the new protocol does not negatively impact the functional 
quality of isolated hepatocytes.  As well as providing the numbers of viable cells required 
for my subsequent experimental work, the outcome of this study in itself will be useful for 
others wishing to work with primary human hepatocytes. 
7.1.2 Adhesion molecules expressed by primary human hepatocytes and 
their role in hepatocyte engraftment into host liver 
Having established a reliable method for isolating primary human hepatocytes, the main 
aim of the rest of the thesis was identify the adhesion molecules expressed by human 
hepatocytes and attempt to modulate their function to improve engraftment in the host liver 
following transplantation.  There is no comprehensive analysis of the surface expression of 
adhesion molecules by human hepatocytes.  However, several studies describe the 
expression of integrins on human or other mammalian hepatocytes, with some 
demonstrating a role in adhesion.  This, and the fact that integrins are known to play a key 
role in the adhesion of many cell types to ECM as well as in the transmigration of cells 
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across sinusoidal endothelium, suggested that examination of the integrin repertoire 
expressed by human hepatocytes would be a useful place to start.   
I demonstrated surface expression of a wide range of integrin subunits by primary human 
hepatocytes, including several which, to the best of my knowledge, have not been 
described on hepatocytes before.  For further functional I concentrated on those which are 
most highly expressed, namely α1, αV and β1 integrins.  Using Huh 7.5 cells as a model of 
human hepatocytes, I showed that blockade of α1 and αV-integrin both resulted in 
reduction of adhesion to various types of liver tissue under static conditions suggesting 
that α1β1 and αVβ1-integrins have a role in hepatocyte adhesion.  Interestingly, β1-
integrin blockade alone did not reduce adhesion.  Furthermore, in modified flow adhesion 
assays, β1-integrin blockade actually resulted in an increase in the proportion of 
hepatocytes remaining adherent to HSEC under flow.  Together with the lack of effect of 
β1-integrin blockade in the static adhesion assay, this was a highly unexpected finding 
given that other groups have previously shown that β1-integrin blockade results in a loss of 
hepatocyte adhesion. 
Despite being contrary to what I had expected, the β1-integrin blocking effect was an 
exciting finding as it could offer a potential means to improve hepatocyte engraftment.  I 
therefore investigated this further, showing that by blocking β1-integrin I could increase 
the transmigration of hepatocytes through an HSEC monolayer.  Most importantly, I 
showed that β1-integrin blockade also increased the initial engraftment of human 
hepatocytes into murine liver following intraportal injection.  On review of the literature, I 
discovered that a similar effect had been demonstrated previously with rat hepatocytes 
although such a finding has not been reported previously with human hepatocytes.  It is 
important, however, to bear in mind that the results of the animal experiments shown in 
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5.2.4 represent only the initial engraftment of transplanted cells during a brief 15 minute 
period.  This, together with the very small number of mice used, clearly limits the 
conclusions that may be drawn.  In order to confidently demonstrate the ability of β1-
integrin blockade to reliably increase engraftment in mice, further longer term experiments 
using larger sample sizes are required.  Nevertheless, with these promising initial results I 
therefore felt that targeting β1-integrin may provide a useful mechanism for improving the 
outcome of hepatocyte transplantation through increased engraftment.  Furthermore, the 
preliminary data obtained from these studies will be useful for developing adequately 
powered longer-term engraftment experiments. 
In order to begin to understand the effects of β1-integrin blockade in human hepatocytes, I 
looked at several aspects of β1-integrin signalling.  Previous studies of hepatocytes and 
other cell types have shown a role for β1-integrin in the prevention of anoikis and that this 
is mediated, at least in part, through PKB/Akt signalling.  Integrin signalling is also known 
to activate FAK/Src which in turn are able to regulate Rho-GTPases.  These have an effect 
on cell migration and cell-cell/cell-ECM interactions.  I have shown that following 
treatment of primary human hepatocytes with a β1-integrin blocking antibody there is 
activation of PKB/Akt signalling with a reduction in caspase-3 activity and an 
improvement in cell viability.  Further, there is evidence of cytoskeletal rearrangement 
with perhaps a more migratory phenotype.  Many of these findings are novel in human 
hepatocytes and offer an exciting starting point for future investigation of integrin 
signalling pathways in primary human hepatocytes in general, and, in particular, for the 
improvement of hepatocyte engraftment in hepatocyte transplantation. 
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7.1.3 Concluding remarks 
Hepatocyte transplantation has the potential to supplement endogenous hepatocyte mass in 
liver failure or to correct genetic deficiencies.  As such, it is one of a number of strategies 
that may help overcome the shortage of deceased donor organs.  However, the success of 
this approach has been limited by inadequate hepatocyte engraftment in the native liver 
(Gupta et al. 1999a).  Little is known about the mechanisms which regulate interactions 
between hepatocytes and liver sinusoidal endothelial cells despite the fact that such 
interactions are critical for successful engraftment.  I therefore initially set out to 
investigate the role of adhesion molecules in this process in the hope that this would 
identify mechanisms that could be modulated to increase engraftment.  An attempt to 
block β1-integrin function in order to demonstrate its role in human hepatocyte adhesion 
resulted in the unexpected finding that this manoeuvre actually increased adhesion to 
sinusoidal endothelium under flow.  This led me to focus further on β1-integrin. 
In conclusion, stimulation of the β1-integrin on the surface of primary human hepatocytes 
using anti-β1-integrin antibodies results in increased adhesion to and transmigration across 
HSEC, as well as increase engraftment in murine liver following intraportal injection.  
This is likely to be due to activation of integrin signalling pathways resulting in increased 
cell survival and cytoskeletal reorganisation.  We and others have shown that the anti-β1-
integrin antibody used in these studies is able to block β1-integrin-mediated adhesion with 
other cell types.  Presumably, therefore, other adhesion molecules must be responsible for 
human hepatocyte adhesion and migration in this context.  Exactly which molecules are 
involved cannot be answered by this study, but remains an important area for future 
research.  However, the demonstration of an intervention to increase human hepatocyte 
engraftment into host liver holds promise for the future of hepatocyte transplantation.  
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7.1.4 Future Work 
The first part of the thesis demonstrated a technique to significantly improve the outcome 
of hepatocyte isolation from human liver tissue.  However, the 70% success rate achieved, 
whilst a great improvement on our previous results, still leaves room for improvement.  
Further research into the optimal preparation of liver tissue for hepatocyte isolation, the 
isolation process itself, and the subsequent culture techniques may yield further benefits. 
 The preparation and storage of liver tissue for hepatocyte isolation 
We have previously shown that time to tissue processing has a significant 
impact on the success of hepatocyte isolation.  However, further 
improvements in outcome may be achieved by greater attention to the 
handling of liver tissue prior to commencement of the isolation procedure, 
for example by using cold storage preservation techniques similar to those 
used for organs to be transplanted.  Furthermore, it is not clear what 
constitutes the optimum `wedge’ for hepatocyte procurement.  Use of a 
whole liver, or an anatomic resection, may offer benefits through 
achieving a more thorough and even perfusion by using segmental vessels. 
 The enzymatic digestion process 
Successful enzymatic digestion requires a balance between using an 
enzyme cocktail of sufficient activity to rapidly digest tissue whilst 
limiting damage due to an overly harsh enzyme preparation or prolonged 
digestion time.  The data suggest that the use of Liberase and NAC goes 
someway to addressing this issue, but there may well be further 
improvements to be made. 
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 The techniques for culturing human hepatocytes 
Much has been published on culture techniques for hepatocytes.  I used 
one such technique that, according to the authors, results in maintenance 
of various aspects of hepatocyte function for several weeks.  However, the 
optimum culture medium and technique has yet to be identified, with most 
systems resulting in dedifferentiation, loss of hepatocytes phenotype and 
loss of viability.  Cryopreservation may offer a solution to the problem of 
prolonged culture, but also requires further investigation and optimisation.  
The remainder of the data presented herein suggests a mechanism to improve the 
engraftment of transplanted hepatocytes.  Furthermore, it confirms for the first time in 
primary human hepatocytes the role of β1-integrin in cell survival signalling and 
cytoskeletal reorganisation that has been demonstrated by others in non-human 
hepatocytes and other cell types.  Further work would improve understanding of β1-
integrin signalling in human hepatocytes, and the mechanisms underlying human 
hepatocyte adhesion: 
 The role of non-integrin adhesion molecules in hepatocyte adhesion 
I have demonstrated gene expression of a range of adhesion molecules by 
primary human hepatocytes.  Further work to quantify surface expression 
and function of these would greatly add to our understanding of hepatocyte 
adhesion and may lead to other interventions to improve engraftment 
following hepatocyte transplantation. 
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 The mechanisms regulating hepatocyte migration 
I have demonstrated the expression of a number of chemokine receptors by 
primary human hepatocytes, and shown that they are able to transmigrate 
through an HSEC monolayer.  Further study of hepatocyte migration and 
the role of individual chemokine receptors and adhesion molecules may 
identify alternative strategies to increase engraftment during hepatocyte 
transplantation.  Furthermore, such studies may add to the current 
understanding of liver development and regeneration as well as the 
behaviour of hepatocellular carcinoma. 
 The precise nature of integrin signalling through PKB/Akt and associated 
signalling molecules 
The data suggest that β1-integrin signalling results in activation of PKB/Akt 
with subsequent improvements in viability most likely due to the 
suppression of anoikis.  However, a more complete understanding of the 
pathway by which β1-integrin ligation results in PKB/Akt phosphorylation 
may offer additional targets for modulation.  Similarly, investigation of the 
mechanisms by which β1-integrin ligation results in changes in cytoskeletal 
arrangement would be of great interest. 
 Longer term engraftment and functional studies 
The data presented demonstrate an increase in hepatocyte engraftment in 
vivo using a murine model of hepatocyte transplantation.  However, I have 
only so far demonstrated short term engraftment.  Whilst there is existing 
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animal data suggesting that once transplanted hepatocytes enter the liver 
parenchyma they are able to engraft and function in the longer term, it is 
important to confirm this with primary human hepatocytes using the 
techniques reported here.  Functional outcome, using models such as the 
FRG mouse, would confirm that the increase in hepatocyte engraftment 
achieved results in a clinically meaningful benefit.
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